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Padmanabhan S, Joe B. Towards Precision Medicine for Hypertension: A Review of
Genomic, Epigenomic, and Microbiomic Effects on Blood Pressure in Experimental Rat
Models and Humans. Physiol Rev 97: 1469–1528, 2017. Published September 20,
2017; doi:10.1152/physrev.00035.2016.—Compelling evidence for the inherited
nature of essential hypertension has led to extensive research in rats and humans.
Rats have served as the primary model for research on the genetics of hypertension resulting
in identification of genomic regions that are causally associated with hypertension. In more
recent times, genome-wide studies in humans have also begun to improve our understanding
of the inheritance of polygenic forms of hypertension. Based on the chronological progression
of research into the genetics of hypertension as the “structural backbone,” this review catalogs
and discusses the rat and human genetic elements mapped and implicated in blood pressure
regulation. Furthermore, the knowledge gained from these genetic studies that provide evi-
dence to suggest that much of the genetic influence on hypertension residing within noncoding
elements of our DNA and operating through pervasive epistasis or gene-gene interactions is
highlighted. Lastly, perspectives on current thinking that the more complex “triad” of the
genome, epigenome, and the microbiome operating to influence the inheritance of hyperten-
sion, is documented. Overall, the collective knowledge gained from rats and humans is disap-
pointing in the sense that major hypertension-causing genes as targets for clinical management
of essential hypertension may not be a clinical reality. On the other hand, the realization that the
polygenic nature of hypertension prevents any single locus from being a relevant clinical target
for all humans directs future studies on the genetics of hypertension towards an individualized
genomic approach.
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I. BLOOD PRESSURE AS A COMPLEX
POLYGENIC TRAIT
The focus on the role of arterial blood pressure as an im-
portant reporter of cardiovascular health has deep histori-
cal roots dating back to the 18th century. In 1733, the
British clergyman Stephen Hales is documented to have
made the first published measurement of blood pressure in
several animals by inserting fine tubes into arteries andmea-
suring the height to which the column of bloodwent up (86,
88, 215). In 1836, Richard Bright found an association
between renal disease and left ventricular hypertrophy (23).
He suggested that left ventricular hypertrophy could be a
consequence of high blood pressure. Clinical features of
essential hypertension were studied by T. C. Allbutt (6),
who then went on to coin the term hyperpiesis to describe
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essential hypertension, but the term was not popular. Eber-
hard Frank is believed to have replaced it with the term
Essentielle Hypertonie, the English translation of which is
Essential Hypertension, i.e., elevated high blood pressure
for no known causes (189). Despite these documented ob-
servations on the very nature of essential hypertension be-
ing noticeable in humans, the clinical significance of hyper-
tension was, interestingly, a discovery attributed to keen
observations of individuals from a nonscientific back-
ground. As early as in 1906, long before the clinical concept
of hypertension as a risk factor became accepted, several
insurance companies required medical examiners to docu-
ment applicants’ blood pressures (44, 190). The extent of
blood pressure being a good predictor of serious illness
from stroke, heart failure, or renal disease was first recog-
nized by L.I. Dublin and A. J. Lotka, who were demogra-
phers working for a life insurance firm in the United States
(71, 72). Soon thereafter, the medical community followed
with evidence from the studies in populations such as the
Framingham study to conclude that essential hypertension
is a condition qualitatively distinct from normotension and
that elevated blood pressure was not just in those able to
afford life insurance (189). There was however the question
of whether there was a “dividing line” between normal
blood pressure and hypertension. Further clarification that
arterial blood pressure did not have a dividing line between
normal blood pressure and hypertension was provided by
Pickering and co-workers (273, 280, 281) who studied
larger populations to study the frequency distributions of
arterial blood pressure in populations and emphasized that
there is a continuous relationship between arterial pressure
and mortality over a full range of arterial pressure. This
definition changed the perception of hypertension being a
qualitatively different feature from normal blood pressure
to a “quantitative” feature, i.e., a trait that varies continu-
ally from low to high in a population. The recognition of
this feature was in itself a milestone in the understanding of
hypertension, but many questions remained as to what
caused this variation in populations.
II. EVIDENCE FOR INHERITANCE
Pickering and co-workers (125–127, 283) were among the
first to recognize familial correlation of blood pressure (BP).
They collected BP data from large groups of normotensive
and hypertensive subjects along with their relatives and
plotted frequency distribution curves after adjustment for
age and gender. BP of relatives of hypertensive subjects were
significantly higher than that of the relatives of normoten-
sives (127). There was a linear relationship between the
level of BP of individual subjects with their relatives (282).
This led to the important conclusion that what was inher-
ited was not only hypertension, but the level of BP regard-
less of whether it was high or normal. To provide some
perspective, this study was published in 1954, which is over
half a century after Mendel’s ideas on inheritance were
applied to medicine by Archibald Garrod (110). Beginning
in 1902, Garrod had studied alkaptonuria, cystinuria, and
albinism in relatives of patients and found that genetics
explained these inborn errors of metabolism as Mendelian
heritable traits, but he also speculated that genetics may
play a role in common diseases (110–114).
More precise evidence for genetic factors to influence BP
came from correlative observations of a history of hyper-
tension in parents of hypertensive subjects in various pop-
ulations in Europe andNorth America (158, 251, 333, 334,
378). Additional evidence was obtained through popula-
tion studies wherein a greater concordance of blood pres-
sure was observed within families than between families
(226), but such studies also raised the question of additional
shared nongenetic, environmental factors such as food hab-
its within a family that could influence blood pressure. Twin
studies wherein a greater similarity of blood pressures was
documented with monozygotic than dizygotic twins (87,
207) suggested that genetic factors strongly influenced the
incidence of hypertension. Other studies suggest that ge-
netic effects on BP are evident early in life by demonstrating
a significant sib-pair and maternal-children correlation of
BP in infants (133, 212) and in children between 2 and 14 yr
of age (409). However, a clarification on environmental
factors overriding the genetic factors was inferred based on
studies of BP variance in a Montreal adoption study of
French-Canadian families with both adopted and natural
children (8, 9, 19, 20, 252). The study pointed to the highest
correlations of BP within children in a shared household
environment, regardless of whether they were adopted or
not. This correlation between the children was more signif-
icant than correlations between the BP of parents and their
natural children, leading to the inference that nongenetic,
environmental factors contribute more than genetic factors
to the extent of BP; however, the identities of both genetic
and environmental factors remained enigmatic. Another
metric that is used tomeasure familial resemblance of a trait
and hence its genetic component is heritability. The higher
the heritability, the stronger is the correlation between phe-
notype and genotype. From twins and family studies, the
heritability of BP ranges from 15 to 40% for the office BP
and around 51–69% for night time blood pressure ob-
tained from ambulatory BP monitoring (131, 192, 207). In
general, low heritability estimates indicate that genetic
mapping would be difficult for that phenotype.
III. WHY AND HOW TO STUDY THE
GENETICS OF BLOOD PRESSURE
CONTROL
Hypertension being inherited in families serves as an impor-
tant clue for the presence of susceptibility factors on our
genomes that predispose some of us but not others to de-
velop high BP. It is interesting to note that most of the
above-mentioned correlative observations were made in the
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first half of the 20th century well ahead of 1953, the year in
which Watson and Crick made the landmark discovery of
the molecular structure of DNA (376, 377). This discovery
marked the dawn of the era ofMolecular Biology and paved
the way for a series of monumental discoveries to follow
that gave fundamental insights into key concepts that sealed
our current understanding of DNA as the genetic material
that is inherited. DNA was therefore accepted as the “mol-
ecule of life,” and the following three decades since 1953
revolutionized our understanding of the structure-function
relationship between the inheritance of DNA and the role it
plays in determining the structure of proteins. While the
definitions of what constitutes a “gene” were being worked
on in the 1950s to the 1980s bymolecular biologists, during
the same period, physiologists interested in the etiology of
hypertension began looking into dietary factors such as the
components of the Kempner rice diet influencing the extent
of hypertension (186, 375, 383). Salt being an important
component influencing BP was inferred by studying various
populations around the globe (55). It was apparent that
dietary salt intake was directly proportional to the extent of
BP observed (55).
IV. RATS AS MODELS TO STUDY THE
GENETICS OF HYPERTENSION
To further address the question of whether salt was respon-
sible for the development of hypertension, Lewis Kitchener
Dahl et al. (56) conducted experiments with a population of
Sprague-Dawley rats, wherein BP of the rats was recorded
following their dietary intake of a high salt (8%NaCl) diet.
If a high dietary salt intake caused an elevation in BP, all the
rats should have developed higher BP. However, this was
not the case. Only a subset of rats developed higher BP in
response to dietary salt. The fundamental factor driving
some but not all rats in the population to develop hyperten-
sion in response to dietary salt is now interpretable as ge-
netic susceptibility. By selectively breeding rats with hyper-
tension in response to a high salt intake, not only was fur-
ther evidence obtained for the inheritance of hypertension,
but also the model that ensued came to be known as the
Dahl salt-sensitive (S) rat (56, 57), the inbred version of
which continues to be one of the most popular models used
to study the genetics of hypertension to date. In addition to
this model developed in the United States, there are several
other models of genetically hypertensive rats that were de-
veloped in other regions of the world. These include the
spontaneously hypertensive rat (SHR) (272) and the spon-
taneously hypertensive rats stroke prone (SHRSP) from Ja-
pan (261, 272), DOCA salt-sensitive (SBH) rat from Israel
(13), Fawn-hooded hypertensive (FHH) rat from TheNeth-
erlands (204), Lyon hypertensive (LH) rat from France (75),
Milan hypertensive strain (MHS) from Italy (15), Prague
hypertensive rat (PHR) from the Czech Republic (132), ge-
netically hypertensive (GH) rat and the albino surgery (AS)
rat from New Zealand (141, 343), and inherited stress-
induced arterial hypertension (ISIAH) rat from Russia
(236). The origins of these models are described in greater
detail in a review by Rapp (298). These inbred rats served as
models to test the hypothesis that there are regions, referred
to as quantitative trait loci (QTLs), on the genome that
cause an elevation in BP of these inbred rats.
To identify such genomic regions, comparisons of inbred
hypertensive strains had to be made at the genomic DNA
level with that of inbred normotensive strains. However,
there was a significant roadblock to study genomic DNA,
because during the 1970s and early 1980s there were few
genetic markers and the technology for genotyping by am-
plification of DNA through the polymerase chain reaction
(PCR) had not yet been developed. The experimental design
used to find DNA regions related to BP was to breed hyper-
tensive rats to their normotensive counterparts to generate
filial generation 1 (F1) rats. The F1 rats were intercrossed to
obtain a filial generation 2 (F2) population. The BP of F2
rats were recorded. Initially, Mendelian genetic markers
were used to detect differences between regions of the ge-
nomes of hypertensive and normotensive rats. Such poly-
morphisms were used to track the cosegregation of marker
genes with BP. The first example of this marker gene ap-
proach was demonstrated in 1972 by Yamori et al. (391)
using an electrophoretic protein polymorphism within the
renal esterase gene as a genetic marker to study the coseg-
regation of BP in populations derived from SHR and
Wistar-Mishima rats. In the same year, another cosegrega-
tion study of BPwith aMendelian polymorphism in adrenal
steroid biosynthesis was reported using the Dahl rats (302).
In this case the genetic marker turned out to be due to
variants in the gene actually causing the BP changes (see
sect. IVA). A DNA restriction fragment length polymor-
phism (RFLP) was also exploited as a marker to demon-
strate cosegregation of a segment of rat chromosome 13
containing the renin gene with hypertension in the Dahl rats
(311).
During the mid 1980s, largely driven by the discovery of the
PCR technology, methods were quickly evolving to im-
prove the detection of DNA polymorphisms on the genome.
RFLP was soon replaced by the relatively more efficient
method of using polymorphic microsatellite markers at the
scale of the entire genome for BP linkage analysis. Such
experiments were first reported in 1991 by Jacob et al. (163)
and Hilbert et al. (142). A major BP QTL on rat chromo-
some 10was thus identified by both these groups (142, 163,
298). This method called as “linkage mapping” or “linkage
analysis” and the subsequent method called “substitution
mapping” were extensively applied to the study of inheri-
tance of hypertension in rat genetic models (298). The re-
sults obtained through these efforts were that specific re-
gions on the rat genome were identified as BP QTLs, mean-
ing regions that were flanked by specific microsatellite
markers (genotyped using PCR), were linked to the inheri-
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tance of BP in segregating populations (usually F2). Follow-
ing the studies in 1991–92, when the first such mapping
studies were reported using rats (78, 142, 163), several such
BP QTLs were either identified solely by linkage analysis or
further validated by substitutionmapping using congenic or
consomic strains. Previous review articles by Rapp (298)
and Cowley Jr (45) are highly recommended for a detailed
understanding of linkage analysis and substitutionmapping
as applied to the study of the inheritance of BP using rat
models of hypertension. For a quick review on the tech-
nique to make congenic strains, which are used for substi-
tution mapping, see Rapp (298). The following section pro-
vides an update to these mapping efforts of rat BP QTLs,
which are important and significant given the rapid rise in
sequencing technology since the review by Rapp in 2000
(298).
The dawn of the 21st Century ushered in the new era of
whole genome sequencing, which served as the next wave of
opportunity to query genomes in further detail. Following
the sequencing of the human genome, the rat genome was
sequenced in 2004 (116). The genome sequence obtained
was from the Brown Norway (BN) rat, which is a relatively
normotensive strain compared with the hypertensive S rat
or the SHR. The BN rat strain is highly polymorphic, im-
plying that there are a large number of sequence variants of
this strain compared with any other rat strain. While the
sequence of this strain served as a general reference for
comparison with the sequence data of other rat strains,
nonavailability of whole genome sequences of other, espe-
cially, genetically hypertensive strains, was an impediment.
However, the availability of an assembled, complete rat
genome sequence served several purposes: 1) provided the
means to define BP loci on the physical map of the rat
genome, whereby BPQTLs could be represented in physical
locations on a chromosome in kilobases or megabases as
units as opposed to genetic distances calculated using re-
combinations with centimorgans as units; 2) served to im-
prove the resolutions of the already identified BP loci be-
cause with the genome sequence, additional markers could
be located. For example, additional polymorphic microsat-
ellite markers (which are tandemly repeated nucleotide se-
quences that range in length from two to five nucleotides
repeated in different numbers in different rat strains) could
be located and exploited to further delimit the genomic
region encompassing a BP locus. 3) Sequences of candidate
genes within the BP QTL could be determined in any strain
by designing primers to amplify genome DNA of any chro-
mosome.
These enhanced features resulted in high-resolution map-
ping of the identified BP QTL. A summary of all linkage
mapping studies, which identified large rat genomic regions
of interest is provided in TABLE 1. The main points to note
from these linkage analyses are as follows:
1. All rat chromosomes harbor BP QTLs, implying that
BP causal genes are not limited to any particular chro-
mosome and that the overall genetic control of BP
could be facilitated by a large number of randomly
distributed genetic elements.
2. Some of the BP QTLs, for example, on rat chromo-
somes 1, 2, and 10 are consistently and recurrently
detected in multiple genetic linkage studies conducted
despite the differences in the hypertensive strains used
for the studies. The density of QTLs is not propor-
tional to the size of the chromosomes. Chromosomes
1 and 2 are the longest, but chromosome 10 is among
the shorter rat chromosomes.
3. The context of genetic background wherein the QTL
alleles are presented in a segregating population has
an important effect on whether a given QTL will be
detected. For example, a BP QTL was detected on
RNO7 in the backcross population generated with the
Dahl S rat, but not in an F2 population.
4. BP QTLs are not always gender independent. Some
are gender specific.
5. BP QTLs are not always salt sensitive.
Some but not all of the linkage mapped regions were cor-
roborated with substitution mapping studies. The substitu-
tion mapping studies are tabulated and schematically rep-
resented in TABLE 2 and FIGURE 1, respectively, and dis-
cussed previously (166, 167, 298). As products of such
substitution mapping studies, several genes have been pri-
oritized as positional candidates for BP regulation. The
genes identified as a result of these mapping efforts are
discussed below through section VIII.
A. Cyp11b1
With the use of the mapping approach, the first locus to be
deduced as a bona fide rat BP QTL was the gene Cyp11b1,
which codes for both 18- and 11-hydroxylation of adrenal
steroids. The premise for this locus to be tested as a BPQTL
was the observation of a striking difference in adrenal ste-
roidogenesis between Dahl S and R rats. Compared with R
rats, S rats had an increased ability to 18-hydroxylate 11-
deoxycorticosterone (DOC) to form 18 hydroxy-11-deoxy-
corticosterone (18OH-DOC) and a reduced ability to 11-
hydroxylate DOC to form corticosterone (300–302, 304).
These biochemical changes resulted in higher circulating
levels of the weak mineralocorticoid 18OH-DOC in S rats
(309), which was interpreted to cause increased BP espe-
cially on a high-salt diet (304). These steroid profiles were
shown to be due to a single genetic locus (302) and the
enzyme responsible (Cyp11b1) was identified in 1976 based
on strain differences in Warburg’s partition constant [inhi-
bition by carbon monoxide (CO)] (303). Further genetic
proof was obtained through the characterization of a con-
genic strain constructed by introgressing ~22 centimorgans
(cM) of rat chromosome 7 including the Cyp11b1 gene
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from the R rat into the S rat. The resultant congenic strain
had a significantly lower BP and increased survival com-
pared with the S rats (38). This locus was defined by further
substitution mapping to be within 177 kb (FIGURE 1,
RNO7) (105). Five S and R allelic single nucleotide poly-
morphisms (SNPs) were identified within the coding region
of Cyp11b1, all of which were nonsynonymous substitu-
tions (41, 238). Further specific evidence was obtained
through site-directed mutagenesis and experiments con-
ducted with artificially constructed chimeric genes of S and
R rats to demonstrate that the strain-specific steroid pat-
terns were due to the substitutions in exon 7 coding for
amino acid residues 381 and 384 which probably alters the
structure of the steroid binding site of the Cyb11b1 enzyme
(238, 269).
Mutations in the CYP11B1 human gene are known to
cause rare monogenic forms of inherited hypertension
(381, 382). In a limited study of essential hypertension
with 160 subjects (12), eight novel missense heterozy-
gous mutations were identified in the CYP11B1 gene that
alters the encoded amino acids: R43Q, L83S, H125R,
P135S, F139L, L158P, L186V, and T196A. None of
these mutations accounted for hypertension; however, in
vitro testing indicated that the variants L158P and L83S
severely impaired while R43Q, F139L, P135S, and
T196A increased the enzymatic activity of 11-hydrox-
ylase, suggesting the importance of these affected resi-
dues to enzyme function (12), which may point to lack of
power for detecting associations. Further evidence for the
association of CYP11B1 in humans, albeit modest, was
obtained through a resequencing approach in 560 indi-
viduals with extreme systolic BP belonging to the GenNet
cohort with European American and African American
ancestry (266). Association of CYP11B1 was detectable
only after pooling all coding and noncoding variants at
evolutionarily conserved sites (266). An interesting rela-
tionship between CYP11B1 and the neighboring gene
CYP11B2, encoding aldosterone synthase, was discov-
ered by haplotypic analysis. The pattern of variation
across the entire CYP11B locus was determined by se-
quencing 26 normotensive subjects homozygous for the
344 and intron conversion variants within CYP11B2.
Four common haplotypes with 83 variants associated
with 344 and intron conversion were identified con-
firming strong linkage disequilibrium across the region.
Two novel CYP11B1 polymorphisms upstream of the
coding region (1889 G/T and 1859 A/G) were iden-
tified as contributing to the common haplotypes. Hyper-
tensive subjects (n  512) from the British Genetics of
Hypertension Study population were genotyped for these
polymorphisms, and the study strongly suggested that
the impaired 11-hydroxylase efficiency associated pre-
viously with the CYP11B2 344 and intron conversion
variants was due to linkage with these polymorphisms in
CYP11B1 (12). Overall, the data from all these studies
points to both coding and noncoding variants of
CYP11B1 as imparting a modest but significant effect
(average allelic effect 1 mmHg, P  0.005), on BP
regulation via regulation of steroidogenesis in humans.
V. BEYOND HIGH-RESOLUTION MAPPING:
POSITIONAL CLONING OF INHERITED
LOCI FOR BLOOD PRESSURE
REGULATION
Substitution mapping using congenic strains has been
highly successful to resolve BP QTLs from large intervals of
a few megabases to, in some cases, very short intervals
encompassing less than a megabase or in some cases, a few
kilobases (104, 105, 120, 122, 268, 318). However, there
are hundreds of variations presenting as candidate quanti-
tative trait nucleotides within each of these highly resolved
loci. Further substitution mapping alone is highly unlikely
to uncover the precise genetic elements imparting the
change in BP because substitution mapping relies on natu-
rally occurring meiotic recombinations, the frequency of
occurrence of which is inversely proportional to the size of
the genomic segment. In other words, the shorter the con-
genic interval, the rarer it is for recombinations to occur
within that interval. Given this impediment, other compli-
mentary approaches were needed to move the field forward
from mapping to positional cloning of BP QTLs.
VI. IDENTIFICATION OF MAPPED BP QTLs
WITH COMPLIMENTARY APPROACHES
A. Transcriptome Analysis
Soon after the sequencing of the human genome, prompted
by the availability of the microarray technology for quan-
titatively evaluating gene expression on a large scale, tran-
scriptomic analyses were superimposed with the substitu-
tion mapping approach to assess whether candidate genes
FIGURE 1. Regions on the rat genome mapped using substitution mapping. *The letters on the x-axis are studies listed with the same alphabet
in TABLE 2. The y-axis of each panel in this figure represents the length of a single rat chromosome. Bars represent the locations of BP QTLs.
These locations were determined by searching the Ensembl data (www.ensembl.org) and the rat genome data (www.rgd.mcw.edu) for the rat
genome version 6.0. In cases where the locations of the end markers were not available on the rat genome version 6.0, other closest markers
or other versions of the rat database were used. Red arrows with names of genes indicate locations on congenic strains where the evidence
for the actual gene accounting for the QTL is “strong.” Data with mapping ambiguity for positioning markers on the rat genome map are not
featured in this diagram.
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with QTLs were differentially expressed between a parental
strain and a congenic strain. Although this method did not
directly test the genomic variation within the QTL segment
causing the BP effect, the hypothesis for such studies was
that variation within the QTL segment within regulatory
regions such as promoters or enhancers could influence the
level of expression of a BP QTL gene. The contemplation of
applying this technology was prompted by the application
of such studies at that time to studies on yeast mutants
(349), in mice (79, 175), and in rats (3). With the use of the
combinatorial approach of mapping andmicroarrays, com-
plement factor was identified as a susceptibility locus in a
murine model of allergic asthma, Cr2 as a susceptibility
locus for murine systemic lupus erythematosus, and Cd36
as a locus causing defective fatty acid and glucose metabo-
lism in the SHR (3, 79, 175).
One of the first genes identified using a combinatorial ap-
proach of mapping and microarray analyses is a fatty acid
transporter called Cd36. Aitman et al. (3) were mapping
genes for metabolic syndrome using the SHR rat. They used
congenic strains with genomic segments introgressed from
the normotensive Brown Norway rat into the SHR back-
ground and observed partially reduced insulin resistance of
the SHR. The QTL interval affecting glucose and fatty acid
metabolism was thereby located to a genomic segment
spanning 36 cM on rat chromosome 4 with Cd36 as a
candidate gene at the peak of the QTL (3). The SHR rat had
lower expression of Cd36 and a functional fatty acid trans-
porter deficiency in both adipose tissue and heart. The
lower expression of Cd36 in SHR rats was traced to a
genomic deletion within the 3=-untranslated region, the
only region represented on the microarray. Congenic sub-
stitution of chromosome 4 (including Cd36) from the
Brown Norway (BN) rat onto the SHR also caused reduc-
tions in BP and ameliorated dietary-induced glucose intol-
erance, hyperinsulinemia, and hypertriglyceridemia. These
results demonstrated that a single chromosome region
could influence a broad spectrum of cardiovascular risk
factors including hypertension and metabolic syndrome.
The interpretation that Cd36 was a genetic determinant of
BP was thwarted by the analysis of Cd36 genotypes in the
stroke-prone SHR strain, which, despite being hyperten-
sive, did not inherit the deletion variant of Cd36 carried by
the SHR. So, for a while, it was inferred that the deletion
polymorphism of Cd36 was not important to the hyperten-
sive phenotype of the SHR (294).
Later however, definitive proof for Cd36 as a BP QTL was
obtained by focusing on the renal expression ofCd36. With
the use of an integrated renal whole transcriptome profiling
experiment coupled with linkage analysis in a BXH/HXB
panel of rat recombinant inbred strains developed from
SHR and BN rats, Cd36 was identified as a potential ex-
pressionQTL (eQTL) linked to BP (156). This evidence was
strengthened by the observation that the renal quantitative
expression of Cd36 correlated inversely with arterial BP in
these recombinant inbred strains (286). Furthermore, an-
other SHR.BN congenic strain (SHR-Chr.4a subline) with a
shorter introgressed segment carrying the wild-type allele
for Cd36 also demonstrated a decrease in BP (FIGURE 1,
RNO4) (286). To investigate whether selective lack of wild-
type Cd36 in the kidney is sufficient to promote increased
BP, renal transplantation experiments were conducted us-
ing donor kidneys from either the SHR progenitor that
lacks wild-type Cd36 or from a SHR-TG19 transgenic
strain with robust renal expression of wild-type Cd36 into
recipient SHR.BN congenic rats. Rats receiving kidneys
from SHR (with mutant Cd36) had significantly higher BP
compared with rats that received kidneys from SHR-TG19
transgenic strain (expressing wild-type Cd36) (286). These
data provided compelling evidence for Cd36 as a genetic
determinant of BP. This conclusion with rat models is also
supported with data from Cd36 knockout mice, which de-
velop hypertension (188). It is to be noted that humans with
CD36 deficiency exist, with prevalence of 2–3% reported in
Asian and African populations (143, 209). BP of Japanese
individuals with CD36 deficiency was reported to be ele-
vated compared with BP in age-matched controls (250).
SNPs of CD36 are also reported to be associated with es-
sential hypertension (222) and ischemic stroke (404) among
Chinese populations.
CD36 is referred to as a scavenger receptor, but has been
demonstrated to transport fatty acids and facilitate the up-
take of long-chain fatty acids and oxidized lipids (43, 182,
210). Although the findings from molecular genetic stud-
ies clearly demonstrate that a primary defect in fatty acid
transport can promote disordered carbohydrate metabo-
lism in the SHR (291) and evidence is mounting (36, 117)
for the involvement of CD36 in metabolic dysfunction
via signaling pathways such as the c-Jun N-terminal ki-
nase (JNK) activation and Toll-like receptors (182), as-
sociation of CD36 with endothelial dysfunction (335),
and the recognition of Cd36 as a multifunctional im-
mune-metabolic receptor with many ligands (2), the crit-
ical question of the precise molecular mechanism im-
pacted by CD36 in the kidney, heart, or blood vessels, to
regulate BP, remains unknown.
B. Targeted Gene-Editing Approaches
In 2003, a set of guidelines was suggested (1) to confirm
candidates within QTLs beyond the fine-mapping stage to
be recognized as bona fide quantitative trait genes (QTGs).
Mentioned among these guidelines is the use of knockout
and knock-in models (1).While knockout (or null alleles) of
a candidate QTL can be used for deficiency-complementa-
tion testing, knock-ins can serve the purpose of direct test-
ing of replacement of one allele with another at the candi-
date QTL to alter BP. Prior to 2009, on one hand, fine-
mapping of BP QTLs was steadily progressing, but on the
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other hand, specific gene-targeting technology was lagging
in the rat (162). In 2009, a major breakthrough was
achieved by the creation of the world’s first targeted knock-
out rat using zinc-finger nucleases (115). This discovery
paved the way for the assessment of several prioritized
genes within fine-mapped BP QTLs to be further examined
for their effect on BP in targeted gene deletion models. Al-
though not directly a candidate gene for a BP QTL, as a
proof-of-principle for this method to work, renin, a major
gene involved in BP regulation, was targeted using the zinc-
finger nuclease system and the resultant Ren/ rats, which
had a 10-bp deletion in exon 5, resulting in a frameshift
mutation, were demonstrated to have almost 50 mmHg
lower BP compared with the heterozygous Ren/ rats
(256).
These studies were conducted by researchers in the Medical
College ofWisconsin using the SS/MCW rat. Since then, it is
important to point out that the Medical College of Wiscon-
sin led a program for creating knockout genes on the back-
ground of the SS/MCW rat. The SS/MCW rat originated
from the Dahl S rat and was rederived from (genetically
contaminated) SS/JrHsd rats originally obtained as a con-
genic control strain from Dr. T. Kurtz (University of Cali-
fornia-San Francisco) in 1991 (257). At the genomic level,
SS/MCW is different from the original colony of inbred
Dahl SS/Jr rats maintained at the University of Toledo by
~1,353,492 base pairs (FIGURE 2A obtained from the Rat
Genome Database, www.rgd.mcw.edu). To assess whether
these genetic differences had any effect on BP, BP readings
from SS/MCW and SS/Jr rats were both measured under
identical housing and dietary conditions in experiments
conducted at the University of Toledo. The data presented
in FIGURE 2B illustrate that these genetic differences cause
the systolic BP of SS/MCW rat to be 40 mmHg lower than
that of the authentic inbred SS/Jr rat. The situation is par-
ticularly unfortunate since in general larger effects of any
genetic or environmental manipulations to alter BP in the
rat are best accomplished on a very permissive genetic back-
ground. The SS/MCW rat is relatively less permissive com-
pared with the SS/Jr based on its BP level. So obviously one
has to be careful about choosing “control” strains for ge-
netically engineered SS rats. To be specific, a targeted gene-
edited model (disruption, knockout, or knock-in strain)
made in the SS/MCW rat should not be comparedwith SS/Jr
rats but only to SS/MCW and a targeted gene-edited model
made in the SS/Jr rat should not be comparedwith SS/MCW
rats.
1. A disintegrin-like metalloproteinase with
thrombospondin motifs 16 (Adamts16)
The first reported application of the use of the ZFNmethod
for tracking down a BP QTL candidate gene was for the
gene Adamts16 (118). Adamts16 was a primary candidate
gene within a BP QTL located on rat chromosome 1. The
QTL was initially detected through a linkage analysis of an
F2 population derived from SS/Jr (or S) and normotensive
LEW rats (101). By substitution mapping, linkage was con-
firmed and demonstrated to be due to three independent BP
QTLs named QTL1a, QTL1b, and QTL2 (170, 319) (FIG-
URE 1, RNO1). QTL2 was further mapped in multiple it-
erations and located within 804.6 kb. The primary con-
genic strain [labeled as S.LEW (D1Mco4) in Ref. 319]
had a BP lowering effect of 30 mmHg and the final two
congenic strains (labeled as D1Mco4x1x3Bx1 and
D1Mco4x1x3Bx2), both spanning 804.6 kb, had BP low-
ering effects of 14 and 18 mmHg. These strains con-
tained two genes, one of which was Adamts16, which
harbored two nonsynonymous variants and five synony-
mous variants (170). Adamts16 was therefore prioritized
as a candidate BP QTL and tested using the ZFN gene-
targeting approach. The Adamts16 gene-edited S rat con-
tained a 17-bp deletion in the first exon, which intro-
duced a stop codon in the transcript. The BP of this
Adamts16/ S rat was significantly lower than that of
the S rat, providing additional evidence for the involve-
ment of Adamts16 in BP regulation (118). Other physi-
ological observations pointed to the vasculature as a po-
tential site of action of Adamts16 to lower BP. Ad-
amts16/ rats exhibited significantly lower aortic pulse
wave velocity and vascular media thickness compared with
S rats. The mechanosensory cilia of vascular endothelial
cells from the Adamts16/ rats were longer than that of
the S rats. Furthermore, Adamts16/ rats survived longer
when compared with the S rats. Further studies will be re-
quired for a deeper molecular mechanistic understanding of
how Adamts16 impacts BP. The translational significance
of this locus as a BP QTL was indicated by the detection of
linkage to BP in the Quebec Family Study of a region on
human chromosome 5 encompassing ADAMTS16 under the
QTL LOD plot (170). While ADAMTS16 was only one of
several candidate genes in the linkage analysis, specific SNPs
(rs2086310 in particular)withinADAMTS16were tested and
confirmed for association with BP not only in the Quebec
Family Study, but also replicated in another cohort, GenNet
(170).
2. p67phox, a cytosolic subunit of NAD(P)H oxidase
Through mapping experiments conducted using the Dahl
SS/MCW and BN rats, four independent genomic regions
ranging from 4.5 to 16Mega basepairs (Mb) were identified
on chromosome 13 (257). Each of these BP QTL regions
significantly lowered salt sensitivity in the SS/MCW rat (TA-
BLE 2 AND FIGURE 1, RNO13) (46). The largest effect
among these QTLs was found in a region that overlapped
with the original renin gene region first mapped by Rapp
(311). The largest region however, spanning 16 Mb, was
mapped using a congenic strain SS.13BN26, which was
reported to be mapped to 12.2 Mb containing p67phox, a
cytosolic subunit of NAD(P)H oxidase, as a candidate
gene. The mRNA expression of p67phox was signifi-
cantly higher in the renal outer medulla of SS/MCW rats
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compared with SS.13BN26 congenic rats (89). SS/MCW
rats had a 204 bp deletion and 4 SNPs within the pro-
moter region of p67phox and the promoter activities
tested through transfection and luciferase reporter stud-
ies in immortalized rat medullary thick ascending limb
cells further supported these genetic variances in the pro-
moter region to contribute to higher mRNA expression
of p67phox in the SS/MCW compared with SS.13BN26
(89). To further examine the functional relevance of
p67phox in salt-sensitive hypertension, a ZFN-based
p67phox null mutant (p67phox/) rat was generated and
tested for BP along with the SS/MCW rat. The p67phox/
rats had a 5 bp deletion in their genomic sequence.
p67phox being a subunit of NADPH oxidase, an enzyme
critical for macrophage respiratory burst activity, mac-
rophage activation in response to phorbol myristate ac-
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etate was examined. Respiratory burst activity was com-
pletely abolished in the p67phox null mutant
(p67phox/) rat compared with controls. Also, salt-sen-
sitive hypertension renal oxidative stress and renal glo-
merular injury were significantly attenuated in the
p67phox null mutant (p67phox/) rat compared with
SS/MCW rats (89). These phenotypes were associated
with a significantly lower H2O2 concentrations in the
medullary interstitial fluid of p67phox null mutant
(p67phox/) rats. Collectively, authors interpreted these
data to suggest that p67phox plays a crucial role in the
development of salt-sensitive hypertension, which at
least in part is due to its effects noted in the kidney. From
a mapping standpoint, the region containing p67phox is
large and cannot be ignored for the presence of other
genetic determinants of BP, but the data on p67phox are
compelling to speculate that it is indeed a genetic deter-
minant of BP. Validation studies will be required to as-
sess the naturally occurring polymorphisms of p67phox as
the precise quantitative nucleotide variants causing alter-
ations in BP and renal phenotypes. Authors also indicate
that SNPs in human p67phox have not been found in
human genetic association studies, but suggest that strat-
ification of populations based on salt sensitivity may
serve as a better design to uncover any association of
p67phox with human salt-sensitive hypertension.
VII. OTHER GENES PRIORITIZED THROUGH
MAPPING STUDIES
A. Pappalysin-2 (Pappa2)
Also known as pregnancy-associated plasma protein-A2,
Pappa2 is a metalloproteinase in the metzincin superfamily.
Pappa2 was prioritized through substitution mapping on
rat chromosome 13, using SS/MCW and BN rats (46, 50,
257). The highest resolution reported within which Pappa2
is mapped is 0.71 Mb (chromosome 13, 81.01–81.72 Mb)
containing two other annotations, a protein coding gene
Astn1 and a microRNA miR-488 (50). BN alleles in this
genomic segment lowered salt-sensitive mean arterial BP by
24mmHg (50). Although no nonsynonymous variants were
observed, eight SNPs, five insertions, and two deletion poly-
morphisms are reported within a 25 kb 5= upstream se-
quence of Pappa2. Expression of Pappa2 was eight times
higher in the renal cortex of the SS/MCW.BN congenic
strain compared with S. By the observation of immuno-
costaining of Pappa2 with a Na-K-Cl2 cotransporter
(Nkcc2), Pappa2 was more precisely located in the cortical
thick ascending limbs of renal proximal tubules (50). Ex-
actly how the upregulation of Pappa2 in the congenic strain
protected from elevated BP is not clear. The authors (50)
point out that Pappa2 is known as a protease that can cleave
Igfbp-5 (insulin-like growth factor binding protein 5) (274,
392) and thereby may regulate hydroxyapatite and insulin-
like growth factor (IGF)-1 binding. Clinical associations
between Pappa2, IGF-1, hypertension, and cardiovascular
risk have also been reported (50, 173, 330, 385). To further
support the candidacy of Pappa2, validation experiments
with gene-edited models to assess the naturally occurring
polymorphisms of Pappa2 will be required.
B. Secreted Phosphoprotein 2 (Spp2)
Substitution mapping of BP QTLs on rat chromosome 9
(FIGURE 1, RNO9) led to the prioritization of Spp2 as the
sole gene with a nonsynonymous variation. The QTL was
mapped using congenic strains developed from the intro-
gression of SHR alleles onto the genome of the S rat, which
demonstrated significant lowering of BP and proteinuria
(268). A nonsynonymous G/T polymorphism was detected
in the Spp2 gene between the S and S.SHR congenic rats.
Interestingly, the T allele was rare, being detected from
among 45 rat strains, only in substrains of SHR and WKY.
Importantly, this polymorphism was potentially pleiotro-
pic, because, in addition to improved cardiovascular and
FIGURE 2. A: Circos plots of genomic variant densities between SS/Jr (or S/Jr) and SS/MCW strains of genetically hypertensive rat strains.
The outermost ring of numbers 1–20 and X indicate rat chromosomes. The numbers beneath the outer ring that are labels of tick marks
represent locations on each chromosome in megabases. The pink-colored outer circumference of Manhattan plots represents the histogram
of variants of the SS/MCW strain compared with the rat reference sequence from Brown Norway rat. The blue innermost circumference of
Manhattan plots is the histogram of variants of the SS/Jr strain compared with the rat reference sequence from Brown Norway rat. The
histograms consist of 10 levels wherein each level represents 2,500 variants. The gray bars in between the 2 histograms (pink and blue) show
the average of the 2 densities with darker bars for higher densities. The key data with regard to SS/MCW and SS/Jr strains in this plot are the
overlaid red and blue bars over the gray bars. The density of variants is overlaid on the gray average bars with red bars for higher SS/MCW
density and blue bars for higher SS/Jr density. The range of density difference from the bottom to the top of a gray bar is minus 12,500 to plus
12,500 variants. This Circos plot was drawn and based on the requested analysis conducted by the Rat Genome Database (www.rgd.mcw.edu).
Comparisons of blood pressure (BP) readings from SS/MCW are lower than that of the SS/Jr rats (see FIGURE 2B). Thus this genetic
difference could be one of the reasons for this observed relatively lower BP reported for the SS/MCW strain compared with the BP of the SS/Jr
strain. B: radiotelemetry measurements of systolic BP of male SS/Mcw and SS/Jr rats. Studies were conducted as per IACUC approved
protocols at the University of Toledo. Rats were weaned at 28–30 days of age and fed a low-salt (0.3% NaCl) Harlan Teklad diet. At 40–42 days
of age, all rats were placed on a 2% NaCl diet and maintained on this diet for 24 days. While on the high-salt diet, rats were surgically implanted
with C40 BP radiotelemetry transmitters. Their BP was monitored on day 25 post the high-salt diet regimen by radiotelemetry. The average
systolic BP data plotted in this graph were collected from 4 independent BP studies for SS/MCW (total n  30) rats and 3 independent BP
studies from SS/Jr rats (total n  21). Data points are 4-h moving averages  SE. The straight lines through the BP data are trend lines.
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renal function, high salt fed congenic animals carrying the
SHR T variant of Spp2 demonstrated a significantly lower
bone mass and altered bone microarchitecture. In addition
to Spp2, the mapped congenic segment contains two other
genes, Arl4c and Trpm8, but neither of these genes had any
nonsynonymous variants (268). The deduced inferences
from the current observations on the candidacy of Spp2 are
nevertheless translationally interesting because a GWAS
study reports an association to systolic BP responses to cold
pressor test (34, 243) and salt-sensitivity (243) on human
chromosome 2q37 to a region close to SPP2 and TRPM8.
An interesting feature to note is that the BP QTL containing
Spp2 is mapped between a relatively salt-insensitive hyper-
tensive rat, the SHR, and a salt-sensitive hypertensive
strain, the S rat. To formally test these genes, further map-
ping and application of targeted gene-edited models will be
required. If indeed Spp2 presents as a valid BP QTL, target-
ing this gene will require caution as the protective allele for
BP has adverse effects on bone mass.
C. Adducin
A linkage analysis using an F2 population of Milan hyper-
tensive and normotensive rats detected a BP QTL on rat
chromosome 14 including the gene Adducin 1 (Add1)
(398). Adducin is a heterodimer of - and -subunits that
functions to promote the assembly of actin with spectrin.
Milan hypertensive and normotensive rats harbor polymor-
phisms at the -adducing locus wherein an A to T polymor-
phism results in a Y316F substitution and at the -adducin
locus wherein a G to A polymorphism results in a R529Q
amino acid substitution in the Milan normotensive strain.
These polymorphisms cosegregate with a significant incre-
ment in BP of the Milan hypertensive strain (16). Congenic
strain analyses (FIGURE 1, RNO14) as well as human asso-
ciations (14, 360) have confirmed that adducin is an impor-
tant gene implicated in BP regulation. To assess mecha-
nisms, renal function was studied. Polymorphisms of addu-
cin affect the development of glomerular lesions by
modulating the expression of podocyte proteins (90). In
humans, three polymorphisms within the ADD genes
[ADD1 (Gly460Trp-rs4961), ADD2 (C1797T-rs4984),
and ADD3 (IVS11386AG-rs3731566)] are reported to
influence brachial arterial diameter, distensibility, and com-
pliance (331). Physiological interaction between the ADD1
and WNK1-NEDD4L pathways influences the effects of
variants in all of these genes on BP and renal sodium han-
dling (234). There was also a strong correlation between
endogenous ouabain levels, renal sodium handling in hy-
pertension, and -adducin polymorphisms (232, 235).
Also, adducin polymorphisms in both rats and humans are
demonstrated to affect renal cellular endocytosis and Na/K
pump activity (359).Much research was since conducted by
the Bianchi group (81) that has resulted in clinical trial for
rostafuroxin, a selective inhibitor of Src-SH2 interaction
with mutant adducin for sodium handling in hypertensives
(347). Unfortunately, the results were not encouraging as
rostafuroxin did not reduce BP at any dose (347). Polygenic
nature of hypertension is perhaps not permissive enough for
a single gene effect to be promising. A personalized thera-
peutic approach is proposed for future approaches to re-
sults from single candidate gene analysis for hypertension
(233).
VIII. PRIORITIZING CANDIDATE GENES
BASED ON HUMAN GENOME-WIDE
ASSOCIATION STUDIES
Technological advancements in targeted gene-editing ap-
proaches in model organisms were not only useful to vali-
date fine-mapped rat BP loci, but were also favored as an
approach to validate genes that were prioritized through
genome-wide association studies (GWAS) in humans.
GWAS, wherein SNPs associated with disease are detected
on a genome-wide scale, are different from linkage studies
in that inheritance is not a consideration, because associa-
tions are reported among unrelated individuals. Neverthe-
less, GWAS came into prominence as the next step after the
human genome sequence was deciphered. The first genome-
wide association study for hypertension was reported in
2007 by the Wellcome Trust Case Control Consortium
(WTCCC) (380). The study included 2,000 cases of es-
sential hypertensives and 3,000 controls, which, at that
time, represented the single largest human association study
for hypertension. Surprisingly, no major association was
detected with any SNP for hypertension. However, six sin-
gle-nucleotide polymorphisms (SNPs) were reported as be-
ing associated with hypertension with marginal significance
(380). Comparative mapping revealed that the homologous
locations of four out of these six human SNPs (rs2820037,
rs6997709, rs11110912, and rs2398162 on human chro-
mosomes 1q43, 8q24, 12q23, and 15q26) map within re-
gions of the rat genome identified as BP quantitative trait
loci (QTL) on rat chromosomes 17, 7, 7, and 1, respectively
(101). It is also interesting that among the many strain
comparisons that were used for mapping BP QTLs, all four
regions are reported as BP QTL containing regions origi-
nally identified from a single linkage analysis between the
hypertensive Dahl Salt-sensitive (S) rat and the Lewis
(LEW) rat (101).
A. Nuclear Receptor 2, Factor 2 (Nr2f2)
The human 15q26 region containing the gene NR2F2 was
tabulated in the supplementary data section of the first hu-
man GWAS conducted for hypertension, the WTCCC
study (380). The homologous rat chromosome 1 region
containing Nr2f2 was identified as a BP QTL within a 13
Mb region (169, 319) (FIGURE 1, RNO1 and TABLE 2),
whereby Nr2f2 was also a positional candidate locus
(one of many genes within the region) for BP control. The
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candidacy of NR2F2 in human hypertension was further
corroborated in humans through a haplotypic analysis of
the WTCCC data (26). All these different studies in both
humans and rats collectively pointed to Nr2f2 as a plau-
sible BP QTL, but fell short of providing conclusive evi-
dence. The targeted gene-editing approach was applied
to address the question of whether disruption of Nr2f2
impacts BP of the S rat (206). A ZFN-based Nr2f2 mu-
tant rat generated for this purpose had a 5-amino acid
deletion (	 amino acid residues159–163) in the hinge
region of the Nr2f2 protein. BP of the Nr2f2 mutant rats
were significantly lower than that of the S rats. An en-
hanced binding of the mutant Nr2f2 with the transcrip-
tion factor Friend of GATA 2 (Fog2) was noted. Further-
more, by chromatin immunoprecipitation, an enhanced
binding of the mutant form of Nr2f2 to the promotor of
atrial natriuretic factor (Anf) was observed. Anf is a direct
target gene influenced by the Nr2f2-Fog2 interaction (157)
and a vasorelaxant (183, 203). Mesenteric arteries from
Nr2f2 mutant rats relaxed better than the S rats. Conclu-
sions from this study were that the extent of BP is inversely
linked to the extent of interaction between Nr2f2 and Fog2
through the hinge region of Nr2f2 and through this inter-
action, transcription of Anf, is regulated.
B. Pleckstrin Homology Domain Containing
Family A Member 7 (Plekha7)
Five independent GWAS in multiple populations associated
the human SNP rs381815 in intron 1 of Pleckha7 with
systolic BP (93, 144, 145, 213, 220). To test this associa-
tion, the rat Plekha7 gene was mutated by applying the
ZFN approach in the SS/MCW rat (85). Plekha7 mutant S
rats had blunted hypertension and renal disease, which the
authors attribute to improvements in vascular function be-
cause in vitro assays revealed enhanced endothelium-de-
pendent and flow-mediated dilation in the mutant vessels
compared with wild-type (WT) controls, which was associ-
ated with augmented intracellular calcium release in endo-
thelial cells and an increased bioavailability of the vasodi-
lator nitric oxide. Plekha7 encodes an adherens 84 junction
protein (295) and is a cytoplasmic protein reported to sta-
bilize cadherins and nectins at adhesion junctions (124,
193, 195, 279, 332). More recently, PLEKHA7 is reported
to regulate cellular behavior via miRNAs by associating
with the microprocessor complex at the apical zonula ad-
herens (193, 194). Through a proteomic approach, proteins
associating with PLEKHA7 were identified to be cytoskel-
etal-related and RNA-binding proteins. Loss of PLEKHA7
activates the actin regulator cofilin by regulating the levels
and associating with PP1alpha, a phosphatase responsible
for cofilin activation (193, 194). Interestingly, cofilin1 is
involved in hypertension-induced renal damage (370).
Therefore, it is possible that Plekha7 affects hypertension-
induced renal function in addition to the alterations in vas-
cular function detailed in the Plekha7mutant SS/MCW rat.
C. Cd247
CD247 encodes the zeta chain of the T-cell receptor. T cells
are increasingly being recognized as important in the etiol-
ogy of salt-sensitive hypertension (60, 134, 366, 386). A
large genome-wide human linkage analysis in the GenNet
Network of the Family Blood Pressure Program (FBPP)
identified a highly significant linkage peak on human chro-
mosome 1q spanning a 100 cM region (354). By genotying
1,569 SNPs within this linkage peak in 2,379 individuals,
associations were found for both systolic and diastolic BP in
or near 2 genes, GPA33 and CD247. In CD247, a single-
nucleotide polymorphism variant in intron 1 is associated
with diastolic and systolic BP in hypertensive black and
European American subjects (82). Given these associations,
Cd247 was tested as a candidate gene for hypertension
through ZFN-mediated deletion of Cd247 in the SS/MCW
rat (316). These mutant Cd247 rats had no functional T
cells and demonstrated significantly lower hypertension, re-
nal disease, and lower infiltration of T cells in to the kidneys
in response to dietary high salt (316). Thus authors con-
clude that Cd247 is an important link between T cell biol-
ogy and development of hypertension and renal disease
(316).
D. Sh2b3
SH2B adaptor protein 3 also known as lymphocyte-specific
adapter protein Lnk is a gene nominated as a candidate gene
by GWAS of hypertension and renal disease (21, 150, 151,
213). Sh2b3 is an intracellular adaptor protein expressed in
hematopoietic and endothelial cells. To test the contribu-
tion of Sh2b3 to hypertension in the Dahl SS/MCW rat, a
ZFNmutant rat with a 6-bp deletion in the Sh2b3 gene was
generated (317, 408). As a result, the native proline-leucine-
glutamic acid sequence is replaced with a single glutamine
in the Sh2b3em1Mcwi mutant rat, resulting in modification
of the phosphotyrosine-peptide binding pocket of the
SH2 domain. BP of the Sh2b3 mutant Dahl SS/MCW rat
was attenuated. Associated with the lowering of BP was
reduced renal damage and blunted infiltration of immune
cells into the kidney (317). Transplanting bone marrow
from Sh2b3em1Mcwi mutants to Dahl SS/MCW rats fed a
high (2% NaCl) salt diet resulted in a significant decrease
in mean arterial pressure and kidney injury (317). Al-
though not proven to be an inherited factor for suscepti-
bility to develop hypertension, studies in Sh2b3/ mice
also confirm these functions of Sh2b3, whereby Sh2b3 is
recognized as a key gene implicated in the development of
hypertension (58).
E. GWAS-Nominated Agtrap-Plod1 Locus
GWAS not only detect single gene associations, but also
present with associations to multiple SNPs clustered by
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proximity within multiple genes in linkage disequilibrium,
thus depriving clarity on which of the closely linked genes
are likely to be significant determinants of BP. An example
of this in the case of a GWAS for BP in a genomic region on
human chromosome 1:11,736,084–11947845bp, contain-
ing six genes, Agtrap, Mthfr, Clcn6, Nppa, Nppb, and
Plod1, reported in 11 human studies (35, 98, 165, 171, 179,
213, 221, 264, 265, 357, 403). To overcome this limitation
of GWAS and to determine the relative contributions of
each of these genes to BP regulation, ZFN-based mutant
rats were individually constructed and characterized on the
Dahl S background (92). The results demonstrated that five
of the six genes influence BP and/or renal function (92),
indicating that multiple genes within a short genomic seg-
ment can individually modulate BP.
IX. HAS RAT GENETICS ADVANCED THE
SEARCH FOR INHERITANCE OF
HYPERTENSION IN HUMANS?
Taking a broad perspective, it is well to recognize that the
fact that rats can be bred for hypertension and for suscep-
tibility to salt-induced hypertension is a profound statement
of what phenomena are also likely in human hypertension.
While this is easily demonstrated in rats because of the
freedom to breed and change the environment for the life of
the rat, similar manipulation in humans is impossible. And
of course the genetic and salt susceptibility data available
from humans are compatible with what is unequivocal in
rats. At the time the initial work in rats was done, such
results were far from given.
This article began with documenting the quest for inherited
factors for the development of hypertension and then cata-
loged a large number of BP QTLs on almost every chromo-
some of the rat. These BP QTLs have yielded only a handful
of genes that have varied tiers of experimental proof to
suggest that inheritance of allelic forms of these protein-
coding genes impact BP. In other words, these genes are
putative BP quantitative trait genes in rats and perhaps in
humans as well. The number of loci mentioned above is
relatively small and by nomeans representative of the entire
blueprint of the genetic/inherited factors responsible for BP
regulation. What are we missing? Observations made dur-
ing the course of the mapping studies that are beyond the
discovery of SNPs within protein-coding genes are worth
noting as they support the reasoning that much remains to
be discovered. These observations are listed below.
1. The numbers of BP QTLs identified in either rats or
humans far exceeds the number of causative genes
identified in these QTLs to date (listed in TABLE 1).
2. Variants within protein-coding genes are not the sole
variants present within positionally mapped BP
QTLs. There are a larger number of variants within
any mapped segment that are outside of protein-cod-
ing genes or other annotations. These may have un-
known effects.
3. Further mapping of BP QTLs that were originally
identified as single LOD peaks have demonstrated
that underneath each of these single LOD peaks is a
cluster of independently operating BP QTLs.
4. Many BP QTLs have also been detected which do not
operate independently, but require allelic interactions
with other QTLs to impart a change in BP. These
observations are mainly in rat genetic studies and pro-
vide important clues to the genomic architecture gov-
erning the pathophysiology of hypertension in hu-
mans. They suggest that inheritance of the level of BP
of an individual attributed to major effects of a small
number of genes is perhaps a gross underestimation.
5. Ideally the discovery of new genetic inputs to BP con-
trol in the rat would lead to new therapies for hyper-
tension in humans. The fact that the work on Adducin
did not result in a successful treatment for hyperten-
sion (347) does not abrogate the desirability for fur-
ther work to truly understand the complex genetics of
hypertension. In addition, if the same result turns out
to be true for all the genes found to be causative for
hypertension in the rat on a very permissive (artifi-
cially constructed by selective breeding) genetic back-
ground, then we need to know that therapeutic target-
ing of singe genes on a nonpermissive outbred genetic
background is an unworkable approach. If that turns
out to be true for the genes found using the rat models,
then the same situation is likely to be true for any
causative genes for hypertension discovered byGWAS
in humans.
X. EPISTASIS OF BP QTLs
Epistasis or gene-gene interactions occur when the effect of
alleles at one locus depends on the alleles at another locus.
In the context of BP studied in rats, such interactions can be
discovered in segregating populations by comparing the ef-
fect on BP of genotypes at one marker versus the effect on
BP of genotypes at another marker. This is done by a two-
way factorial analysis of variance and finding a significant
interaction term.Note that in an F2 population this analysis
will include all three possible genotypes at each marker.
In working with congenic strains for BP QTL on the back-
ground of a given strain, epistasis can be defined as the
nonadditive effect (positive or negative) when combining
two congenic strains into a new double congenic strain. In
this case it is important to appreciate that only homozygous
genotypes are being compared at the two QTLs involved.
The BP of four strains (the background strain, two congenic
strains, and the double congenic strain) is required. The
analysis of BP again involves a two-way factorial analysis of
variance on the genotypes at the QTLs being tested (306).
Epistasis is present if this analysis yields a significant inter-
action term.
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One of the early reports of such an epistasis between two BP
QTLs was weak statistical evidence for epistasis between
two BP QTLs on rat chromosomes 2 and 10 (69). Subse-
quently, separate congenic strains were constructed on the S
background for the appropriate regions of Chr 2 (D2Mit5-
D2Mit8) or 10 (D10Mco1-D10Mco6) introgressed from a
normotensive strain (66, 73). Evidence for individual effects
of these two segments was obtained by the observation that
each congenic strain had lower BP than the S rats. However,
when a double congenic strain was constructed containing
low BP QTL alleles from both chromosomes 2 and 10 and
tested for BP, the sum effect of the two regions was smaller
than the additive effects of decreasing BP relative to S. This
provided definitive evidence for a strong epistatic interac-
tion on BP of the QTL on chromosomes 2 and 10. At that
time, this was the only documentation of an interaction on
a quantitative trait in a mammalian system (306). Unfortu-
nately, the identities of the two genes in epistasis remain
unknown as there are no further reports of mapping of the
QTLs involved. Epistasis has been reported for a number of
other BP QTLs (29–31, 33, 39, 63, 77, 187, 253, 277, 284,
326, 355). Furthermore, a theoretical modeling study of
epistasis of BP QTLs through analysis of data obtained by
substitution mapping using congenic rats is reported by
Rapp (299). In the case of human hypertension, detections
of epistatic relationships are largely limited with the current
approach of querying for individual loci that are associated
with BP.
In working with Dahl rats in particular, the usual practice is
to make congenic strains introgressing QTL segments of
chromosome from the normotensive strain into the S-rat
genetic background. There is a good reason for this. It is
simply that in early work the S-rat genetic background was
found to be permissive for finding genetic effects but the
R-rat genetic background was not (40, 41, 310). The same
is true for the LEW rat background. In this case the LEW
background has been studied extensively using congenic
strains, by introgressing S rat QTL chromosomal segments
(associated with increasing BP) on the LEW background.
No or minimal effects on BP were observed (30, 51, 52)
even when multiple S rat QTL chromosomal segments were
introgressed into the same congenic strain (52). Additional
work suggests that a segment on rat chromosome 18may be
important in maintaining low BP in the LEW rat (52). The
result of this is that one should not expect the relatively
large observable effects of introgressed chromosomal seg-
ments on the S genetic background to translate into effects
on other genetic backgrounds. Such a profound influence of
genetic background is presumably due to epistatic effects.
An attempt has been made to place interacting pairs of
QTLs into two “epistatic modules” wherein pairs of QTLs
within a module show epistatic effects but pairs of QTLs
from different modules show only additive effects (32).
Whether such modules are actually a valid concept has been
questioned on the basis of biased sampling and lack of a
statistical analysis to establish their existence (307). Such
objections could be overcome by the systematic collection
of further data, but for now the concept, albeit interesting,
remains to be adequately supported.
There are some interesting effects of epistasis on dominance
in comparing Dahl S rats to LEW rats. An F1 cross between
S and LEW has a BP equal to LEW (52), that is, the LEW
phenotype is dominant. Interestingly, the LEW alleles at 9
out of 10 BP QTL when studied individually on the S back-
ground were dominant to the S alleles (74). This strong
dominance is lost in an F2 population derived from S and
LEW (101), suggesting that dominance of LEWQTL alleles
is highly dependent on genetic background.
When repeated backcrosses of LEWwere made to S, it took
three backcrosses (after making the initial F1 cross) for the
BP of the backcross population to increase only modestly
(52), and it was still well below that of S rats. After back-
cross 3, the population would be expected to have only
6.25% of LEW alleles. This again demonstrates the power-
ful effect of the LEW background to lower BP. This is sur-
prising because the inbred LEW rats used were never selec-
tively bred for low BP.
The focus on genetic interactions between pairs of QTL is
an oversimplification because: 1) a given gene may interact
pairwise with several other genes; and 2) higher order inter-
actions exist (128, 353) but have not been addressed in
hypertensive rats. A study on higher order QTL interactions
involving insulin-like growth factor-1 in mice (128) is espe-
cially interesting because the three-locus and four-locus in-
teractions were considerably larger than the component
two-locus interactions. One can speculate that S rats might
accumulate QTL alleles leading to higher-order interactions
increasing BP during selective breeding while the LEW rat
would not accumulate (by chance) QTL alleles leading to
higher-order interactions decreasing BP because inbred
LEW rats were never selectively bred for BP. Thus substitu-
tion of a LEW allele on the S background at a QTL that was
part of a haplotype creating a higher-order interaction
would be expected to disrupt the higher-order interaction
and show a disproportionately large effect. In contrast, the
reciprocal substitution of an S allele on the LEW back-
ground at one of the QTLs in such a complex would not
disrupt a higher order interaction that did not exist and
would, therefore, be expected to have a lesser effect.
It is anticipated that the genes underlying BP QTL exist in
metabolic pathways which eventually impinge on BP and
that any given pair is either in series or in parallel. A model
for pairwise QTL interactions using congenic strains has
been constructed assuming the QTL act like switches that
can be either on or off (299). The switches themselves are
not imaginary, but are based on the basic biochemical con-
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struct of binding curves between twomolecules of any type.
The binding curves (and therefore the switches) have allelic
and metabolic inputs.
FIGURE 3 gives actual data from the literature showing epi-
static patterns. It is often convenient in this work to express
the effect of a congenic strain as the deviation from the S
strain. Thus S rat BP is always at zero, and if a congenic
strain decreases (or increases) BP compared with S, the de-
viation is negative (or positive). This convention is used in
FIGURE 3, but the reader is advised that sometimes the dou-
ble congenic is used as a baseline in the literature. This
results in a purely technical artifact causing what looks like
positive epistasis in one frame of reference to look like neg-
ative epistasis in the other, and vice versa (299).
The data in FIGURE 3A (284) are identical to the pattern
predicted if two QTL switches are in parallel, and in both
congenic strains the S allelic switch (an on switch) is re-
placed by a LEW allelic switch (an off switch). The data in
FIGURE 3B (32) are identical to the pattern predicted if two
QTL switches are in series, and in both congenic strains the
S allelic switch (an on switch) is replaced by a LEW allelic
switch (an off switch). Other more common patterns can be
simulated by assigning leak properties to the switches under
certain logical constraints, but such patterns do not always
result in a unique solution as to the relative position of the
QTL in metabolic pathways, possibly because most of the
QTL involved are not due to a single genetic factor. The point
is, however, that the epistatic patterns vary and contain infor-
mation that can be extracted (299).
Note in FIGURE 3A that the congenic strains are both on the
same chromosome (chromosome 5) and that individually
they would be undetectable. The complex was of course
found when a QTL on chromosome 5 was dissected by
construction of nested congenic substrains from either end
of the original congenic segment, resulting in the finding
that the effect of the original QTL disappeared when its
components were separated (107). The structure and its
epistatic effect have been confirmed and the location of the
components better defined with the component QTL sepa-
rated by ~2 Mb (284). If two such subcomponents, each
without a BP effect of its own, were on different chromo-
somes, they could only be discovered by testing genetic
markers for interactions throughout the genome in a segre-
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FIGURE 3. Epistatis in rat models. The data in A are re-
drawn from Pillai et al. (284), and the data in B are redrawn
from Figure 1D of Chauvet et al. (39). In each panel BP is
given for two congenic strains each for a different QTL and
for a double congenic strain which has the introgressed
chromosomal segments from both of the original congenic
strains. All congenic strains are on the Dahl S genetic back-
ground. BP of each congenic strain is expressed as a
deviation from Dahl S rats which is defined as the zero
point. Blue arrows on the right of the figures show the
effect expected if the two QTL effects were additive, and
the red arrows show the difference between expected and
observed. In both panels the epistatic effects were re-
ported to be significant (P  0.05). The pattern in A is
compatible with two QTL in parallel metabolic pathways,
and the pattern in B is compatible with two QTL in series
in the same metabolic pathway (299).
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gating population. As an aside, the merits of dissecting QTL
using nested or contiguous congenic strains has been dis-
cussed (308).
Another property of the QTL switches is that one of the
inputs is the concentration of one of the ligands, and this of
course can vary. This lends itself to inputs subject to meta-
bolic changes induced by environmental challenges or, for
example, by sex hormones. The quintessential environmen-
tal factor is of course dietary sodium chloride and the
changes it induces in the renin-angiotensin-aldosterone sys-
tem. Dietary salt does increase rat [Na] in cerebrospinal
fluid (153). One example of a salt-sensitive QTL that alters
BP, heart rate, and renal sympathetic nerve activity in re-
sponse to changes in cerebrospinal fluid [Na] is on chro-
mosome 10 (152). Dietary salt also markedly influences the
mRNA for the strong candidate gene Pappa2 on chromo-
some 13 noted above (50). Suppression of aldosterone by
dietary salt is also necessary for the steroid changes result-
ing from the Cyp11b1 polymorphism between S and R rats
to be effective (304). Dietary factors other than salt are also
known to influence BP in the Dahl S rat (239, 240), and
sex-dependent QTL are also known in the this model (67,
138, 139).
One thing that has not been done intensively enough in
work with hypertensive rats is to look systematically for
two-way interactions between genetic markers throughout
the genome, similar to studies in other model organisms
(154, 229, 358), although the techniques used in some
model organisms are not always applicable to the rat.
Higher order interactions on BP in the rat also need to be
sought. In the original study of an F2 population derived
from S and LEW, several QTL interactions were found by
testing markers against each other, but this was not exten-
sive enough to uncover larger scale networks of interactions
(101). Programs for this that would be applicable to the rat
have been developed (329, 362), and one was used success-
fully in a time study of urinary albumin excretion (UAE)
using a backcross population F1(SxSHR)xS. In this study
11 pairwise interactions were observed, most of which were
age dependent (100). Viewed in the context of variable
environmental and metabolic inputs into the statistical ex-
istence and presumed associated functional importance of
QTL, the expression of QTL and interaction networks can
be viewed as somewhat ephemeral.
Most of the QTL in the Dahl S rat that have been exten-
sively dissected by substitution mapping using congenic
strains have (as predicted) turned out to be compound (con-
tain multiple loci harboring alleles with both positive, neg-
ative, and interactive effects on BP). Having dissected the
QTL into components, we now need to understand why
clusters of interacting loci influencing BP (that is, the ob-
servable QTL) in a genome scan of a segregating population
exist in the first place. It is interesting that it was relatively
easy to obtain Dahl S rats with hypertension by only several
generations of selection (56) in spite of the fact that many
genes are involved. This implies, although it seems unlikely,
that haplotypes favoring high (or low) BP in relatively few
chromosomal segments (equates to already known com-
pound QTL) should exist in the outbred Sprague-Dawley
rats from which Dahl rats were selected. Or, more likely, it
could be that compound QTL are in a sense an artifact of
the selection process, during which highly interactive alleles
for increased BP (in the case of the S rat) are assembled
relatively quickly by chromosomal crossover events into
hypertensive haplotypes where the loci involved happen to
be loosely linked. This would explain why essentially all
observable BP QTL turn out to be compound QTL. The
same perspective could be applied to compoundQTL found
in studies by crossing any selectively inbred strains for any
trait.
It hardly seems likely that an essential hypertensive human
is genetically assembled by the chance association of alleles
each with a BP effect of about1 mmHg at 25 or more loci
(as GWAS studies would lead us to contemplate) and that
this could result in a 15–20% prevalence of hypertension in
human populations. In any case it appears that we are miss-
ing some fundamental genetic phenomenon in rats and hu-
mans. That “missing something” is probably our lack of an
adequate understanding of the complex architecture of ge-
netic interactions.
Unlike in rat models, genetic background is not taken into
consideration as a critical factor in human studies, so
candidate genes in epistasis are not detected, let alone
validated in any other species. The status of human re-
search into finding loci linked or associated with hyper-
tension is captured in the following sections describing
studies conducted in humans that encompass investiga-
tions on monogenic forms of hypertension and more re-
cent queries on a genome-wide scale for individual loci
that are associated with BP.
XI. GENETIC STUDIES OF HUMAN
HYPERTENSION AND HYPOTENSION
Diseases or traits can be broadly classified as common
(complex, polygenic) or simple (Mendelian, monogenic).
Simple traits are attributed to dysfunction of a single
gene, whereas a complex interplay of genetic and envi-
ronmental factors contribute to the pathogenesis of com-
mon diseases (sometimes referred to as multifactorial in-
heritance). Genetic variants with large effect sizes mani-
fest as Mendelian or single-gene disorders, accounting
for only a small fraction of cases in the population and
manifest in infancy and early adulthood. Mendelian dis-
ease mutations are highly penetrant and under a very
strong selection, which ensures lower frequencies in pop-
ulations. Tracing patterns of genetic segregation in fam-
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FIGURE 4. Mutations altering blood pressure in humans and GWAS loci linked to plausible genes. The figure
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mutations that cause monogenic high or low blood pressure syndromes. In addition, plausible genes linked
GWAS loci are shown based on multiple lines of evidence (eQTL or nonsynonymous SNPs or genome-wide 3D
proximity maps) (374).
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Table 4. Summary of all GWAS results for BP and hypertension in different ancestries
Coded Allele Frequency BP Effect
Locus SNP Genotype
Coded
Allele European Asian African European Asian African Nearest Gene(s)
1p36.2 rs880315 C/T C 0.35 0.59 0.16 1 1 CASZ1
1p36.22 rs17367504 A/G G 0.17 0.10 0.06 2 2 MTHFR, CLCN6, NPPA,
NPPBrs5068 C/T C 0.07 0.00 0.01 2
1p13.2 rs2932538 C/T C 0.73 0.80 0.85 2 SLC16A1, CAPZA1,
ST7L, MOV10rs17030613 A/C C 0.19 0.45 0.05 1
rs10745332 A/G A 0.74 0.81 0.77 1
1q32.1 rs2169137 C/G G 0.74 0.94 0.80 1 MDM4
1q42.2 rs2004776 A/G A 0.26 0.67 0.54 1 AGT
2p23.2 rs1275988 A/G A 0.60 0.23 0.08 2 KCNK3
2q11.2 rs7599598 A/G A 0.57 0.63 0.09 2 FER1L5
2q24.3 rs1446468 A/G A 0.53 0.47 0.96 2 FIGN
rs13002573 A/G G 0.25 0.40 0.11 2 FIGN
rs16849225 C/T C 0.75 0.59 0.94 1 FIGN
rs6749447 G/T G 0.28 0.72 0.58 1 STK39
2q32.1 rs16823124 A/G A 0.23 0.51 0.10 1 PDE1A
3p25.3 rs347591 G/T G 0.33 0.23 0.51 2 HRH1-ATG7
3p24.1 rs13082711 C/T T 0.80 0.94 0.96 2 SLC4A
rs820430 C/T T 0.64 0.40 1.00 1
3p22.1 rs9815354 A/G/T A 0.23 0.12 0.17 1 1 ULK4
rs3774372 C/T T 0.77 0.87 0.81 2
rs1717027 C/T T 0.22 0.12 0.66 1
3p21.31 rs319690 A/G A 0.51 0.75 0.41 1 MAP4
rs7651237 A/G G 0.64 0.94 0.88 1
3p21.1 rs9810888 G/T G 0.53 0.59 0.46 1 CACNA1D
3q26.1 rs16833934 A/G G 0.37 0.17 0.65 2 MIR1263
3q26.2 rs419076 G/T T 0.48 0.13 0.57 1 MECOM
4q12 rs871606 A/G A 0.87 0.78 0.76 1 1 CHIC2
4q21.21 rs16998073 A/T T 0.19 0.30 0.05 1 1 FGF5
rs1458038 A/G A 0.27 0.34 0.05 1
4q24 rs13107325 A/C/T T 0.10 0.00 0.00 2 SLC39A8
4q25 rs6825911 C/T C 0.20 0.48 0.54 1 ENPEP, PITX2
4q32.1 rs13139571 A/C C 0.74 0.68 0.88 1 GUCY1A3-GUCY1B3
5p13.3 rs1173771 C/T C 0.51 0.57 0.81 1 NPR3-C5orf23
rs7733331 C/T T 0.50 0.42 0.42 2
rs1173766 C/T C 0.52 0.59 0.62 1
5q33.3 rs11953630 A/C/T T 0.34 0.06 0.15 2 EBF1
6p22.2 rs1799945 C/G G 0.18 0.04 0.00 1 1 HFE
rs198823 G/T T 0.65 0.23 0.60 2
6p21.33 rs805303 C/T C 0.70 0.57 0.30 1 BAG1
rs2021783 C/T C 1.00 0.81 1.00 1 CYP21A2
6p21.32 rs2854275 G/T T 0.08 0.03 0.08 2 HLA-DQB1
6p21.1 rs10948071 C/T T 0.70 0.67 0.05 2 CRIP3
6q22.33 rs13209747 C/G/T T 0.45 0.48 0.12 1 1 1 RSPO3
6q25.1 rs17080102 C/G C 0.06 0.01 0.09 2 2 2 PLEKHG1
7p15.2 rs17428471 G/T T 0.08 0.05 0.14 1 1 1 EVX1-HOXA
7p12.3 rs2949837 A/T A 0.23 0.61 0.00 1 IGFBP3
7q21.2 rs2282978 C/T C 0.36 0.06 0.43 1 CDK6
Continued
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Table 4.—Continued
Coded Allele Frequency BP Effect
Locus SNP Genotype
Coded
Allele European Asian African European Asian African Nearest Gene(s)
7q22.3 rs17477177 C/T T 0.72 0.91 0.93 2 PIK3CG
rs12705390 A/G G 0.72 0.91 0.93 2
7q36.1 rs3918226 C/T T 0.10 0.00 0.00 1 NOS3
8p23.1 rs4841569 A/G G 0.57 1.00 0.89 1 BLK-GATA4
rs2898290 C/T C 0.58 0.02 0.55 NR
8q24.12 rs2071518 C/T T 0.20 0.19 0.60 1 NOV
10p12.31 rs11014166 A/T A 0.63 0.97 0.89 1 2 CACNB2
rs1813353 A/G A 0.65 0.92 0.85 1
rs4373814 C/G G 0.63 0.53 0.43 2
rs12258967 C/G C 0.64 1.00 0.73 1
10q21.2 rs1530440 C/T T 0.16 0.20 0.02 2 c10orf107
rs4590817 C/G G 0.82 1.00 0.82 1
rs12244842 G/T T 0.25 0.19 0.35 2
rs7070797 A/G A 0.15 0.00 0.00 2
10q22.2 rs4746172 C/T C 0.23 0.56 0.19 1 VCL
10q23.33 rs932764 A/G G 0.43 0.58 0.15 1 PLCE1
10q24.32 rs1004467 C/T T 0.92 0.67 0.81 1 CYP17A1-NT5C2
rs11191548 C/T T 0.92 0.72 0.99 1 1
rs12413409 A/G G 0.92 0.72 0.98 1
rs4409766 C/T T 0.93 0.78 0.82 1
rs3824755 C/G C 0.07 0.23 0.17 2
10q25.3 rs2782980 C/T T 0.27 0.15 0.44 2 ADRB1
rs7076938 C/T C 0.33 0.17 0.45 2
rs1801253 C/G G 0.32 0.15 0.41 2
11p15.5 rs661348 C/T C 0.45 0.58 0.11 1 LSP1-TNNT3
11p15.4 rs7129220 A/G G 0.89 1.00 0.95 2 ADM
11p15.1 rs381815 A/C/T T 0.30 0.25 0.18 1 PLEKHA7
rs757081 C/G G 0.63 0.66 1.00 1 PIK3C2A, NUCB2,
NCR3LG1
11p15.2 rs2014408 C/T T 0.20 0.21 0.03 1 1 1 SOX6
rs4757391 C/T C 0.18 0.17 0.23 1
11q13.1 rs4601790 A/G G 0.25 0.42 0.07 1 EHBP1L1
rs3741378 A/G A 0.15 0.38 0.36 2 RELA
11q22.1 rs633185 C/G G 0.68 0.55 0.82 2 FLJ32810-TMEM133
11q24.3 rs11222084 A/T T 0.40 0.07 0.26 1 ADAMTS8
12q13.13 rs7297416 A/C C 0.25 0.62 0.38 2 HOXC4
12q21.33 rs11105354 A/G G 0.12 0.42 0.11 2 ATP2B1
rs2681492 A/G A 0.88 0.58 0.84 1
rs2681472 C/T T 0.88 0.58 0.89 1 1
rs17249754 A/G G 0.88 0.59 0.84 1 1
12q24.12 rs3184504 C/T T 0.45 0.00 0.00 1 SH2B3
rs653178 A/G A 0.56 1.00 1.00 2
12q24.13 rs11066280 A/T T 1.00 0.75 1.00 1 RPL6-ALDH2
12q24.21 rs35444 C/T T 0.59 0.73 0.55 1 TBX5-TBX3
rs2384550 A/G A 0.37 0.09 0.34 2
rs10850411 C/T T 0.72 0.46 0.66 1
rs1991391 C/T C 0.64 0.91 0.58 1
rs11067763 A/G A 0.89 0.61 0.65 1 MED13L
Continued
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ilies have been used successfully in Mendelian diseases as
exemplified by discoveries using linkage analysis.
Susceptibility variants involved in common (complex) dis-
eases/traits, unlike monogenic traits, do not have high pen-
etrance, are not under a strong selection, and present with
lower allelic heterogeneity. Nevertheless, previous selection
can be a factor in hypertension, which is a modern disease
and could very well be an undesirable pleiotropic effect of a
preserved genotype that was perhaps optimized for fitness
in the ancient environment. Compared with populations of
European ancestry, susceptibility to develop hypertension is
higher in people of African ancestry (27). Ancestral sodium-
conserving alleles are more prevalent in people of African
origin, who also demonstrate increased rates of hyperten-
sion and sodium sensitivity (262, 379, 396). These variants
may have exerted significant adaptive phenotypic effects in
the past, for example, in the time of low salt intake, and
now under changed environmental circumstances may have
become maladaptive.
The role of genetics in human BP regulation and hyperten-
sion was established through family and twin studies which
showed a significantly higher risk of hypertension among
subjects with one or two hypertensive parents, and a greater
correlation of BP levels in monozygotic twins compared
with dizygotic twins (178, 281) (see sect. II). The distribu-
tion of BP in the population shows a normal unimodal
pattern which supports a complexmultifactorial basis of BP
regulation. GWAS are the standard methods for genetic
dissection of complex traits, which is based on the common
disease/common variant hypothesis stated as follows: “the
genetic variants underlying complex traits occur with a rel-
atively high frequency (1%), have undergone little or no
selection in earlier populations and are likely to date back to
100,000 yr ago” (216). The spectrum of genetic variants
and their target tissues that affect blood pressure regulation
are summarized in FIGURE 4.
A. Monogenic Pathways of BP Regulation
and Hypertension
Discovery of the monogenic Mendelian forms of hyper-
tension has mainly been through positional cloning using
large family pedigrees, with multiple members of the
family showing a clear inheritance pattern. Patients with
these types of disorders represent 1% of the hyperten-
sive population and are considered to have secondary
hypertension. Mutations causing monogenic hyperten-
sion are characterized by being rare with a major defect
that usually disrupts a single pathway. Despite the com-
plexity and the presence of several systems and physio-
logical pathways that control BP, the majority of mapped
monogenic hypertension syndromes are due to mutations
in genes that play key roles in renal-sodium handling
(228, 369), which have contributed enormously to our
understanding of salt and water homeostasis and blood
pressure regulation. TABLE 3 summarizes the different
forms of monogenic hypertension, their key features, and
causal genes.
Table 4.—Continued
Coded Allele Frequency BP Effect
Locus SNP Genotype
Coded
Allele European Asian African European Asian African Nearest Gene(s)
15q21.1 rs1036477 A/G G 0.10 0.42 0.61 2 FBN1
15q24.1 rs6495122 A/C A 0.38 0.78 0.78 1 CYP1A1-ULK3
rs1378942 G/T G 0.32 0.79 1.00 1
15q24.2 rs11072518 C/T T 0.34 0.42 0.44 1 COX5A
rs1133323 A/G A 0.59 0.17 0.00 2
15q26.1 rs2521501 A/T T 0.63 0.93 0.80 1 FURIN-FES
16p12.3 rs13333226 A/G G 0.18 0.05 0.38 1 UMOD
16q22.1 rs33063 A/G A 0.19 0.15 0.00 1 NFAT5
17q21.31 rs12946454 C/T T 0.71 0.62 0.80 1 PLCD3
17q21.32 rs17608766 C/T T 0.91 1.00 1.00 2 GOSR2
17q21.33 rs12940887 C/T T 0.41 0.09 0.03 1 ZNF652
rs16948048 A/G G 0.42 0.09 0.42 1
20p12.2 rs1327235 A/G G 0.52 0.48 0.53 1 JAG1
rs1887320 A/G A 0.58 0.43 0.54 1
20q13.32 rs6015450 A/G G 0.07 0.00 0.22 1 GNAS-EDN3
rs6092743 A/G A 0.06 0.00 0.06 1 C20orf174
rs12244842 G/T T 0.25 0.19 0.35 2
rs7070797 A/G A 0.15 0.00 0.00 2
BP, blood pressure; 1, increase; 2, decrease.
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B. Polygenic Pathways of BP Regulation and
Hypertension
Several GWAS have been conducted using BP as a quan-
titative trait, or by using a binary definition of hyperten-
sion. All the significant GWAS signals are summarized in
TABLE 4, and additional unpublished efforts are ongoing
to discover more common variants associated with BP
using larger and larger population samples. The first
GWAS was a case-control design from the WTCCC, pub-
lished in 2007 (380). The study examined seven common
complex diseases using 2,000 cases each and 3,000
shared controls. The study genotyped ~500,000 SNPs
using the 500 K Affymetrix SNP chip and reported a total
of 24 significant disease-SNP association signals (P 
5.0
 107). Hypertension was the only trait without any
significant association signal across the genome. Follow-
ing this a series of large collaborative GWAS (95, 160,
180, 213, 214, 227, 276, 321, 367) with increasing sam-
ple sizes and in different ancestries resulted in the discov-
ery of several common SNPs associated with BP and hy-
pertension. The largest of these was the International
Consortium for Blood Pressure genome-wide association
studies (ICBP-GWAS) which conducted a GWAS meta-
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analysis for systolic and diastolic BP in 69,899 Euro-
pean individuals, followed by validation in 132,000 in-
dividuals (160). The study identified 29 independent
SNPs at 28 loci. Although the majority of SNPs identified
by ICBP were intragenic, some loci were in gene desert
regions or in genomic regions that has no gene encoding
protein with a biological plausible effect on BP.
While most of the GWAS for BP have taken the quantitative
route studying BP as a continuous variable, two studies
analyzed hypertension as a binary trait (276, 321). These
studies identified a novel locus located in the promoter re-
gion of Uromodulin gene (UMOD), which is exclusively
expressed in the kidney and may influence BP by a novel
sodium homeostatic pathway (276) and another locus in
the promoter region of NOS3 (321) which codes for nitric
oxide synthase 3 implicated in vascular smooth muscle re-
laxation, angiogenesis, and renal tubular response to salt
loading.
GWAS for populations other than European descent
were also performed with the aim of replicating the vari-
ants identified in European populations, and also finding
new population-specific loci (95, 180, 227). The success
of replicating the previously reported loci for European
population in the other population suggests that the
physiological effects of these loci may be generalized
across populations with diverse genetic backgrounds.
Yet, identifying novel loci also suggests that populations
with different genetic background may have unique ge-
netic factors as a result of differences in allele frequencies
or population-specific factors that interact with genes to
influence BP.
In contrast to monogenic syndromes, interpreting the sig-
nals from GWAS is not straight forward. The success of
GWAS is dependent on three critical factors: 1) suffi-
ciently large sample size drawn from a population of
appropriate genetic background, 2) efficient genotyping
panel that adequately covers variation within the whole
genome, and 3) powerful statistical methods that can
reveal genuine association signals. A major drawback is
the large number of statistical tests performed in GWAS
which increases the chance of type I error. The penalty
applied for multiple testing is to use a genome-wide sig-
nificant P value threshold of 5 
 108 or lower which is
the Bonferroni-corrected alpha of 0.05 for testing a mil-
lion markers. As the design of GWAS chips are based on
whole genome coverage using linkage disequilibrium,
most of the significant SNPs reported by GWAS of all
traits lie within noncoding regions. These SNPs are not
the causal variant for the trait studied, but are likely to be
in linkage disequilibrium with the causal variant nearby.
While this approach has been extremely fruitful in dis-
covering novel loci, several challenges exist in the inter-
pretation of GWAS findings. For each SNP mapped by
GWAS, it is likely that within 100,000 bases of the
locus, there exists a causal gene. The biggest challenge of
GWAS is not the discovery of significant trait associated
SNPs, but the need to understand for each GWAS SNP: 1)
the causal variant, 2) the causal gene, 3) the mechanism
by which the variant affects the gene function, and 4) the
mechanism by which the gene function affects the phe-
notype. However, as most of the GWAS signals occur in
the noncoding regions of the genome, they require com-
plementary mechanistic studies to delineate the physio-
logical mechanisms underlying their genetic association
with BP. Around 85–90% of GWAS hits tag noncoding
variants only and identifying causal regulatory variants
and target gene require a combination of genetic fine
mapping, epigenomic profiling, individual reporter as-
says, expression quantitative trait loci (eQTL) studies in
appropriate tissues, or creating isogenic cellular models
[e.g., via genome editing (80)]. The putative gene thus
identified is then modulated in vitro in primary cell cul-
FIGURE 5. Chromosome 1-4: genetic landscape of monogenic and polygenic blood pressure/hypertension syndromes, causal genes, GWAS
loci, and information used to prioritize functional genes and variants tagged by the GWAS SNPs (154). The Circos plot tracks from outside inward
are as follows: 1) chromosome ideogram; 2) location and ID of GWAS SNPs for BP and hypertension; 3) CpG islands: epigenetic markers such
as methylation sites can mark transcriptional activity; 4) DNAse I hypersensitivity sites are open chromatin sites and GWAS variants located in
these sites have been shown to control distant genes; 5) genes underlying GWAS SNPs or monogenic BP syndromes: genes in red are
monogenic BP genes, while genes in blue are plausible candidate genes that may be causal for the GWAS SNP. For each SNP mapped by GWAS,
it is likely that within 100,000 bases of the locus, there exists a causal gene. This track just highlights a fraction of the genes present within
the selected genetic loci that are most plausible candidates for BP, and the innermost track depicts all the genes that are present within each
genetic loci from which the plausible candidates are selected. 6) Regulatory polymorphisms from ORegAnno (Open Regulatory Annotation):
location of regulatory regions, transcription factor binding sites, RNA binding sites, regulatory variants, haplotypes, and other regulatory
elements from the Open Regulatory Annotation; 7) structural variation (deletion  red, insertion  blue, duplication  yellow): location of
structural variation where low frequency and rare variants with intermediate to large effect sizes may lie and require further targeted sequencing
studies; 8) multiple alignments of 100 vertebrate species and measurements of evolutionary conservation: highly conserved sites indicating
possibly functional sites depicted by size and color intensity of the filled squares; 9) monogenic BP syndromes and GWAS traits for the SNPs and
monogenic genes in the outer 2 tracks; 10) GTEX expression data of genes within the selected chromosomal segments: adipose, adrenal, aorta,
artery, brain, left ventricle, kidney cortex, liver, muscle, and blood; 11) genes within the chromosome segment. The loops on the top of the
ideograms are representation of eQTL locations of GWAS SNPs. Expression quantitative trait loci (eQTL) mapping is performed to find statistical
association between a genetic variant and the transcript level of a gene considered as a quantitative trait. eQTL studies can be used as a general
method to help identify a set of target genes as many SNPs associated with GWAS traits were shown to be eQTLs.
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ture or in vivo in animal models to identify its role in
determining the original phenotype (259).
The success of GWAS in identifying a multitude of robust
signals for BP is summarized in TABLE 4 and illustrated in
FIGURES 5–8, which present all the GWAS signals for BP
and hypertension along with details of genomic features
near the GWAS SNPS including proximate genes that
may help identify the causal variant tagged by the GWAS
SNP.
C. Specific Genetic Pathways of BP
Regulation and Dysregulation
We now describe the genetic pathways the perturb BP reg-
ulation that manifest as clinical syndromes associated with
high or low blood pressure in humans. While the majority
of the pathways are rare monogenic syndromes (TABLE 3),
we also describe a novel pathway for BP regulation identi-
fied through GWAS.
FIGURE 6. Chromosome 5-8: genetic landscape of monogenic and polygenic blood pressure/hypertension
syndromes, causal genes, GWAS loci, and information used to prioritize functional genes and variants tagged
by the GWAS SNPs (154). See legend to Figure 5 for Circos plot track details.
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1. Glucocorticoid-remediable aldosteronism or
familial hyperaldosteronism type 1
This is a rare autosomal dominant disorder characterized by
early-onset hypertension, hyperaldosteronism, variable hypo-
kalemia, low plasma renin activity (PRA), and abnormal pro-
duction of 18-oxocortisol and 18-hydroxycortisol. This is at-
tributed to a chimeric gene caused by the fusion of the 5=
regulatory sequences of 11-hydroxylase [CYP11B1; which
confers adrenocorticotropic hormone (ACTH) responsive-
ness] with the distal coding sequences of aldosterone synthase
(CYP11B2). This leads to ACTH becoming the main control-
ler of aldosterone secretion, rather than angiotensin II or po-
tassium (218). Low-dose glucocorticoids to suppress ACTH
secretion, or amiloride to directly block the epithelial sodium
channel (ENaC), or spironolactone to block binding of aldo-
sterone to the mineralocorticoid receptor (MCR) are the spe-
cific treatment options for hypertension in these individuals.
FIGURE 7. Chromosome 10-12: genetic landscape of monogenic and polygenic blood pressure/hyperten-
sion syndromes, causal genes, GWAS loci, and information used to prioritize functional genes and variants
tagged by the GWAS SNPs (154). See legend to Figure 5 for Circos plot track details.
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2. Apparent mineralocorticoid excess
Hypertension due to apparent mineralocorticoid excess
(AME) ensues due to the absence or reduced activity of
11-hydroxysteroid dehydrogenase (HSD11B2), an en-
zyme which metabolizes cortisol to prevent its binding to
the mineralocorticoid receptor. Reduced activity of
HSD11B2 results in cortisol to not be metabolized but acts
as if it were a potent mineralocorticoid (28). Patients diag-
nosed with AME syndrome respond well to low-sodium
diet and are treated with spironolactone, which blocks
binding of both cortisol and aldosterone to mineralocorti-
coid receptors.
3. Pseudohypoaldosteronism type II (Gordon’s
syndrome)
This is a form of hypertension associated with hyperkale-
mia, non-anion gap metabolic acidosis, and increased salt
reabsorption by the kidney. The WNK (with-no-lysine [K])
FIGURE 8. Chromosome 15-X: genetic landscape of monogenic and polygenic blood pressure/hypertension
syndromes, causal genes, GWAS loci, and information used to prioritize functional genes and variants tagged
by the GWAS SNPs (154). See legend to Figure 5 for Circos plot track details.
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kinases play central roles in regulating mammalian BP by
initiating a signaling pathway that controls the activity of
critical ion cotransporters in the kidney NCC (Na/Cl ion
cotransporter) and NKCC2 (Na/K/2Cl cotransporter
2). Gordon’s syndrome is caused by mutations in WNK1,
WNK4, Kelch-like 3 (KLHL3), and Cullin 3 (CUL3) genes.
CUL3 and KLHL3 mutations putatively inhibit the ubiqui-
tylation of WNK4, and probably other WNK isoforms,
resulting in the the overactivation of NCC/NKCC2 ion
cotransporters, and consequently, increased salt retention
and hypertension (22, 384). Treatment consists of either a
low-salt diet or thiazide diuretics, aimed at decreasing chlo-
ride intake and blocking Na-Cl- cotransporter activity,
respectively.
4. Liddle’s syndrome
Liddle’s syndrome is an autosomal dominant condition
presenting with hypertension and aldosterone excess, but
associated with low renin and aldosterone levels. It is
caused by mutations in the genes coding the - or -sub-
units of ENaC, SCNN1B and SCNN1G. The mutations
result in deletions of proline-rich regions of the protein
products of these ENaC subunits, which are essential for
binding of Nedd4–2 (NEDD4L), a regulatory repressor
that promotes ENaC channel degradation (336). In-
creased rates of sodium reabsorption, volume expansion,
and hypertension result due to lack of binding activity of
- and -subunits to Nedd4, which results in constitutive
expression of sodium channels and prolongation of the
half-life of ENaCs at the renal distal tubule apical cell
surface. Patients with Liddle’s syndrome are treated with
amiloride or triamterene to lower BP and correct acidosis
and hypokalemia.
5. Bartter’s syndrome
This is a salt-losing condition characterized by hypokalemic
metabolic alkalosis and normal or low BP with increased
renin activity and high aldosterone levels. The defective
mechanism is located in the thick ascending limb (TAL)
of Henle’s loop and comprises loss of function of NKCC2
or a group of other proteins which lead to secondary loss
of function of NKCC2-ROMK channel, chloride channel
Kb (ClC-Kb), Bartin, and calcium sensing receptor
(CaSR) (341). Increased urine levels of prostaglandin E2
(PGE2) and diminished susceptibility to the pressor effect
of ANG II and norepinephrine are features of Bartter’s
syndrome. Patients with Bartter’s syndrome are more
prone to volume depletion, diarrhea, spasm, fever, and
dangerous hypokalemia, which are life-threatening com-
plications, especially during the postnatal period.
Chronic treatment of underlying abnormalities of Bart-
ter’s syndrome including features to treat increased pros-
taglandin synthesis and RAAS activity, which aggravate
electrolyte and acid base disturbances, are potassium
supplementation and use of cyclooxygenase inhibitors,
angiotensin converting enzyme (ACE)-inhibitors, and
potassium sparing diuretics.
6. Gitelman’s syndrome
In Gitelman’s syndrome, the defective mechanism is lo-
cated in the distal convoluted tubule and comprises loss
of function of the sodium-chloride cotransporter (NCC)
(342) and is characterized by hypokalemic metabolic al-
kalosis along with significant hypomagnesemia, low uri-
nary calcium excretion, and low blood pressure. The
prevalence of Gitelman’s syndrome is very low, estimated
to be 1:40,000 in the general population and the preva-
lence of heterozygotes in the Caucasian population is
~1%. Chronic treatment of patients with Gitelman’s syn-
drome comprises maintaining effective extracellular vol-
ume with adequate salt and water consumption along
with oral potassium and magnesium supplementation.
Indomethacin, amiloride, and eplerenone are also used to
treat hypokalemia.
7. Primary aldosteronism
Individuals with primary aldosteronism constitutively pro-
duce aldosterone from the adrenal gland, resulting in hy-
pertension with variable hypokalemia and a suppressed
circulating renin. A gain-of-function somatic mutation in
a K channel, KCNJ5, which results in membrane depo-
larization and enhanced aldosterone production, is a
common genetic defect noted for ~40% of aldosterone
producing adenomas. Mutations in three other genes,
encoding the 1-subunit of Na-K-ATPase itself; and
ATP2B3, a plasma membrane Ca2-ATPase 3 homolo-
gous to the sarcoplasmic endoplasmic reticulum Ca2-
ATPases (SERCA); and CACNA1D, encoding an L-type
Ca2 channel CaV1.3, are observed in ~7% of the cases
(399). Whereas APAs in adrenal zona glomerulosa cells
harbor gain-of-function mutations in genes important
for the regulation of Na and Ca2, ATP1A1, and
CACNA1D, respectively, KCNJ5 mutations are common
in APAs resembling cortisol-secreting cells of the adrenal
zona fasciculata (25). Adrenalectomy of the affected ad-
renal gland in APAs cures or ameliorates hypertension in
the majority of patients.
8. Phaeochromocytomas and paragangliomas
Rare neuroendocrine tumors of the adrenal glands and
the sympathetic and parasympathetic paraganglia are
called phaeochromocytomas and paragangliomas, re-
spectively. RET pro-to-oncogene mutations cause auto-
somal dominantly inherited phaeochromocytomas.
Other susceptibility genes include genes that encode suc-
cinate dehydrogenase subunits A, B, C, and D (SDHA,
SDHB, SDHC, and SDHD, respectively) with heterozy-
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gous germline mutations of SDHB, SDHC, and SDHD
causing familial pheochromocytoma-paraganglioma syndromes
known, respectively, as paraganglioma 4, paraganglioma
3, and paraganglioma 1 and the tumor suppressor gene
VHL observed in families with von Hippel-Lindau syn-
drome (91). Recently discovered predisposing genes for
pheochromocytoma/paraganglioma include KIF1Bbeta,
PHD2, and SDHAF2 (91).
9. Uromodulin
A GWAS of BP extremes showed the minor G allele of a
UMOD promoter SNP, rs13333226, was associated with a
lower risk of hypertension and reduced urinary UMOD
excretion (276). Uromodulin gene expression is exclusively
localized to the thick ascending limb of the loop of Henle
(TAL) in the kidney where 25% of the filtered sodium is
reabsorbed. An increased localization of the salt-retaining
NKCC2 (sodium-potassium-chloride cotransporter 2) in
subapical vesicles of TAL cells with reduced phosphoryla-
tion, both resulting in reduced cotransporter activity was
noted in UMOD knockout mice (260). The resulting effects
noted are a greater sodium excretion as compared with
wild-type mice, and a 20 mmHg lower BP in the knockout
mice at baseline, as measured by radiotelemetry (123). No-
tably, this difference in BP was exacerbated with salt,
whereby the knockout mice were resistant to the hyperten-
sive effects of salt (123). Conversely, UMOD overexpres-
sion was associated with an increase in BP (361). The main
sodium transporter in TAL is NKCC2, which is blocked by
the commonly used loop-diuretic furosemide. Trudu et al.
(361) showed furosemide treatment significantly enhanced
natriuresis and reduced BP levels both in the transgenicmice
and in the hypertensive individuals homozygous for the
UMOD increasing allele. Thus GWAS has directed focus on
a novel pathway of BP regulation involving altered expres-
sion of uromodulin which appear to influence sodium ho-
meostasis and opens an avenue for translational studies to
discover or repurpose drugs for treatment of hypertension.
10. Natriuretic peptide
Common SNPs in the chromosomal region containing
NPPA and NPPB, the genes encoding the ANP and BNP
propeptides, show consistently that alleles associated
with increased circulating natriuretic peptide concentra-
tions are also associated with lower systolic blood pres-
sure (264, 265). The GWAS SNP rs5068 lies in the 3=-UTR of
the NPPA gene which encodes the pro-peptide of ANP, NT-
proANP.Healthy volunteers, whichwere homozygous for the
risk allele of rs5068 showed lower NT-proANP expression
possibly mediated through a microRNA miR-425 and pro-
vides a putative mechanism to explain how the risk allele re-
duces ANP level and consequently increases BP (11). The ge-
netic effect of rs5068 on circulating NT-pro-ANP levels is
comparable to the environmental change induced by switch-
ing froman extremely low-salt diet (230mg/day) to a dietwith
salt content typical of a Western diet (4600 mg/day) (11).
XII. EMERGING CONCEPTS
A. Noncoding RNA, Epigenome, and the
Inheritance of Hypertension
Variations within the protein-coding genome and epistatic
interactions therein do not completely account for the her-
itability of hypertension. A vast majority of variants de-
tected through human GWAS for hypertension are within
noncoding genomic segments. These can be categorized
into variants that are within regions that can generate non-
coding RNA and variants that are within segments with no
evidence of any annotation. Research on the latter is rather
difficult and stagnant at this point; however, the hypothesis
that variants within noncoding RNA molecules that can
influence BP has gained some attention (201). In rat models
of hypertension, various classes of noncoding RNAs have
been profiled. With the ue of the Dahl SS/MCW rat and a
consomic model (SS13.BN), wherein substitution of chro-
mosome 13 of the Dahl SS/MCW rat with that of the BN rat
lowered BP, a total of 377 microRNAs were profiled in the
renal medulla under the conditions of a high-salt diet (224).
In this study, five microRNAs are reported as differentially
expressed between the SS/MCW and the SS13.BN strain
(224). Of these two microRNAs, Mir214 and Mir29b are
located on chromosome 13. miR-214 was readily detect-
able in the SS/MCW strain, but undetectable in the
SS13.BN strain. miR-29b was expressed higher in the
SS13.BN strain relative to the SS/MCW strain. The Dahl S
rat demonstrates substantial renal medullary interstitial fi-
brosis, which was hypothesized as at least in part due to the
upregulation of miR-29b, which was predicted to regulate
genes encoding many proteins of the extracellular matrix.
The observation that the expression of nine collagen genes
and matrix metalloproteinase 2 (Mmp2), integrin 1
(Itgb1), and other genes related to the extracellular matrix
were all downregulated in the renal medulla of SS13.BN
provided further proof for the link between miR-29b and
associated renal medullary interstitial fibrosis and hyper-
tension. Further evidence was provided through luciferase
construct assays wherein miR-29b suppressed the activity
of luciferase when the reporter gene was linked to a 3=-
untranslated segment of collagen genes Col1a1, Col3a1,
Col4a1, Col5a1, Col5a2, Col5a3, Col7a1, Col8a1,Mmp2,
or Itgb1. While miR-29b is an attractive candidate as an
inherited element that may regulate BP, formal detection of
variants within miR-29b or factors that influence its expres-
sion differentially would support its candidacy. For now, it
appears to be an important mediator of renal fibrosis and
related hypertension.
The second class of noncoding RNAs are the long noncod-
ing RNAs. In rats, there are very few investigations that
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have led to the prioritization of noncoding elements as in-
herited factors for the development of hypertension partly
due to the fact that the rat genome annotation for noncod-
ing RNA genes is limited. There are two reports of profiling
for rat long noncoding RNAs (119, 368). These are impor-
tant starting points for future investigations into the rela-
tionships between variants within long noncoding RNAs
and hypertension. As far as inheritance of noncoding RNA
variants as BP QTLs, there is indirect evidence provided by
mapping of a BP QTL on rat chromosome 9 through the
congenic approach by introgressing normotensive Dahl R
rat alleles onto the genome of the Dahl S rat to a 81.8 kb
segment (122). This relatively short genome segment has no
protein-coding gene annotations within it, but the congenic
strain demonstrated a strong BP lowering effect, thus pro-
viding evidence for variants within noncoding regions of the
genome to influence BP. A second report is on an even
shorter segment of42.5 kb, which when replaced by LEW
rat alleles on the genome of the S rat, accounts for a BP
increasing effect. There is a single protein-coding gene
within this region called rififylin, but the gene itself does not
have coding-sequence variants between S and LEW (121).
The expression of rififylin is higher in the congenic strain
with the increased BP compared with the S rat, and this
increased expression is demonstrated to cause a delay in
cellular recycling, a molecular mechanism linked to the ob-
servation of not only increased BP, but also shorter QT
intervals (121). The expression of rififylin to be higher in the
congenic strain is circumstantial to indicate that a variant or
variants that are not responsible for coding for a protein are
responsible for the observed BP effect. If these sequence
variants are noncoding in the rat, it is of interest to note a
parallel in humans wherein SNPs within noncoding regions
around the rififilyin gene are also associated with aberrant,
shorter QT intervals in humans (264).
B. Epigenetics and Hypertension
Epigenetics refers to molecular changes and associated phe-
notypes that are inherited, but do not involve variations in
the DNA nucleotide sequence. Epigenetic mechanisms in-
volve modification of DNA through methylation or histone
modification or noncoding RNA, which then contribute to
biological regulation by influencing the expression of pro-
tein-coding genes. Due to the feature that epigenetic marks
such as methylation or histone modification are heritable
and can be transmitted either through mitosis or meiosis
even without altering the underlying DNA sequence, epige-
netics is an inherited factor contributing to the genesis of
hypertension. Epigenetic inheritance is an essential mecha-
nism that accounts for the stable propagation of gene activ-
ity from one generation of cells to the next. Unlike genomic
variants, epigenetic alterations can be difficult to study as
they are often tissue or cell-type specific. There are very few
studies reported that test the hypothesis that methylation of
genomes at CpG sites is associated with hypertension. A
study was conducted on a genome-wide scale using DNA
from leukocytes from a small cohort of eight African-Amer-
ican hypertensive subjects and eight normotensive age-
matched controls, but this initial study lacked power to
detect any significant associations (371). Validations were
conducted with additional subjects to demonstrate that
higher methylation of at least one gene, the sulfatase 1
(SULF1) gene, was associated with hypertension (371). A
recent study in humans was conducted using thin-layer
chromatography to determine 5-methylcytosine (5mC) lev-
els in blood DNA samples from 60 subjects with essential
hypertension and 30 control subjects (344). Lower levels of
5mC were observed in DNA of patients with essential
hypertension that correlated with the stage of hyperten-
sion (344). Among animal models, a similar approach of
genome-wide methylation status analysis is reported us-
ing renal outer medullary tissue from the Dahl S hyper-
tensive rat model and the SS.13BN26 congenic strain with
a significantly attenuated salt-induced hypertension and renal
injury. The SS.13BN26 congenic strain has a 12.9Mbp segment
introgressed from the BN rat. The specific methylations char-
acterized were 5mC and 5-hydroxymethylcytosines (5hmC),
both of which were mapped at single-base resolutions (223).
The study also examined the effect of increased dietary salt
intake and compared the SS rat with the congenic SS.13BN26
rat to investigate the effect of genomic segment substitution on
5mC and 5hmC and the association of 5mC and 5hmC with
changes in the disease phenotypes.While therewere no detect-
able alterations in DNA methylation as a result of the chro-
mosome 13 substitution, there was a notable alteration in
response to dietary salt in both the strains examined. Nearly
80% of the CpG islands that were differentially methylated in
response to salt and associated with differential mRNA abun-
dance were intragenic CpG islands.
Overall, it has become quite clear that a DNA sequence-
based approach may only partially explain the involve-
ment of our genome in the genesis of hypertension. Epi-
genetics is an attractive proposition for explaining some
of the “missing heritability” (47, 97, 191, 216, 372, 373)
for further studies, which are clearly needed to test and
ascertain the causal implications of epigenetics in BP reg-
ulation.
C. Microbiome and the Inheritance of
Hypertension
Beyond all the features presenting as genomic or epig-
enomic factors for the inheritance of hypertension, investi-
gations into the realm of the microbiome have opened a
new and previously unsuspected role of microbiota in reg-
ulating BP (FIGURE 9). Early clues for the involvement of the
genome in microbiotal influenced alterations in BP came
from the reports on short-chain fatty acid (SCFA) receptor
knockout mice (285). Circulating SCFAs originate largely
from gut microbiota as they are the end products of bacte-
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rial fermentation, which are absorbed into the host circula-
tion. The link between SCFAs produced by the gut micro-
biota and modulation of BP via these SCFA receptors was
demonstrated by using antibiotics to reduce the biomass of
the gut microbiota before monitoring BP in these SCFA
receptor gene deletion models described below.
Olfactory receptor 78 and G protein-coupled receptor 41
are both receptors for short-chain fatty acids. Both Gpr41
and Olfr78 are expressed in smooth muscle cells. Olfr78 is
expressed in the renal arterioles and the juxtaglomerular
apparatus. In the juxtaglomerular cells, Olfr78 mediates
renin secretion in response to short-chain fatty acids. Dele-
tion of theOlfr gene inOlfr78/ knockoutmice resulted in
lower BP associated with lower levels of plasma renin which
was demonstrated to be due to modulation of short-chain
fatty acid-mediated renin release from the juxtaglomerular
cells. Gpr41 is expressed in smooth muscle cells of small
resistant blood vessels. Gpr41 contributes to the hypoten-
sive effect of the short-chain fatty acid propionate. Further-
more, a relationship was demonstrated between these two
receptors, wherebyOlfr78 functions to raise BP and thereby
antagonizes the contribution of Gpr41 to hypotensive ef-
fects of propionate (285). These studies provided some ba-
sic insights into the relationship between gut microbiota
and previously unknown mechanisms leading to hyperten-
sion.
Soon thereafter, two studies were reported on the influence
of microbiota on the development of inherited hypertension
in rats. The first study was conducted to test the hypothesis
that the extent of hypertension of the Dahl S rat can be
determined by an alteration in its gut microbiotal composi-
tion (245). Gut microbiotal composition of the Dahl S rat
was altered by transplantation of the relatively normoten-
sive Dahl R rat microbiota. As a result of the transplanta-
tion, a significant increase in BP of the Dahl S rat was
documented. The reciprocal transfer of S rat microbiota to
the R rats did not alter the BP of the R rats. 16S RNA
analysis of the microbiotal compositions combined with
plasma short-chain fatty acid profiles revealed that micro-
biotal compositions were indeed altered and that the short-
chain fatty acids acetate and heptanoate were higher in the
S rats transplanted with microbiota from the R rats com-
pared with the S rats given microbiota from the S rats (245).
These data suggest that inherited levels of elevated BP can
be further augmented by the type of gut microbiota. The
second reported study is on the SHR rat (394). The gut
microbiota of the hypertensive SHR was decreased in mi-
crobial richness, evenness, and diversity compared with the
normotensive WKY rats (394). Administration of an anti-
biotic, minocycline, lowered BP of the SHR. The effect of
this particular antibiotic is interesting because it crosses the
blood-brain barrier and has neuronal effects on lowering
BP. The microbiotal influence of minocycline was demon-
strated through alterations in the 16S RNA composition of
microbiota post minocycline treatment that was associated
with a decrease in ANG II-induced BP as well as a reduction
in the Firmicutes to Bacteriodetes (F/B) ratio and an increase
in plasma butyrate, a short-chain fatty acid known to in-
duce vasodilation. Cross-transplantation of microbiota
from WKY to SHR and vice versa will be interesting, but
has not yet been reported. Collectively, these data point to
the importance ofmicrobiota and their genomes, referred to
as the microbiome in the pathogenesis of hypertension. The
historical relevance of these studies is summarized in an
editorial by Honor who draws attention to studies con-
ducted in the late 1970s and early 1980s, which have sug-
gested a role for the gut microbiome in the development of
hypertension in rats and man (147). Early work conducted
in humans and experimental rats (146, 148, 149) suggests
that an increase in BP through the action of steroids was
prevented by administration of antibiotics (146, 148). Stud-
ies in rats were conducted in Sprague-Dawley (SD) rats
rendered hypertensive with corticosterone or by adminis-
tration of ACTH. Hypertension was prevented by prior
treatment of the rats with neomycin and to a lesser extent
with vancomycin (146, 148). Neomycin also slowed the
development of hypertension in the SHRSP rat (148). Since
modern methods to detect microbiota through 16S se-
quencing was not available at that time, gut flora was ex-
amined with conventional techniques such as diluting of
fecal samples that were then spread on agar plates enriched
to selectively support growth of organisms. The findings
were insufficiently detailed to assign links with steroid me-
tabolism; however, the effect of neomycin on BP was re-
Pathophysiology
(Elevated BP)
Genome
Microbiome
Non-genomic factors
Gender
Stress
Lifestyle
Geography
Metabolism
Epigenome
Diet, Salt
Exercise
Race
Age
Physiology
(Normal BP) Essential Hypertension
FIGURE 9. Cartoon representation of
factors influencing the etiology of hyperten-
sion. The red double-sided arrow repre-
sents the interactions between the host
genome and nongenomic factors that act
in concert to influence the transition from
normal physiology of BP regulation to the
pathophysiological state of elevated BP.
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peated in the Florey Institute, Melbourne, Australia with
rats given ACTH and corticosterone (159) and in the rat
model of one clip, one kidney (CSK) hypertension (94).
Three decades later, the two reports on the Dahl S rat and
the SHR and their links tomicrobiota as a factor influencing
development of hypertension (245, 394) has generated
much excitement in the field as is evident from a number of
review articles (4, 172, 242, 246, 263, 296, 324, 407) and a
working group report from the National Heart, Lung, and
Blood Institute of the National Institutes of Health, USA
(270) related to the importance of salt, immunity, the mi-
crobiome and hypertension, or kidney disease.
Thus the microbiome now belongs to the long list of factors
beyond inheritance of the host genome that influence the
etiology of hypertension (FIGURE 9). Admittedly the discov-
eries thus far, albeit associations, are in need of further
studies for cause-effect relationships between the host ge-
nome and the microbiome to impact a change in BP. This
could be challenging because unlike the single host genome,
the microbiome consists of a group of genomes, which
means that these groups of genomes will have collective
transcriptomes that are influenced by the host genome and
vice versa. However, the microbiome cannot explain inher-
ited difference in blood pressure in human or animal stud-
ies. It serves as a complicating factor that obscures the in-
fluence of genetics on blood pressure regulation. Environ-
mental factors such as, for example, dietary proteins, which
are known to alter blood pressure, at least in the Dahl S
model (61, 239), may do so via the microbiome or by alter-
ing the meta-transcriptome, epigenome, or the metabo-
lome. Contemplation of these many possibilities is impos-
sible unless one considers these host-microbiotal interac-
tions in the context of a “holobiont,” which is defined as an
ecosystem consisting of a macro-organism (the host) with a
group of microorganisms (microbiota). Galla et al. (99)
provide a perspective leading to this concept along with an
update on the status of research on microbiota in hyperten-
sion.
XIII. LOOKING AHEAD
In conclusion, research into the inherited susceptibility fac-
tors for BP, which perhaps began with the ambitious view
of finding a handful of causal variants with major effects on
BP, which could be used as targets for better clinical man-
agement of hypertension, has not proven to be the case.
Instead, a small number of genes have been identified
through positional mapping approaches, and a deeper un-
derstanding of additional mechanisms as being operational
at the genomic level has emerged. These mechanisms are
depicted in FIGURE 10 as epistasis, epigenetics, chromosome
conformations, and interactions with genomes of microbi-
ota, all of which impact molecular pathways converging to
causally influence BP regulation.
For the future of research on the genetics of hypertension,
the following are a few considerations and anticipatory re-
marks.
A. Missing Heritability
Despite the identification of numerous SNPs associated
with hypertension and BP traits, the proportion of phe-
notypic variance that is explained by all of these loci
together is2.5%. This phenomenon has been described
as the problem of “missing heritability” and is not re-
stricted to BP traits (230). For instance, a classic complex
trait such as height, which has a very large heritability
estimate from family studies (~80%), has 10% of the
phenotypic variance explained from the SNPs identified
using very large sample sizes (180,000 individuals). A
different way of estimating heritability using SNP data of
unrelated individuals is the GCTA approach introduced
by Yang et al. (h2SNP) (393). This is based on estimating
the heritability from unrelated individuals using common
SNPs with the assumption that heritability estimates in
unrelated individuals is only attributable to the common
SNPs, while the estimation in related individuals is at-
tributed to the entire genome. Applying this method to
systolic BP has shown that h2SNP was ~24%, which is
~50% of the heritability estimates from other twin stud-
ies, and ~80% of the same study heritability estimate
(h2  30%). Furthermore, the number of independent
variants with similar effect size to those reported in the
ICBP study was estimated to be 116 (95% CI: 57–174),
which can collectively explain around 2.2% of the phe-
notypic variance for BP phenotypes, compared with only
0.9% explained by the 29 SNPs identified by ICBP (160).
These findings indicate that a large proportion of the
heritability of BP is “hidden” rather than “missing” be-
cause of a large number of common variants, each of
which has too small an effect to be detected at the strin-
gent genome-wide significance level using current sample
sizes.
The search for missing heritability is one of the primary
goals for research on hypertension and other complex con-
ditions. Among the hypotheses contemplated to explain
“missing heritability” of complex traits are overestimates of
heritability, genomic regions that are unexplored, genetic
variants that remain untested, rare genetic variants that are
yet unknown or not associated, gene interactions or epista-
sis (230, 231), and more recently the underrecognized role
of the host genomic interactions with the microbiome. Thus
there is no question that the quest for genetic analysis of
hypertension thus far has opened up more avenues to pur-
sue. Appropriate experimental designs have to be employed
that allow for investigations to be focused on causal rela-
tionships rather than mere associations. Determining the
full extent to which each of these additional avenues con-
tributes to the genotype-BP relationship is expected to im-
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prove our understanding of the biological systems that un-
derpin variation conferring susceptibility to the develop-
ment of hypertension as well as increase the accuracy of
individual risk prediction.
B. Emerging Insights From Other “Omics”:
Metabolomics
Other omics technologies such as metabolomics are po-
tentially powerful tools to identify molecular pathways.
They can capture both intrinsic and extrinsic factors, and
their dynamic nature makes them ideal for measuring
physiological response to external stimuli or the develop-
ment of pathogenic processes. Metabolomics, which is
the systematic study of small molecule metabolites, may
have an important role in defining candidate systems/
pathways in the pathogenesis of hypertension. Further-
more, metabolomic markers are closer to the phenotype
of interest in contrast to the genotype which is static and
unchanged throughout life. Metabolomic profiling of
over 3,000 adult twins identified a putative novel path-
way for BP regulation involving a dicarboxylic acid
(hexadecanedioate) with a causal role supported by in
vivo studies in rats (248). The role of hexadecanedioate
in a vascular mechanism for hypertension is supported
by evidence from a study of pulmonary hypertension,
indicating a disruption of -oxidation and an increase of
-oxidation in this condition and pointing to a putative
role in elevating pressure in both the systemic and the
pulmonary circulations (405). The strongest genetic as-
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sociation seen with hexadecanedioate maps to SLCO1B1,
an association previously reported in a metabolome-wide
genetic study in caucasians (350). Targeted metabolomics
profiling in the European Prospective Investigation Into
Cancer andNutrition (EPIC)-Potsdam study showed higher
concentrations of serine, glycine, and acyl-alkyl-phosphati-
dylcholines C42:4 and C44:3 tended to be associated with
higher and diacyl-phosphatidylcholines C38:4 and C38:3
with lower predicted 10-yr hypertension-free survival (70).
Other metabolite associations with incident hypertension
and BP come from two US studies which found 4-hydroxy-
hippurate, a metabolic sex steroids pattern and 2 diacylg-
lycerols 16:0/22:5 and 16:0/22:6 to be associated with BP
and incident hypertension (205, 406). Finally, Menni et al.
(249) showed 12 metabolites to be strongly associated with
pulse wave velocity with uridine, phenylacetylglutamine,
and serine appearing to strongly correlate with PWV in
women.
C. Networks of Relationships and Pathways
Influencing the Inheritance of
Hypertension
Beyond the factors listed above, investigations into the gen-
otype-phenotype relationship of BP regulation is expected
to follow the genetic investigations conducted in lower or-
der organisms such as yeast and Drosophila. FIGURE 11
(154) is provided as an example to illustrate the point that
quantitative traits studied extensively in Drosophila have
revealed pervasive networks of epistatic interactions that
recapitulate known as well as candidate genetic networks
affecting complex traits (154). It is tempting to speculate
that similar extensive networks of pathways govern the gen-
otype-BP causality relationship. Others have also proposed
similar regulatory networks operating within specific
genomic contexts that interact with environmental factors
such as dietary salt levels in the context of epigenomic con-
tributions to salt-sensitive hypertension (216). Further-
more, a treelike paradigm has been proposed for under-
standing such pathway networks underlying the develop-
ment of salt-sensitive hypertension (216). On one hand,
reductionistic approaches of modeling single genes in suit-
able experimental designs for assessing causal effects on BP
are expected to progress further, but on the other hand, it is
also important to test the molecular network hypothesis
on a genome-wide scale to fully assess the genetic contri-
butions to the development of hypertension. Technolog-
ical advances in machine-learning and other computa-
tional approaches will perhaps be required to test the
molecular network hypothesis in the context of BP regu-
lation. Mackay andMoore (230, 231) point out that “the
most important short-term goal is to develop, evaluate
and employ statistical and computational methods that
embrace, rather than ignore, the complexity of the geno-
type to phenotype map.” They predict as quoted below:
“artificial intelligence is poised to have a big impact on
the genetic analysis of complex traits by generating inter-
esting and unexpected models of genotype to phenotype
relationships” (230, 231).
D. Chromosome Conformations
Another emerging hypothesis for contributions from the
genome to complex traits is that alterations in nuclear or-
ganization of DNA resulting in higher order structures such
as folds of DNA within chromatin confer differential sus-
ceptibility. Fueled primarily by advances in chromosome
conformation capture assay (3C) and sequencing-based
chromosomal contact mapping (Hi-C, 5C and 4C-seq) that
is applicable on a genome-wide scale (62, 217, 315, 325,
364), it is now technically feasible to detect such spatial
organization of nuclear DNA. However, there is little
known about how such folds affect the ways in which cells
access, read, and interpret genetic information pertinent to
BP regulation.
A B
FIGURE 11. Networks of epistatic inter-
actions. Interaction networks are depicted
for starvation resistance (A) and chill coma
recovery (B). Nodes depict genes, and
edges significant interactions. Red nodes
are genes containing significant SNPs from
the Flyland analysis. Blue nodes are genes
containing significant SNPs from DGRP
analysis. [From Huang et al. (123), with
permission from Proceedings of the Na-
tional Academy of Sciences USA.]
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XIV. CONCLUDING REMARKS
To conclude, advances in genomics have accelerated over
the last decade leading to an unparalleled leap in our
understanding of the genetic architecture of BP and hy-
pertension. While the technological and analytic aspects
of genomics have been very successful in discovering
DNA sequence variants associated with BP and hyperten-
sion, the functional and biological significance of the vast
number of these variants in the human genome are un-
known. In the near future, integrated analyses of whole
genome sequences along with other “-omics” is antici-
pated to mature and lead to better insights, which can
then be accommodated into the decision-making tree of
health care for every individual. The challenging task will
be to identify variants or biomarkers or pathways that
are disease-causing or disease-modifying or treatment-
stratifying, and to develop strategies to prevent or treat
hypertension while keeping the ethical and social impli-
cations constantly aligned with technical and clinical lim-
itations of the diagnostic/therapeutic used.
NOTE ADDED IN PROOF
Since this article was accepted, a new study has been pub-
lished (36a), wherein a precise 19 bp indel polymorphism
was positionally cloned as quantitative trait nucleotides
(QTNs) for blood pressure and short QT intervals. This
study is a follow-up of the work presented in Table 2 on rat
chromosome 10, study “o”. The BP QTL was previously
located within 45 kb of the rat genome (121). ln the new
study, using CRISPR/Cas9 technology, both targeted dis-
ruption and targeted knock-in rescue approaches were ap-
plied to validate the 19 bp of the DNA sequence variation
between S and Lew rats as QTNs. The 19 bp sequence was
discovered to be part of the genomic sequence which is
transcribed into a long noncoding RNA called Rffl-lnc1.
Secondary structural alterations ofRffl-lnc1were noted as a
result of the 19 bp indel polymorphism. This study is not
only the first to define genomic variation at the highest level
of precision for mapping inherited elements that control a
complex trait among mammalian models, but also the first
to identify the inheritance of a variation within a long non-
coding RNA as a causal factor for BP regulation.
ACKNOWLEDGMENTS
Our thanks to Saroj Chakraborty, Graduate Research As-
sistant, and Dr. Sivarajan Kumarasamy, University of To-
ledo College of Medicine, for tabulating data presented in
Table 1 and Figure 2B, respectively; Alisha Aman, Research
Assistant, Institute of Cardiovascular andMedical Sciences,
University of Glasgow, for assistance with Figures 4–8; and
Prof. John Paul Rapp for critical reading and a contribution
to the section on epistasis in rat models of hypertension.
Address for reprint requests and other correspondence: B.
Joe, Dept. of Physiology and Pharmacology, Center for Hy-
pertension and Personalized Medicine, University of To-
ledo College of Medicine and Life Sciences, 237 Block
Health Science Bldg., 3000 Arlington Ave., Toledo, OH
43614 (e-mail: bina.joe@utoledo.edu).
GRANTS
S. Padmanabhan is funded by Medical Research Council
Grant MR/M016560/1, The AIM-HY Study, and British
Heart Foundation Grants PG/12/85/29925 and CS/16/1/
31878. B. Joe acknowledges continued grant support
from National Heart, Lung, and Blood Institute Grants
HL020176 and HL112641.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared
by the authors.
REFERENCES
1. Abiola O, Angel JM, Avner P, Bachmanov AA, Belknap JK, Bennett B, Blankenhorn
EP, Blizard DA, Bolivar V, Brockmann GA, Buck KJ, Bureau JF, Casley WL, Chesler
EJ, Cheverud JM, Churchill GA, Cook M, Crabbe JC, Crusio WE, Darvasi A, de
Haan G, Dermant P, Doerge RW, Elliot RW, Farber CR, Flaherty L, Flint J, Ger-
shenfeld H, Gibson JP, Gu J, Gu W, Himmelbauer H, Hitzemann R, Hsu HC,
Hunter K, Iraqi FF, Jansen RC, Johnson TE, Jones BC, Kempermann G, Lammert
F, Lu L, Manly KF, Matthews DB, Medrano JF, Mehrabian M, Mittlemann G, Mock
BA, Mogil JS, Montagutelli X, Morahan G, Mountz JD, Nagase H, Nowakowski RS,
O’Hara BF, Osadchuk AV, Paigen B, Palmer AA, Peirce JL, Pomp D, Rosemann M,
Rosen GD, Schalkwyk LC, Seltzer Z, Settle S, Shimomura K, Shou S, Sikela JM,
Siracusa LD, Spearow JL, Teuscher C, Threadgill DW, Toth LA, Toye AA, Vadasz
C, Van Zant G, Wakeland E, Williams RW, Zhang HG, Zou F; The Complex Trait
Consortium. The nature and identification of quantitative trait loci: a community’s
view. Nat Rev Genet 4: 911–916, 2003. doi:10.1038/nrg1206.
2. Abumrad NA, Goldberg IJ. CD36 actions in the heart: lipids, calcium, inflammation,
repair and more? Biochim Biophys Acta 1861: 1442–1449, 2016. doi:10.1016/j.bbalip.
2016.03.015.
3. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN,
Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz
TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identi-
fication of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and
glucose metabolism in hypertensive rats. Nat Genet 21: 76 – 83, 1999. doi:10.
1038/5013.
4. Al Khodor S, Shatat IF. Gut microbiome and kidney disease: a bidirectional relation-
ship. Pediatr Nephrol 32: 921–931, 2017. doi:10.1007/s00467-016-3392-7.
5. Alemayehu A, Breen L, Krenova D, Printz MP. Reciprocal rat chromosome 2 congenic
strains reveal contrasting blood pressure and heart rate QTL. Physiol Genomics 10:
199–210, 2002. doi:10.1152/physiolgenomics.00065.2002.
6. Allbutt TC.Diseases of the Arteries, Including Angina Pectoris. London: Macmillan, 1915.
7. Aneas I, Rodrigues MV, Pauletti BA, Silva GJ, Carmona R, Cardoso L, Kwitek AE, Jacob
HJ, Soler JM, Krieger JE. Congenic strains provide evidence that four mapped loci in
chromosomes 2, 4, and 16 influence hypertension in the SHR. Physiol Genomics 37:
52–57, 2009. doi:10.1152/physiolgenomics.90299.2008.
8. Annest JL, Sing CF, Biron P, Mongeau JG. Familial aggregation of blood pressure and
weight in adoptive families. I. Comparisons of blood pressure and weight statistics
among families with adopted, natural, or both natural and adopted children. Am J
Epidemiol 110: 479–491, 1979. doi:10.1093/oxfordjournals.aje.a112829.
SANDOSH PADMANABHAN AND BINA JOE
1514 Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
9. Annest JL, Sing CF, Biron P, Mongeau JG. Familial aggregation of blood pressure
and weight in adoptive families. II. Estimation of the relative contributions of
genetic and common environmental factors to blood pressure correlations be-
tween family members. Am J Epidemiol 110: 492–503, 1979. doi:10.1093/
oxfordjournals.aje.a112830.
10. Ariyarajah A, Palijan A, Dutil J, Prithiviraj K, Deng Y, Deng AY. Dissecting quan-
titative trait loci into opposite blood pressure effects on Dahl rat chromosome 8
by congenic strains. J Hypertens 22: 1495–1502, 2004. doi:10.1097/01.hjh.
0000133720.94075.6f.
11. Arora P, Wu C, Khan AM, Bloch DB, Davis-Dusenbery BN, Ghorbani A, Spagnolli E,
Martinez A, Ryan A, Tainsh LT, Kim S, Rong J, Huan T, Freedman JE, Levy D, Miller
KK, Hata A, Del Monte F, Vandenwijngaert S, Swinnen M, Janssens S, Holmes TM,
Buys ES, Bloch KD, Newton-Cheh C, Wang TJ. Atrial natriuretic peptide is negatively
regulated by microRNA-425. J Clin Invest 123: 3378–3382, 2013. doi:10.1172/
JCI67383.
12. Barr M, MacKenzie SM, Wilkinson DM, Holloway CD, Friel EC, Miller S, MacDonald
T, Fraser R, Connell JM, Davies E. Functional effects of genetic variants in the 11beta-
hydroxylase (CYP11B1) gene. Clin Endocrinol (Oxf) 65: 816–825, 2006. doi:10.1111/
j.1365-2265.2006.02673.x.
13. Ben-Ishay D, Saliternik R, Welner A. Separation of two strains of rats with inbred
dissimilar sensitivity to Doca-salt hypertension. Experientia 28: 1321–1322, 1972.
doi:10.1007/BF01965321.
14. Bianchi G, Ferrari P, Staessen JA. Adducin polymorphism: detection and impact on
hypertension and related disorders. Hypertension 45: 331–340, 2005. doi:10.1161/01.
HYP.0000156497.39375.37.
15. Bianchi G, Fox U, Imbasciati E. The development of a new strain of spontaneously
hypertensive rats. Life Sci 14: 339–347, 1974. doi:10.1016/0024-3205(74)90064-2.
16. Bianchi G, Tripodi G, Casari G, Salardi S, Barber BR, Garcia R, Leoni P, Torielli L, Cusi
D, Ferrandi M. Two point mutations within the adducin genes are involved in blood
pressure variation. Proc Natl Acad Sci USA 91: 3999–4003, 1994. doi:10.1073/pnas.
91.9.3999.
17. Bilusic M, Bataillard A, Tschannen MR, Gao L, Barreto NE, Vincent M, Wang T, Jacob
HJ, Sassard J, Kwitek AE. Mapping the genetic determinants of hypertension, meta-
bolic diseases, and related phenotypes in the lyon hypertensive rat. Hypertension 44:
695–701, 2004. doi:10.1161/01.HYP.0000144542.57306.5e.
18. Bilusic´ M, Moreno C, Barreto NE, Tschannen MR, Harris EL, Porteous WK, Thomp-
son CM, Grigor MR, Weder A, Boerwinkle E, Hunt SC, Curb JD, Jacob HJ, Kwitek AE.
Genetically hypertensive Brown Norway congenic rat strains suggest intermediate
traits underlying genetic hypertension. Croat Med J 49: 586–599, 2008. doi:10.3325/
cmj.2008.5.586.
19. Biron P, Mongeau JG, Bertrand D. Blood pressure values in 1116 French-Canadian
children. Can Med Assoc J 114: 432, 1976.
20. Biron P, Mongeau JG, Bertrand D. Familial aggregation of blood pressure in 558
adopted children. Can Med Assoc J 115: 773–774, 1976.
21. Böger CA, Heid IM. Chronic kidney disease: novel insights from genome-wide asso-
ciation studies. Kidney Blood Press Res 34: 225–234, 2011. doi:10.1159/000326901.
22. Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tik-
honova IR, Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot
BA, Poujol A, Välimäki MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR,
Stockigt JR, Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML, Davis ID,
Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW, Hunley TE, Nelson RD, Tracht-
man H, Cole TR, Pinsk M, Bockenhauer D, Shenoy M, Vaidyanathan P, Foreman
JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, Gharavi AG,
Goilav B, Lifton RP. Mutations in kelch-like 3 and cullin 3 cause hypertension and
electrolyte abnormalities. Nature 482: 98 –102, 2012. doi:10.1038/nature10814.
23. Bright R. Tabular view of the morbid appearances in 100 cases connected with
albuminous urine. Guys Hosp Rep 1: 132–152, 1836.
24. Brown DM, Provoost AP, Daly MJ, Lander ES, Jacob HJ. Renal disease susceptibility
and hypertension are under independent genetic control in the fawn-hooded rat. Nat
Genet 12: 44–51, 1996. doi:10.1038/ng0196-44.
25. Brown MJ. Ins and outs of aldosterone-producing adenomas of the adrenal: from
channelopathy to common curable cause of hypertension. Hypertension 63: 24–26,
2014. doi:10.1161/HYPERTENSIONAHA.113.01833.
26. Browning BL, Browning SR. Haplotypic analysis of Wellcome Trust Case Control
Consortium data. Hum Genet 123: 273–280, 2008. doi:10.1007/s00439-008-0472-1.
27. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe
D. Prevalence of hypertension in the US adult population. Results from the Third
National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25:
305–313, 1995. doi:10.1161/01.HYP.25.3.305.
28. Cerame BI, New MI. Hormonal hypertension in children: 11beta-hydroxylase defi-
ciency and apparent mineralocorticoid excess. J Pediatr Endocrinol Metab 13: 1537–
1547, 2000. doi:10.1515/JPEM.2000.13.9.1537.
29. Charron S, Duong C, Ménard A, Roy J, Eliopoulos V, Lambert R, Deng AY. Epistasis,
not numbers, regulates functions of clustered Dahl rat quantitative trait loci applicable
to human hypertension. Hypertension 46: 1300–1308, 2005. doi:10.1161/01.HYP.
0000192024.72367.c3.
30. Charron S, Lambert R, Eliopoulos V, Duong C, Ménard A, Roy J, Deng AY. A loss of
genome buffering capacity of Dahl salt-sensitive model to modulate blood pressure as
a cause of hypertension. Hum Mol Genet 14: 3877–3884, 2005. doi:10.1093/hmg/
ddi412.
31. Chauvet C, Charron S, Ménard A, Xiao C, Roy J, Deng AY. Submegabase resolution
of epistatically interacting quantitative trait loci for blood pressure applicable for
essential hypertension. J Hypertens 26: 893–901, 2008. doi:10.1097/HJH.
0b013e3282f85ded.
32. Chauvet C, Crespo K, Ménard A, Roy J, Deng AY. Modularization and epistatic
hierarchy determine homeostatic actions of multiple blood pressure quantitative trait
loci. Hum Mol Genet 22: 4451–4459, 2013. doi:10.1093/hmg/ddt294.
33. Chauvet C, Ménard A, Tremblay J, Xiao C, Shi Y, L’Heureux N, Cardin S, Tardif JC,
Nattel S, Deng AY. Cardiac pathways distinguish two epistatic modules enacting BP
quantitative trait loci and candidate gene analysis. Hypertens Res 32: 631–637, 2009.
doi:10.1038/hr.2009.70.
34. Chen J, Gu D, Jaquish CE, Chen CS, Rao DC, Liu D, Hixson JE, Hamm LL, Gu CC,
Whelton PK, He J; GenSalt Collaborative Research Group. Association between
blood pressure responses to the cold pressor test and dietary sodium intervention
in a Chinese population. Arch Intern Med 168: 1740 –1746, 2008. doi:10.1001/
archinte.168.16.1740.
35. Chen M, Chen X, Guo Y, Shi R, Zhang G. Brain natriuretic peptide rs198388
polymorphism and essential hypertension in Hunan Han people. Zhong Nan Da
Xue Xue Bao Yi Xue Ban 35: 1207–1213, 2010. doi:10.3969/j.issn.1672-7347.2010.
12.001.
36. Chen YP, Tsai CW, Shen CY, Day CH, Yeh YL, Chen RJ, Ho TJ, Padma VV, Kuo WW,
Huang CY. Palmitic acid interferes with energy metabolism balance by adversely
switching the SIRT1-CD36-fatty acid pathway to the PKC zeta-GLUT4-glucose path-
way in cardiomyoblasts. J Nutr Biochem 31: 137–149, 2016. doi:10.1016/j.jnutbio.
2016.01.007.
36a.Cheng X, Waghulde H, Mell B, Morgan EE, Pruett-Miller SM, Joe B. Positional cloning
of quantitative trait nucleotides for blood pressure and cardiac QT-interval by tar-
geted CRISPR/Cas9 editing of a novel long non-coding RNA. PLoS Genet 13: e1006961,
2017. doi:10.1371/journa1.pgen.1006961.
37. Cicila GT, Choi C, Dene H, Lee SJ, Rapp JP. Two blood pressure/cardiac mass
quantitative trait loci on chromosome 3 in Dahl rats. Mamm Genome 10: 112–116,
1999. doi:10.1007/s003359900954.
38. Cicila GT, Dukhanina OI, Kurtz TW, Walder R, Garrett MR, Dene H, Rapp JP. Blood
pressure and survival of a chromosome 7 congenic strain bred from Dahl rats. Mamm
Genome 8: 896–902, 1997. doi:10.1007/s003359900607.
39. Cicila GT, Morgan EE, Lee SJ, Farms P, Yerga-Woolwine S, Toland EJ, Ramdath RS,
Gopalakrishnan K, Bohman K, Nestor-Kalinoski AL, Khuder SA, Joe B. Epistatic ge-
netic determinants of blood pressure and mortality in a salt-sensitive hypertension
model. Hypertension 53: 725–732, 2009. doi:10.1161/HYPERTENSIONAHA.108.
126649.
40. Cicila GT, Rapp JP, Bloch KD, Kurtz TW, Pravenec M, Kren V, Hong CC, Querter-
mous T, Ng SC. Cosegregation of the endothelin-3 locus with blood pressure and
relative heart weight in inbred Dahl rats. J Hypertens 12: 643–651, 1994. doi:10.1097/
00004872-199406000-00004.
TOWARDS PRECISION MEDICINE FOR HYPERTENSION
1515Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
41. Cicila GT, Rapp JP, Wang JM, St Lezin E, Ng SC, Kurtz TW. Linkage of 11 beta-
hydroxylase mutations with altered steroid biosynthesis and blood pressure in the
Dahl rat. Nat Genet 3: 346–353, 1993. doi:10.1038/ng0493-346.
42. Clark JS, Jeffs B, Davidson AO, Lee WK, Anderson NH, Bihoreau MT, Brosnan MJ,
Devlin AM, Kelman AW, Lindpaintner K, Dominiczak AF. Quantitative trait loci in
genetically hypertensive rats. Possible sex specificity. Hypertension 28: 898–906,
1996. doi:10.1161/01.HYP.28.5.898.
43. Coburn CT, Hajri T, Ibrahimi A, Abumrad NA. Role of CD36 in membrane transport
and utilization of long-chain fatty acids by different tissues. J Mol Neurosci 16: 117–122,
2001. doi:10.1385/JMN:16:2-3:117.
44. Cook HW. Additional notes on blood pressure in life insurance prognosis. TheMedical
Examiner and Practitioner XVI: 335–336, 1906.
45. Cowley AW Jr. The genetic dissection of essential hypertension. Nat Rev Genet 7:
829–840, 2006. doi:10.1038/nrg1967.
46. Cowley AW Jr, Moreno C, Jacob HJ, Peterson CB, Stingo FC, Ahn KW, Liu P, Van-
nucci M, Laud PW, Reddy P, Lazar J, Evans L, Yang C, Kurth T, Liang M. Character-
ization of biological pathways associated with a 1.37 Mbp genomic region protective
of hypertension in Dahl S rats. Physiol Genomics 46: 398–410, 2014. doi:10.1152/
physiolgenomics.00179.2013.
47. Cowley AW Jr, Nadeau JH, Baccarelli A, Berecek K, Fornage M, Gibbons GH,
Harrison DG, Liang M, Nathanielsz PW, O’Connor DT, Ordovas J, Peng W,
Soares MB, Szyf M, Tolunay HE, Wood KC, Zhao K, Galis ZS. Report of the
National Heart, Lung, and Blood Institute Working Group on epigenetics
and hypertension. Hypertension 59: 899 –905, 2012. doi:10.1161/
HYPERTENSIONAHA.111.190116.
48. Cowley AW Jr, Roman RJ, Kaldunski ML, Dumas P, Dickhout JG, Greene AS, Jacob HJ.
Brown Norway chromosome 13 confers protection from high salt to consomic Dahl
S rat. Hypertension 37: 456–461, 2001. doi:10.1161/01.HYP.37.2.456.
49. Cowley AW Jr, Stoll M, Greene AS, Kaldunski ML, Roman RJ, Tonellato PJ, Schork NJ,
Dumas P, Jacob HJ. Genetically defined risk of salt sensitivity in an intercross of Brown
Norway and Dahl S rats. Physiol Genomics 2: 107–115, 2000.
50. Cowley AW Jr, Yang C, Kumar V, Lazar J, Jacob H, Geurts AM, Liu P, Dayton A, Kurth
T, Liang M. Pappa2 is linked to salt-sensitive hypertension in Dahl S rats. Physiol
Genomics 48: 62–72, 2016. doi:10.1152/physiolgenomics.00097.2015.
51. Crespo K, Chauvet C, Blain M, Ménard A, Roy J, Deng AY. Normotension in Lewis
and Dahl salt-resistant rats is governed by different genes. J Hypertens 29: 460–465,
2011. doi:10.1097/HJH.0b013e328341f1cc.
52. Crespo K, Ménard A, Deng AY. Hypertension Suppression, Not a Cumulative Thrust
of Quantitative Trait Loci, Predisposes Blood Pressure Homeostasis to Normoten-
sion. Circ Cardiovasc Genet 8: 610–617, 2015. doi:10.1161/CIRCGENETICS.114.
000965.
52a.Crespo K, Menard A, Deng AY. Retinoblastoma-associated protein 140 as a candidate
for a novel etiological gene to hypertension. Clin Exp Hypertens 38: 533–540, 2016.
doi:10.3109/10641963.2016.1163373.
53. Cui ZH, Ikeda K, Kawakami K, Gonda T, Masuda J, Nabika T. Exaggerated response
to cold stress in a congenic strain for the quantitative trait locus for blood pressure. J
Hypertens 22: 2103–2109, 2004. doi:10.1097/00004872-200411000-00011.
54. Cui ZH, Ikeda K, Kawakami K, Gonda T, Nabika T, Masuda J. Exaggerated response
to restraint stress in rats congenic for the chromosome 1 blood pressure quantitative
trait locus. Clin Exp Pharmacol Physiol 30: 464–469, 2003. doi:10.1046/j.1440-1681.
2003.03860.x.
55. Dahl LK. Possible role of salt intake in the development of essential hypertension.
1960. Int J Epidemiol 34: 967–972, 2005. doi:10.1093/ije/dyh317.
56. Dahl LK, Heine M, Tassinari L. Effects of chronia excess salt ingestion. Evidence that
genetic factors play an important role in susceptibility to experimental hypertension.
J Exp Med 115: 1173–1190, 1962. doi:10.1084/jem.115.6.1173.
57. Dahl LK, Heine M, Tassinari L. Role of genetic factors in susceptibility to experimental
hypertension due to chronic excess salt ingestion. Nature 194: 480–482, 1962. doi:
10.1038/194480b0.
58. Dale BL, Madhur MS. Linking inflammation and hypertension via LNK/SH2B3. Curr
Opin Nephrol Hypertens 25: 87–93, 2016. doi:10.1097/MNH.0000000000000196.
59. Davidson AO, Schork N, Jaques BC, Kelman AW, Sutcliffe RG, Reid JL, Dominiczak
AF. Blood pressure in genetically hypertensive rats. Influence of the Y chromosome.
Hypertension 26: 452–459, 1995. doi:10.1161/01.HYP.26.3.452.
60. De Miguel C, Das S, Lund H, Mattson DL. T lymphocytes mediate hypertension and
kidney damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 298:
R1136–R1142, 2010. doi:10.1152/ajpregu.00298.2009.
61. De Miguel C, Lund H, Mattson DL. High dietary protein exacerbates hypertension
and renal damage in Dahl SS rats by increasing infiltrating immune cells in the
kidney. Hypertension 57: 269 –274, 2011. doi:10.1161/HYPERTENSIONAHA.
110.154302.
62. Dekker J, Marti-Renom MA, Mirny LA. Exploring the three-dimensional organization
of genomes: interpreting chromatin interaction data. Nat Rev Genet 14: 390–403,
2013. doi:10.1038/nrg3454.
63. Deng AY. Genetic basis of polygenic hypertension. Hum Mol Genet 16, R2: R195–
R202, 2007. doi:10.1093/hmg/ddm126.
64. Deng AY, Chauvet C, Ménard A. Alterations in Fibronectin Type III Domain Contain-
ing 1 Protein Gene Are Associated With Hypertension. PLoS One 11: e0151399, 2016.
doi:10.1371/journal.pone.0151399.
65. Deng AY, Dene H, Pravenec M, Rapp JP. Genetic mapping of two new blood pressure
quantitative trait loci in the rat by genotyping endothelin system genes. J Clin Invest 93:
2701–2709, 1994. doi:10.1172/JCI117284.
66. Deng AY, Dene H, Rapp JP. Congenic strains for the blood pressure quantitative trait
locus on rat chromosome 2. Hypertension 30: 199–202, 1997. doi:10.1161/01.HYP.
30.2.199.
67. Deng AY, Ménard A, Xiao C, Roy J. Sexual dimorphism on hypertension of quantita-
tive trait loci entrapped in Dahl congenic rats. Clin Exp Hypertens 30: 511–519, 2008.
doi:10.1080/10641960802251933.
68. Deng AY, Rapp JP. Locus for the inducible, but not a constitutive, nitric oxide synthase
cosegregates with blood pressure in the Dahl salt-sensitive rat. J Clin Invest 95: 2170–
2177, 1995. doi:10.1172/JCI117906.
69. Deng Y, Rapp JP. Cosegregation of blood pressure with angiotensin converting en-
zyme and atrial natriuretic peptide receptor genes using Dahl salt-sensitive rats. Nat
Genet 1: 267–272, 1992. doi:10.1038/ng0792-267.
70. Dietrich S, Floegel A, Weikert C, Pischon T, Boeing H, Drogan D. Identification of
Serum Metabolites Associated With Incident Hypertension in the European Prospec-
tive Investigation Into Cancer and Nutrition-Potsdam Study. Hypertension 68: 471–
477, 2016. doi:10.1161/HYPERTENSIONAHA.116.07292.
71. Dublin LI, Lotka AJ. Length of Life: A Study of the Life Table. New York: Ronald Press,
1936.
72. Dublin LI, Lotka AJ, Spiegelman M. Length of Life: A Study of the Life Table. New York:
Ronald Press, 1949.
73. Dukhanina OI, Dene H, Deng AY, Choi CR, Hoebee B, Rapp JP. Linkage map and
congenic strains to localize blood pressure QTL on rat chromosome 10. Mamm
Genome 8: 229–235, 1997. doi:10.1007/s003359900399.
74. Duong C, Charron S, Deng Y, Xiao C, Ménard A, Roy J, Deng AY. Individual QTLs
controlling quantitative variation in blood pressure inherited in a Mendelian mode.
Heredity (Edinb) 98: 165–171, 2007. doi:10.1038/sj.hdy.6800920.
75. Dupont J, Dupont JC, Froment A, Milon H, Vincent M. Selection of three strains of
rats with spontaneously different levels of blood pressure. Biomedicine 19: 36 – 41,
1973.
76. Dutil J, Deng AY. Further chromosomal mapping of a blood pressure QTL in Dahl rats
on chromosome 2 using congenic strains. Physiol Genomics 6: 3–9, 2001.
77. Dutil J, Eliopoulos V, Tremblay J, Hamet P, Charron S, Deng AY. Multiple quantitative
trait loci for blood pressure interacting epistatically and additively on Dahl
rat chromosome 2. Hypertension 45: 557–564, 2005. doi:10.1161/01.HYP.
0000158841.71658.5e.
78. Dzau VJ, Jacob HJ, Lindpainter K, Ganten D, Lander ES. Genetic mapping in hyper-
tension. J Vasc Surg 15: 930–931, 1992. doi:10.1016/0741-5214(92)90757-Y.
79. Eaves IA, Wicker LS, Ghandour G, Lyons PA, Peterson LB, Todd JA, Glynne RJ.
Combining mouse congenic strains and microarray gene expression analyses to
SANDOSH PADMANABHAN AND BINA JOE
1516 Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
study a complex trait: the NOD model of type 1 diabetes. Genome Res 12:
232–243, 2002. doi:10.1101/gr.214102. Article published online before print in
January 2002.
80. Edwards SL, Beesley J, French JD, Dunning AM. Beyond GWASs: illuminating the dark
road from association to function. Am J Hum Genet 93: 779–797, 2013. doi:10.1016/
j.ajhg.2013.10.012.
81. Efendiev R, Krmar RT, Ogimoto G, Zwiller J, Tripodi G, Katz AI, Bianchi G, Pede-
monte CH, Bertorello AM. Hypertension-linked mutation in the adducin alpha-sub-
unit leads to higher AP2-mu2 phosphorylation and impaired Na,K-ATPase traf-
ficking in response to GPCR signals and intracellular sodium. Circ Res 95: 1100–1108,
2004. doi:10.1161/01.RES.0000149570.20845.89.
82. Ehret GB, O’Connor AA, Weder A, Cooper RS, Chakravarti A. Follow-up of a major
linkage peak on chromosome 1 reveals suggestive QTLs associated with essential
hypertension: GenNet study. Eur J Hum Genet 17: 1650–1657, 2009. doi:10.1038/
ejhg.2009.94.
83. Eliopoulos V, Dutil J, Deng Y, Grondin M, Deng AY. Severe hypertension caused by
alleles from normotensive Lewis for a quantitative trait locus on chromosome 2.
Physiol Genomics 22: 70–75, 2005. doi:10.1152/physiolgenomics.00019.2005.
84. Ely DL, Turner ME. Hypertension in the spontaneously hypertensive rat is linked to
the Y chromosome. Hypertension 16: 277–281, 1990. doi:10.1161/01.HYP.16.
3.277.
85. Endres BT, Priestley JR, Palygin O, Flister MJ, Hoffman MJ, Weinberg BD, Grzybowski
M, Lombard JH, Staruschenko A, Moreno C, Jacob HJ, Geurts AM. Mutation of
Plekha7 attenuates salt-sensitive hypertension in the rat. Proc Natl Acad Sci USA 111:
12817–12822, 2014. doi:10.1073/pnas.1410745111.
86. Esunge PM. From blood pressure to hypertension: the history of research. J R SocMed
84: 621, 1991.
87. Feinleib M, Garrison RJ, Fabsitz R, Christian JC, Hrubec Z, Borhani NO, Kannel WB,
Rosenman R, Schwartz JT, Wagner JO. The NHLBI twin study of cardiovascular
disease risk factors: methodology and summary of results. Am J Epidemiol 106: 284–
295, 1977. doi:10.1093/oxfordjournals.aje.a112464.
88. Felts JH. Stephen Hales and the measurement of blood pressure. N C Med J 38:
602–603, 1977.
89. Feng D, Yang C, Geurts AM, Kurth T, Liang M, Lazar J, Mattson DL, O’Connor PM,
Cowley AW Jr. Increased expression of NAD(P)H oxidase subunit p67(phox) in the
renal medulla contributes to excess oxidative stress and salt-sensitive hypertension.
Cell Metab 15: 201–208, 2012. doi:10.1016/j.cmet.2012.01.003.
90. Ferrandi M, Cusi D, Molinari I, Del Vecchio L, Barlassina C, Rastaldi MP, Schena FP,
Macciardi F, Marcantoni C, Roccatello D, Peters LL, Armelloni S, Min L, Giardino L,
Mattinzoli D, Camisasca C, Palazzo F, Manunta P, Ferrari P, Bianchi G. Alpha- and
beta-adducin polymorphisms affect podocyte proteins and proteinuria in rodents and
decline of renal function in human IgA nephropathy. J Mol Med (Berl) 88: 203–217,
2010. doi:10.1007/s00109-009-0549-x.
91. Fishbein L. Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treat-
ment. Hematol Oncol Clin North Am 30: 135–150, 2016. doi:10.1016/j.hoc.2015.09.
006.
92. Flister MJ, Tsaih SW, O’Meara CC, Endres B, Hoffman MJ, Geurts AM, Dwinell MR,
Lazar J, Jacob HJ, Moreno C. Identifying multiple causative genes at a single GWAS
locus. Genome Res 23: 1996–2002, 2013. doi:10.1101/gr.160283.113.
93. Fox ER, Young JH, Li Y, Dreisbach AW, Keating BJ, Musani SK, Liu K, Morrison AC,
Ganesh S, Kutlar A, Ramachandran VS, Polak JF, Fabsitz RR, Dries DL, Farlow DN,
Redline S, Adeyemo A, Hirschorn JN, Sun YV, Wyatt SB, Penman AD, Palmas W,
Rotter JI, Townsend RR, Doumatey AP, Tayo BO, Mosley TH Jr, Lyon HN, Kang SJ,
Rotimi CN, Cooper RS, Franceschini N, Curb JD, Martin LW, Eaton CB, Kardia SL,
Taylor HA, Caulfield MJ, Ehret GB, Johnson T, Chakravarti A, Zhu X, Levy D; Inter-
national Consortium for Blood Pressure Genome-wide Association Studies (ICBP-
GWAS). Association of genetic variation with systolic and diastolic blood pressure
among African Americans: the Candidate Gene Association Resource study. HumMol
Genet 20: 2273–2284, 2011. doi:10.1093/hmg/ddr092.
94. Fraillon D, Wynne KN, Funder JW. Further studies on neomycin and experimental
hypertension. Clin Exp Pharmacol Physiol 11: 339–342, 1984. doi:10.1111/j.1440-
1681.1984.tb00274.x.
95. Franceschini N, Fox E, Zhang Z, Edwards TL, Nalls MA, Sung YJ, Tayo BO, Sun YV,
Gottesman O, Adeyemo A, Johnson AD, Young JH, Rice K, Duan Q, Chen F, Li Y,
Tang H, Fornage M, Keene KL, Andrews JS, Smith JA, Faul JD, Guangfa Z, Guo W, Liu
Y, Murray SS, Musani SK, Srinivasan S, Velez Edwards DR, Wang H, Becker LC, Bovet
P, Bochud M, Broeckel U, Burnier M, Carty C, Chasman DI, Ehret G, Chen WM,
Chen G, Chen W, Ding J, Dreisbach AW, Evans MK, Guo X, Garcia ME, Jensen R,
Keller MF, Lettre G, Lotay V, Martin LW, Moore JH, Morrison AC, Mosley TH,
Ogunniyi A, Palmas W, Papanicolaou G, Penman A, Polak JF, Ridker PM, Salako B,
Singleton AB, Shriner D, Taylor KD, Vasan R, Wiggins K, Williams SM, Yanek LR, Zhao
W, Zonderman AB, Becker DM, Berenson G, Boerwinkle E, Bottinger E, Cushman M,
Eaton C, Nyberg F, Heiss G, Hirschhron JN, Howard VJ, Karczewsk KJ, Lanktree MB,
Liu K, Liu Y, Loos R, Margolis K, Snyder M, Psaty BM, Schork NJ, Weir DR, Rotimi CN,
Sale MM, Harris T, Kardia SL, Hunt SC, Arnett D, Redline S, Cooper RS, Risch NJ, Rao
DC, Rotter JI, Chakravarti A, Reiner AP, Levy D, Keating BJ, Zhu X, Go MJ, Kim YJ,
Lee J-Y, Jeon J-P, Kim SS, Han B-G, Cho YS, Sim X, Tay WT, Ong RTH, Seielstad M,
Liu JJ, Aung T, Wong TY, Teo YY, Tai ES, Chen C-H, Chang L, Chen Y-T, Wu J-Y, Kelly
TN, Gu D, Hixson JE, Sung YJ, He J, Tabara Y, Kokubo Y, Miki T, Iwai N, Kato N,
Takeuchi F, Katsuya T, Nabika T, Sugiyama T, Zhang Y, Huang W, Zhang X, Zhou X,
Jin L, Zhu D; Asian Genetic Epidemiology Network Consortium. Genome-wide as-
sociation analysis of blood-pressure traits in African-ancestry individuals reveals com-
mon associated genes in African and non-African populations. Am J Hum Genet 93:
545–554, 2013 doi:10.1016/j.ajhg.2013.07.010.
96. Frantz S, Clemitson JR, Bihoreau MT, Gauguier D, Samani NJ. Genetic dissection
of region around the Sa gene on rat chromosome 1: evidence for multiple loci
affecting blood pressure. Hypertension 38: 216 –221, 2001. doi:10.1161/01.HYP.
38.2.216.
97. Friso S, Carvajal CA, Fardella CE, Olivieri O. Epigenetics and arterial hypertension:
the challenge of emerging evidence. Transl Res 165: 154–165, 2015. doi:10.1016/j.
trsl.2014.06.007.
98. Fung MM, Salem RM, Lipkowitz MS, Bhatnagar V, Pandey B, Schork NJ, O’Connor
DT; AASK Study Investigators. Methylenetetrahydrofolate reductase (MTHFR) poly-
morphism A1298C (Glu429Ala) predicts decline in renal function over time in the
African-American Study of Kidney Disease and Hypertension (AASK) Trial and Vet-
erans Affairs Hypertension Cohort (VAHC). Nephrol Dial Transplant 27: 197–205,
2012. doi:10.1093/ndt/gfr257.
99. Galla S, Chakraborty S, Mell B, Vijay-Kumar M, Joe B. Microbiotal-host interactions
and hypertension. Physiology (Bethesda) 32: 224–233, 2017. doi:doi:10.1152/physiol.
00003.2017.
100. Garrett MR, Dene H, Rapp JP. Time-course genetic analysis of albuminuria in Dahl
salt-sensitive rats on low-salt diet. J Am Soc Nephrol 14: 1175–1187, 2003. doi:10.
1097/01.ASN.0000060572.13794.58.
101. Garrett MR, Dene H, Walder R, Zhang QY, Cicila GT, Assadnia S, Deng AY, Rapp JP.
Genome scan and congenic strains for blood pressure QTL using Dahl salt-sensitive
rats. Genome Res 8: 711–723, 1998. doi:10.1101/gr.8.7.711.
102. Garrett MR, Joe B, Dene H, Rapp JP. Identification of blood pressure quantitative trait
loci that differentiate two hypertensive strains. J Hypertens 20: 2399–2406, 2002.
doi:10.1097/00004872-200212000-00019.
103. Garrett MR, Joe B, Yerga-Woolwine S. Genetic linkage of urinary albumin excretion in
Dahl salt-sensitive rats: influence of dietary salt and confirmation using congenic strains.
Physiol Genomics 25: 39–49, 2006. doi:10.1152/physiolgenomics.00150.2005.
104. Garrett MR, Meng H, Rapp JP, Joe B. Locating a blood pressure quantitative trait
locus within 117 kb on the rat genome: substitution mapping and renal expression
analysis. Hypertension 45: 451– 459, 2005. doi:10.1161/01.HYP.0000154678.
64340.7f.
105. Garrett MR, Rapp JP. Defining the blood pressure QTL on chromosome 7 in Dahl rats
by a 177-kb congenic segment containing Cyp11b1. Mamm Genome 14: 268–273,
2003. doi:10.1007/s00335-002-2245-9.
106. Garrett MR, Rapp JP. Multiple blood pressure QTL on rat Chromosome 2 defined by
congenic Dahl rats. Mamm Genome 13: 41–44, 2002. doi:10.1007/s00335-001-
2114-y.
107. Garrett MR, Rapp JP. Two closely linked interactive blood pressure QTL on rat
chromosome 5 defined using congenic Dahl rats. Physiol Genomics 8: 81–86, 2002.
doi:10.1152/physiolgenomics.00080.2001.
108. Garrett MR, Saad Y, Dene H, Rapp JP. Blood pressure QTL that differentiate Dahl
salt-sensitive and spontaneously hypertensive rats. Physiol Genomics 3: 33–38, 2000.
TOWARDS PRECISION MEDICINE FOR HYPERTENSION
1517Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
109. Garrett MR, Zhang X, Dukhanina OI, Deng AY, Rapp JP. Two linked blood pressure
quantitative trait loci on chromosome 10 defined by dahl rat congenic strains. Hyper-
tension 38: 779–785, 2001. doi:10.1161/hy1001.091503.
110. Garrod AE. About Alkaptonuria. Med Chir Trans 85: 69–78, 1902.
111. Garrod AE. Inborn Errors ofMetabolism. London: H. Frowde and Hodder & Stoughton,
1923.
112. Garrod AE. The incidence of alkaptonuria: a study in chemical individuality. 1902. Mol
Med 2: 274–282, 1996.
113. Garrod AE. The incidence of alkaptonuria: a study in chemical individuality. 1902
[classical article]. Yale J Biol Med 75: 221–231, 2002.
114. Garrod AE. The Lancet. The incidence of alkaptonuria: a study in chemical individu-
ality. Nutr Rev 33: 81–83, 1975. doi:10.1111/j.1753-4887.1975.tb06025.x.
115. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, Choi VM, Jenkins SS, Wood A,
Cui X, Meng X, Vincent A, Lam S, Michalkiewicz M, Schilling R, Foeckler J, Kalloway
S, Weiler H, Ménoret S, Anegon I, Davis GD, Zhang L, Rebar EJ, Gregory PD, Urnov
FD, Jacob HJ, Buelow R. Knockout rats via embryo microinjection of zinc-finger
nucleases. Science 325: 433, 2009. doi:10.1126/science.1172447.
116. Gibbs RA, Weinstock GM, Metzker ML, Muzny DM, Sodergren EJ, Scherer S,
Scott G, Steffen D, Worley KC, Burch PE, Okwuonu G, Hines S, Lewis L, DeRamo
C, Delgado O, Dugan-Rocha S, Miner G, Morgan M, Hawes A, Gill R, Celera, Holt
RA, Adams MD, Amanatides PG, Baden-Tillson H, Barnstead M, Chin S, Evans CA,
Ferriera S, Fosler C, Glodek A, Gu Z, Jennings D, Kraft CL, Nguyen T, Pfannkoch
CM, Sitter C, Sutton GG, Venter JC, Woodage T, Smith D, Lee HM, Gustafson E,
Cahill P, Kana A, Doucette-Stamm L, Weinstock K, Fechtel K, Weiss RB, Dunn
DM, Green ED, Blakesley RW, Bouffard GG, De Jong PJ, Osoegawa K, Zhu B,
Marra M, Schein J, Bosdet I, Fjell C, Jones S, Krzywinski M, Mathewson C, Siddiqui
A, Wye N, McPherson J, Zhao S, Fraser CM, Shetty J, Shatsman S, Geer K, Chen
Y, Abramzon S, Nierman WC, Havlak PH, Chen R, Durbin KJ, Egan A, Ren Y, Song
XZ, Li B, Liu Y, Qin X, Cawley S, Worley KC, Cooney AJ, D’Souza LM, Martin K,
Wu JQ, Gonzalez-Garay ML, Jackson AR, Kalafus KJ, McLeod MP, Milosavljevic A,
Virk D, Volkov A, Wheeler DA, Zhang Z, Bailey JA, Eichler EE, Tuzun E, Birney E,
Mongin E, Ureta-Vidal A, Woodwark C, Zdobnov E, Bork P, Suyama M, Torrents
D, Alexandersson M, Trask BJ, Young JM, Huang H, Wang H, Xing H, Daniels S,
Gietzen D, Schmidt J, Stevens K, Vitt U, Wingrove J, Camara F, Mar Alba` M, Abril
JF, Guigo R, Smit A, Dubchak I, Rubin EM, Couronne O, Poliakov A, Hübner N,
Ganten D, Goesele C, Hummel O, Kreitler T, Lee YA, Monti J, Schulz H, Zimdahl
H, Himmelbauer H, Lehrach H, Jacob HJ, Bromberg S, Gullings-Handley J, Jensen-
Seaman MI, Kwitek AE, Lazar J, Pasko D, Tonellato PJ, Twigger S, Ponting CP,
Duarte JM, Rice S, Goodstadt L, Beatson SA, Emes RD, Winter EE, Webber C,
Brandt P, Nyakatura G, Adetobi M, Chiaromonte F, Elnitski L, Eswara P, Hardison
RC, Hou M, Kolbe D, Makova K, Miller W, Nekrutenko A, Riemer C, Schwartz S,
Taylor J, Yang S, Zhang Y, Lindpaintner K, Andrews TD, Caccamo M, Clamp M,
Clarke L, Curwen V, Durbin R, Eyras E, Searle SM, Cooper GM, Batzoglou S,
Brudno M, Sidow A, Stone EA, Venter JC, Payseur BA, Bourque G, López-Otín C,
Puente XS, Chakrabarti K, Chatterji S, Dewey C, Pachter L, Bray N, Yap VB, Caspi
A, Tesler G, Pevzner PA, Haussler D, Roskin KM, Baertsch R, Clawson H, Furey
TS, Hinrichs AS, Karolchik D, Kent WJ, Rosenbloom KR, Trumbower H, Weirauch
M, Cooper DN, Stenson PD, Ma B, Brent M, Arumugam M, Shteynberg D, Copley
RR, Taylor MS, Riethman H, Mudunuri U, Peterson J, Guyer M, Felsenfeld A, Old
S, Mockrin S, Collins F; Rat Genome Sequencing Project Consortium. Genome
sequence of the Brown Norway rat yields insights into mammalian evolution. Nature
428: 493–521, 2004. doi:10.1038/nature02426.
117. Glatz JF, Nabben M, Heather LC, Bonen A, Luiken JJ. Regulation of the subcellular
trafficking of CD36, a major determinant of cardiac fatty acid utilization. Biochim
Biophys Acta 1861: 1461–1471, 2016 doi:10.1016/j.bbalip.2016.04.008.
118. Gopalakrishnan K, Kumarasamy S, Abdul-Majeed S, Kalinoski AL, Morgan EE, Gohara
AF, Nauli SM, Filipiak WE, Saunders TL, Joe B. Targeted disruption of Adamts16 gene
in a rat genetic model of hypertension. Proc Natl Acad Sci USA 109: 20555–20559,
2012. doi:10.1073/pnas.1211290109.
119. Gopalakrishnan K, Kumarasamy S, Mell B, Joe B. Genome-wide identification of long
noncoding RNAs in rat models of cardiovascular and renal disease. Hypertension 65:
200–210, 2015. doi:10.1161/HYPERTENSIONAHA.114.04498.
120. Gopalakrishnan K, Kumarasamy S, Yan Y, Liu J, Kalinoski A, Kothandapani A, Farms P,
Joe B. Increased Expression of Rififylin in A  330 Kb Congenic Strain is Linked to
Impaired Endosomal Recycling in Proximal Tubules. Front Genet 3: 138, 2012. doi:10.
3389/fgene.2012.00138.
121. Gopalakrishnan K, Morgan EE, Yerga-Woolwine S, Farms P, Kumarasamy S, Kalinoski
A, Liu X, Wu J, Liu L, Joe B. Augmented rififylin is a risk factor linked to aberrant
cardiomyocyte function, short-QT interval and hypertension. Hypertension 57: 764–
771, 2011. doi:10.1161/HYPERTENSIONAHA.110.165803.
122. Gopalakrishnan K, Saikumar J, Peters CG, Kumarasamy S, Farms P, Yerga-Woolwine
S, Toland EJ, Schnackel W, Giovannucci DR, Joe B. Defining a rat blood pressure
quantitative trait locus to a 81.8 kb congenic segment: comprehensive sequencing
and renal transcriptome analysis. Physiol Genomics 42A: 153–161, 2010. doi:10.1152/
physiolgenomics.00122.2010.
123. Graham LA, Padmanabhan S, Fraser NJ, Kumar S, Bates JM, Raffi HS, Welsh P, Beattie
W, Hao S, Leh S, Hultstrom M, Ferreri NR, Dominiczak AF, Graham D, McBride MW.
Validation of uromodulin as a candidate gene for human essential hypertension. Hy-
pertension 63: 551–558, 2014. doi:10.1161/HYPERTENSIONAHA.113.01423.
123a.Grondin M, Eliopoulos V, Lambert R, Deng Y, Ariyarajah A, Moujahidine M, DutiI J,
Charron S, Deng AY. Complete and overlapping congenics proving the existence of a
quantitative trait locus for blood pressure on Dahl rat chromosome 17. Physiol Genom-
ics 21: 112–116, 2005.
124. Guerrera D, Shah J, Vasileva E, Sluysmans S, Méan I, Jond L, Poser I, Mann M, Hyman
AA, Citi S. PLEKHA7 Recruits PDZD11 to Adherens Junctions to Stabilize Nectins. J
Biol Chem 291: 11016–11029, 2016. doi:10.1074/jbc.M115.712935.
125. Hamilton M, Pickering GW, Roberts JA, Sowry GS. The aetiology of essential hyper-
tension. 4. The role of inheritance. Clin Sci 13: 273–304, 1954.
126. Hamilton M, Pickering GW, Roberts JA, Sowry GS. The aetiology of essential
hypertension. I. The arterial pressure in the general population. Clin Sci 13: 11–35,
1954.
127. Hamilton M, Pickering GW, Roberts JA, Sowry GS. The aetiology of essential hyper-
tension. II. Scores for arterial blood pressures adjusted for differences in age and sex.
Clin Sci 13: 37–49, 1954.
128. Hanlon P, Lorenz WA, Shao Z, Harper JM, Galecki AT, Miller RA, Burke DT.
Three-locus and four-locus QTL interactions influence mouse insulin-like growth
factor-I. Physiol Genomics 26: 46 –54, 2006. doi:10.1152/physiolgenomics.00247.
2005.
129. Harris EL, Grigor MR, Thompson CM. Cosegregation of the Tnfalpha locus with
cardiovascular phenotypes in the F2 generation of a New Zealand genetically hyper-
tensive and Brown Norway cross. Clin Exp Pharmacol Physiol 25: 204–207, 1998.
doi:10.1111/j.1440-1681.1998.t01-17-.x.
130. Harris EL, Phelan EL, Thompson CM, Millar JA, Grigor MR. Heart mass and blood
pressure have separate genetic determinants in the New Zealand genetically hyper-
tensive (GH) rat. J Hypertens 13: 397–404, 1995. doi:10.1097/00004872-199504000-
00004.
131. Havlik RJ, Garrison RJ, Feinleib M, Kannel WB, Castelli WP, McNamara PM. Blood
pressure aggregation in families. Am J Epidemiol 110: 304–312, 1979. doi:10.1093/
oxfordjournals.aje.a112815.
132. Heller J, Hellerová S, Dobesová Z, Kunes J, Zicha J. The Prague Hypertensive Rat: a
new model of genetic hypertension. Clin Exp Hypertens 15: 807–818, 1993. doi:10.
3109/10641969309041643.
133. Hennekens CH, Jesse MJ, Klein BE, Gourley JE, Blumenthal S. Aggregation of blood
pressure in infants and their siblings. Am J Epidemiol 103: 457–463, 1976. doi:10.1093/
oxfordjournals.aje.a112247.
134. Hernandez AL, Kitz A, Wu C, Lowther DE, Rodriguez DM, Vudattu N, Deng S,
Herold KC, Kuchroo VK, Kleinewietfeld M, Hafler DA. Sodium chloride inhibits the
suppressive function of FOXP3 regulatory T cells. J Clin Invest 125: 4212–4222,
2015. doi:10.1172/JCI81151.
135. Herrera VL, Lopez LV, Ruiz-Opazo N. Alpha1 Na,K-ATPase and Na,K,2Cl-cotrans-
porte/D3mit3 loci interact to increase susceptibility to salt-sensitive hypertension in
Dahl S(HSD) rats. Mol Med 7: 125–134, 2001.
136. Herrera VL, Pasion KA, Moran AM, Ruiz-Opazo N. Dahl (S x R) congenic strain
analysis confirms and defines a chromosome 5 female-specific blood pressure quan-
titative trait locus to 7 Mbp. PLoS One 7: e42214, 2012. doi:10.1371/journal.pone.
0042214.
137. Herrera VL, Pasion KA, Tan GA, Moran AM, Ruiz-Opazo N. Sex-specific effects on
spatial learning and memory, and sex-independent effects on blood pressure of a
SANDOSH PADMANABHAN AND BINA JOE
1518 Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
3.3 Mbp rat chromosome 2 QTL region in Dahl salt-sensitive rats. PLoS One 8:
e67673, 2013. doi:10.1371/journal.pone.0067673.
138. Herrera VL, Pasion KA, Tan GA, Ruiz-Opazo N. Dahl (S 
 R) rat congenic strain
analysis confirms and defines a chromosome 17 spatial navigation quantitative trait
locus to10 Mbp. PLoS One 8: e58280, 2013. doi:10.1371/journal.pone.0058280.
139. Herrera VL, Tsikoudakis A, Ponce LR, Matsubara Y, Ruiz-Opazo N. Sex-specific QTLs
and interacting loci underlie salt-sensitive hypertension and target organ complica-
tions in Dahl S/jrHS hypertensive rats. Physiol Genomics 26: 172–179, 2006. doi:10.
1152/physiolgenomics.00285.2005.
140. Herrera VL, Xie HX, Lopez LV, Schork NJ, Ruiz-Opazo N. The alpha1 Na,K-ATPase
gene is a susceptibility hypertension gene in the Dahl salt-sensitiveHSD rat. J Clin Invest
102: 1102–1111, 1998. doi:10.1172/JCI3868.
141. Heslop BF, Phelan EL. The GH and AS hypertensive rat strains. Lab Anim 7: 41–46,
1973. doi:10.1258/002367773781005932.
142. Hilbert P, Lindpaintner K, Beckmann JS, Serikawa T, Soubrier F, Dubay C, Cartwright
P, De Gouyon B, Julier C, Takahasi S, . Chromosomal mapping of two genetic loci
associated with blood-pressure regulation in hereditary hypertensive rats. Nature
353: 521–529, 1991. doi:10.1038/353521a0.
143. Hirano K, Kuwasako T, Nakagawa-Toyama Y, Janabi M, Yamashita S, Matsuzawa Y.
Pathophysiology of human genetic CD36 deficiency. Trends Cardiovasc Med 13: 136–
141, 2003. doi:10.1016/S1050-1738(03)00026-4.
144. Ho JE, Levy D, Rose L, Johnson AD, Ridker PM, Chasman DI. Discovery and replica-
tion of novel blood pressure genetic loci in the Women’s Genome Health Study. J
Hypertens 29: 62–69, 2011. doi:10.1097/HJH.0b013e3283406927.
145. Hong KW, Jin HS, Lim JE, Kim S, Go MJ, Oh B. Recapitulation of two genomewide
association studies on blood pressure and essential hypertension in the Korean pop-
ulation. J Hum Genet 55: 336–341, 2010. doi:10.1038/jhg.2010.31.
146. Honour J. The possible involvement of intestinal bacteria in steroidal hypertension.
Endocrinology 110: 285–287, 1982. doi:10.1210/endo-110-1-285.
147. Honour JW. Historical perspective: gut dysbiosis and hypertension. Physiol Genomics
47: 443–446, 2015. doi:10.1152/physiolgenomics.00063.2015.
148. Honour JW, Borriello SP, Ganten U, Honour P. Antibiotics attenuate experimental
hypertension in rats. J Endocrinol 105: 347–350, 1985. doi:10.1677/joe.0.1050347.
149. Honour JW, Tourniaire J, Biglieri EG, Shackleton CH. Urinary steroid excretion in 17
alpha-hydroxylase deficiency. J Steroid Biochem 9: 495–505, 1978. doi:10.1016/0022-
4731(78)90115-2.
150. Huan T, Esko T, Peters MJ, Pilling LC, Schramm K, Schurmann C, Chen BH, Liu C,
Joehanes R, Johnson AD, Yao C, Ying SX, Courchesne P, Milani L, Raghavachari N,
Wang R, Liu P, Reinmaa E, Dehghan A, Hofman A, Uitterlinden AG, Hernandez DG,
Bandinelli S, Singleton A, Melzer D, Metspalu A, Carstensen M, Grallert H, Herder C,
Meitinger T, Peters A, Roden M, Waldenberger M, Dörr M, Felix SB, Zeller T, Vasan
R, O’Donnell CJ, Munson PJ, Yang X, Prokisch H, Völker U, van Meurs JB, Ferrucci L,
Levy D; International Consortium for Blood Pressure GWAS (ICBP). A meta-analysis
of gene expression signatures of blood pressure and hypertension. PLoS Genet 11:
e1005035, 2015 doi:10.1371/journal.pgen.1005035.
151. Huan T, Meng Q, Saleh MA, Norlander AE, Joehanes R, Zhu J, Chen BH, Zhang B,
Johnson AD, Ying S, Courchesne P, Raghavachari N, Wang R, Liu P, O’Donnell CJ,
Vasan R, Munson PJ, Madhur MS, Harrison DG, Yang X, Levy D. Integrative network
analysis reveals molecular mechanisms of blood pressure regulation. Mol Syst Biol 11:
799, 2015. doi:10.15252/msb.20145399.
152. Huang BS, Ahmad M, Deng AY, Leenen FH. Neuronal responsiveness to central Na
in 2 congenic strains of Dahl salt-sensitive rats. Hypertension 49: 1315–1320, 2007.
doi:10.1161/HYPERTENSIONAHA.106.086363.
153. Huang BS, Van Vliet BN, Leenen FH. Increases in CSF [Na] precede the increases in
blood pressure in Dahl S rats and SHR on a high-salt diet. Am J Physiol Heart Circ Physiol
287: H1160–H1166, 2004. doi:10.1152/ajpheart.00126.2004.
154. Huang W, Richards S, Carbone MA, Zhu D, Anholt RR, Ayroles JF, Duncan L, Jordan
KW, Lawrence F, Magwire MM, Warner CB, Blankenburg K, Han Y, Javaid M, Jayas-
eelan J, Jhangiani SN, Muzny D, Ongeri F, Perales L, Wu YQ, Zhang Y, Zou X, Stone
EA, Gibbs RA, Mackay TF. Epistasis dominates the genetic architecture of Drosophila
quantitative traits. Proc Natl Acad Sci USA 109: 15553–15559, 2012. doi:10.1073/pnas.
1213423109.
155. Hübner N, Lee YA, Lindpaintner K, Ganten D, Kreutz R. Congenic substitution map-
ping excludes Sa as a candidate gene locus for a blood pressure quantitative trait locus
on rat chromosome 1. Hypertension 34: 643–648, 1999. doi:10.1161/01.HYP.34.4.
643.
156. Hubner N, Wallace CA, Zimdahl H, Petretto E, Schulz H, Maciver F, Mueller M,
Hummel O, Monti J, Zidek V, Musilova A, Kren V, Causton H, Game L, Born G,
Schmidt S, Müller A, Cook SA, Kurtz TW, Whittaker J, Pravenec M, Aitman TJ.
Integrated transcriptional profiling and linkage analysis for identification of genes un-
derlying disease. Nat Genet 37: 243–253, 2005. doi:10.1038/ng1522.
157. Huggins GS, Bacani CJ, Boltax J, Aikawa R, Leiden JM. Friend of GATA 2 physically
interacts with chicken ovalbumin upstream promoter-TF2 (COUP-TF2) and COUP-
TF3 and represses COUP-TF2-dependent activation of the atrial natriuretic factor
promoter. J Biol Chem 276: 28029–28036, 2001. doi:10.1074/jbc.M103577200.
158. Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of
future hypertension in Utah. A screening analysis. Hypertension 17: 969–976, 1991.
doi:10.1161/01.HYP.17.6.969.
159. Ingram BW, Funder JW. Neomycin and experimental hypertension. Clin Exp Pharma-
col Physiol 9: 331–333, 1982. doi:10.1111/j.1440-1681.1982.tb00816.x.
160. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV,
Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O’Reilly PF, Amin
N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer L, Zhao JH, Aulchenko Y,
Heath S, Sõber S, Parsa A, Luan J, Arora P, Dehghan A, Zhang F, Lucas G, Hicks
AA, Jackson AU, Peden JF, Tanaka T, Wild SH, Rudan I, Igl W, Milaneschi Y, Parker
AN, Fava C, Chambers JC, Fox ER, Kumari M, Go MJ, van der Harst P, Kao WH,
Sjögren M, Vinay DG, Alexander M, Tabara Y, Shaw-Hawkins S, Whincup PH, Liu
Y, Shi G, Kuusisto J, Tayo B, Seielstad M, Sim X, Nguyen KD, Lehtimäki T, Matullo
G, Wu Y, Gaunt TR, Onland-Moret NC, Cooper MN, Platou CG, Org E, Hardy R,
Dahgam S, Palmen J, Vitart V, Braund PS, Kuznetsova T, Uiterwaal CS, Adeyemo
A, Palmas W, Campbell H, Ludwig B, Tomaszewski M, Tzoulaki I, Palmer ND,
Aspelund T, Garcia M, Chang YP, O’Connell JR, Steinle NI, Grobbee DE, Arking
DE, Kardia SL, Morrison AC, Hernandez D, Najjar S, McArdle WL, Hadley D,
Brown MJ, Connell JM, Hingorani AD, Day IN, Lawlor DA, Beilby JP, Lawrence
RW, Clarke R, Hopewell JC, Ongen H, Dreisbach AW, Li Y, Young JH, Bis JC,
Kähönen M, Viikari J, Adair LS, Lee NR, Chen MH, Olden M, Pattaro C, Bolton JA,
Köttgen A, Bergmann S, Mooser V, Chaturvedi N, Frayling TM, Islam M, Jafar TH,
Erdmann J, Kulkarni SR, Bornstein SR, Grässler J, Groop L, Voight BF, Kettunen J,
Howard P, Taylor A, Guarrera S, Ricceri F, Emilsson V, Plump A, Barroso I, Khaw
KT, Weder AB, Hunt SC, Sun YV, Bergman RN, Collins FS, Bonnycastle LL, Scott
LJ, Stringham HM, Peltonen L, Perola M, Vartiainen E, Brand SM, Staessen JA,
Wang TJ, Burton PR, Soler Artigas M, Dong Y, Snieder H, Wang X, Zhu H, Lohman
KK, Rudock ME, Heckbert SR, Smith NL, Wiggins KL, Doumatey A, Shriner D,
Veldre G, Viigimaa M, Kinra S, Prabhakaran D, Tripathy V, Langefeld CD, Rosen-
gren A, Thelle DS, Corsi AM, Singleton A, Forrester T, Hilton G, McKenzie CA,
Salako T, Iwai N, Kita Y, Ogihara T, Ohkubo T, Okamura T, Ueshima H,
Umemura S, Eyheramendy S, Meitinger T, Wichmann HE, Cho YS, Kim HL, Lee
JY, Scott J, Sehmi JS, Zhang W, Hedblad B, Nilsson P, Smith GD, Wong A, Narisu
N, Stanáková A, Raffel LJ, Yao J, Kathiresan S, O’Donnell CJ, Schwartz SM, Ikram
MA, Longstreth WT Jr, Mosley TH, Seshadri S, Shrine NR, Wain LV, Morken MA,
Swift AJ, Laitinen J, Prokopenko I, Zitting P, Cooper JA, Humphries SE, Danesh J,
Rasheed A, Goel A, Hamsten A, Watkins H, Bakker SJ, van Gilst WH, Janipalli CS,
Mani KR, Yajnik CS, Hofman A, Mattace-Raso FU, Oostra BA, Demirkan A, Isaacs
A, Rivadeneira F, Lakatta EG, Orru M, Scuteri A, Ala-Korpela M, Kangas AJ,
Lyytikäinen LP, Soininen P, Tukiainen T, Würtz P, Ong RT, Dörr M, Kroemer HK,
Völker U, Völzke H, Galan P, Hercberg S, Lathrop M, Zelenika D, Deloukas P,
Mangino M, Spector TD, Zhai G, Meschia JF, Nalls MA, Sharma P, Terzic J, Kumar
MV, Denniff M, Zukowska-Szczechowska E, Wagenknecht LE, Fowkes FG, Char-
char FJ, Schwarz PE, Hayward C, Guo X, Rotimi C, Bots ML, Brand E, Samani NJ,
Polasek O, Talmud PJ, Nyberg F, Kuh D, Laan M, Hveem K, Palmer LJ, van der
Schouw YT, Casas JP, Mohlke KL, Vineis P, Raitakari O, Ganesh SK, Wong TY, Tai
ES, Cooper RS, Laakso M, Rao DC, Harris TB, Morris RW, Dominiczak AF,
Kivimaki M, Marmot MG, Miki T, Saleheen D, Chandak GR, Coresh J, Navis G,
Salomaa V, Han BG, Zhu X, Kooner JS, Melander O, Ridker PM, Bandinelli S,
Gyllensten UB, Wright AF, Wilson JF, Ferrucci L, Farrall M, Tuomilehto J, Pram-
staller PP, Elosua R, Soranzo N, Sijbrands EJ, Altshuler D, Loos RJ, Shuldiner AR,
Gieger C, Meneton P, Uitterlinden AG, Wareham NJ, Gudnason V, Rotter JI,
Rettig R, Uda M, Strachan DP, Witteman JC, Hartikainen AL, Beckmann JS, Boer-
winkle E, Vasan RS, Boehnke M, Larson MG, Järvelin MR, Psaty BM, Abecasis GR,
Chakravarti A, Elliott P, van Duijn CM, Newton-Cheh C, Levy D, Caulfield MJ,
Johnson T; International Consortium for Blood Pressure Genome-Wide Associa-
tion Studies; CARDIoGRAM consortium; CKDGen Consortium; KidneyGen Con-
sortium; EchoGen consortium; CHARGE-HF consortium. Genetic variants in novel
TOWARDS PRECISION MEDICINE FOR HYPERTENSION
1519Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
pathways influence blood pressure and cardiovascular disease risk. Nature 478: 103–
109, 2011 doi:10.1038/nature10405.
161. Iwai N, Inagami T. Quantitative analysis of renin gene expression in extrarenal tissues
by polymerase chain reaction method. J Hypertens 10: 717–724, 1992. doi:10.1097/
00004872-199208000-00004.
162. Jacob HJ, Lazar J, Dwinell MR, Moreno C, Geurts AM. Gene targeting in the rat:
advances and opportunities. Trends Genet 26: 510–518, 2010. doi:10.1016/j.tig.2010.
08.006.
163. Jacob HJ, Lindpaintner K, Lincoln SE, Kusumi K, Bunker RK, Mao YP, Ganten D, Dzau
VJ, Lander ES. Genetic mapping of a gene causing hypertension in the stroke-prone
spontaneously hypertensive rat. Cell 67: 213–224, 1991. doi:10.1016/0092-
8674(91)90584-L.
164. Jaworski RL, Jirout M, Closson S, Breen L, Flodman PL, Spence MA, Kren V, Krenova
D, Pravenec M, Printz MP. Heart rate and blood pressure quantitative trait loci for the
airpuff startle reaction. Hypertension 39: 348–352, 2002. doi:10.1161/hy0202.
103419.
165. Jiang S, Hsu YH, Xu X, Xing H, Chen C, Niu T, Zhang Y, Peng S, Xu X. The C677T
polymorphism of the methylenetetrahydrofolate reductase gene is associated with
the level of decrease on diastolic blood pressure in essential hypertension patients
treated by angiotensin-converting enzyme inhibitor. Thromb Res 113: 361–369, 2004.
doi:10.1016/j.thromres.2004.04.005.
166. Joe B, Garrett M. Substitution Mapping using congenic strains to detect genes con-
trolling blood pressure. In: Cardiovascular Genomics, edited by Raizada MK, Paton JFR,
Kasparov S, Katovich MJ. New York: Humana, 2005, p. 41–58. doi:10.1385/1-59259-
883-8:041
167. Joe B, Garrett MR. Genetic analysis of inherited hypertension in the rat. In: Genetics of
Hypertension, edited by Dominiczak AF, Connell JMC. Netherlands: Elsevier, 2007, p.
177–200.
168. Joe B, Garrett MR, Dene H, Rapp JP. Substitution mapping of a blood pressure
quantitative trait locus to a 2.73 Mb region on rat chromosome 1. J Hypertens 21:
2077–2084, 2003. doi:10.1097/00004872-200311000-00017.
169. Joe B, Letwin NE, Garrett MR, Dhindaw S, Frank B, Sultana R, Verratti K, Rapp JP, Lee
NH. Transcriptional profiling with a blood pressure QTL interval-specific oligonucle-
otide array. Physiol Genomics 23: 318–326, 2005. doi:10.1152/physiolgenomics.
00164.2004.
170. Joe B, Saad Y, Dhindaw S, Lee NH, Frank BC, Achinike OH, Luu TV, Gopalakrishnan
K, Toland EJ, Farms P, Yerga-Woolwine S, Manickavasagam E, Rapp JP, Garrett MR,
Coe D, Apte SS, Rankinen T, Pérusse L, Ehret GB, Ganesh SK, Cooper RS, O’Connor
A, Rice T, Weder AB, Chakravarti A, Rao DC, Bouchard C. Positional identification of
variants of Adamts16 linked to inherited hypertension. HumMol Genet 18: 2825–2838,
2009. doi:10.1093/hmg/ddp218.
170a.Johnson MD, He L, Herman D, Wakimoto H, Wallace CA, Zidek V, Mlejnek P,
Musilova A, Simakova M, Vorlicek J, Kren V, Viklicky O, Qi NR, Wang J, Seidman CE,
Seidman J, Kurtz TW, Aitman TJ, Pravenec M. Dissection of chromosome 18 blood
pressure and salt-sensitivity quantitative trait loci in the spontaneously hypertensive
rat. Hypertension 54: 639–645, 2009. doi:10.1161/HYPERTENSIONAHA.108.
126664.
171. Johnson T, Gaunt TR, Newhouse SJ, Padmanabhan S, Tomaszewski M, Kumari M,
Morris RW, Tzoulaki I, O’Brien ET, Poulter NR, Sever P, Shields DC, Thom S,
Wannamethee SG, Whincup PH, Brown MJ, Connell JM, Dobson RJ, Howard PJ,
Mein CA, Onipinla A, Shaw-Hawkins S, Zhang Y, Davey Smith G, Day IN, Lawlor
DA, Goodall AH, Fowkes FG, Abecasis GR, Elliott P, Gateva V, Braund PS, Burton
PR, Nelson CP, Tobin MD, van der Harst P, Glorioso N, Neuvrith H, Salvi E,
Staessen JA, Stucchi A, Devos N, Jeunemaitre X, Plouin PF, Tichet J, Juhanson P,
Org E, Putku M, Sõber S, Veldre G, Viigimaa M, Levinsson A, Rosengren A, Thelle
DS, Hastie CE, Hedner T, Lee WK, Melander O, Wahlstrand B, Hardy R, Wong A,
Cooper JA, Palmen J, Chen L, Stewart AF, Wells GA, Westra HJ, Wolfs MG, Clarke
R, Franzosi MG, Goel A, Hamsten A, Lathrop M, Peden JF, Seedorf U, Watkins H,
Ouwehand WH, Sambrook J, Stephens J, Casas JP, Drenos F, Holmes MV, Kivi-
maki M, Shah S, Shah T, Talmud PJ, Whittaker J, Wallace C, Delles C, Laan M, Kuh
D, Humphries SE, Nyberg F, Cusi D, Roberts R, Newton-Cheh C, Franke L,
Stanton AV, Dominiczak AF, Farrall M, Hingorani AD, Samani NJ, Caulfield MJ,
Munroe PB; Cardiogenics Consortium; Global BPgen Consortium. Blood pres-
sure loci identified with a gene-centric array. Am J Hum Genet 89: 688 –700, 2011.
doi:10.1016/j.ajhg.2011.10.013.
172. Jose PA, Raj D. Gut microbiota in hypertension. Curr Opin Nephrol Hypertens 24:
403–409, 2015. doi:10.1097/MNH.0000000000000149.
173. Kalousová M, Muravská A, Zima T. Pregnancy-associated plasma protein A (PAPP-A)
and preeclampsia. Adv Clin Chem 63: 169–209, 2014. doi:10.1016/B978-0-12-
800094-6.00005-4.
174. Kantachuvesiri S, Haley CS, Fleming S, Kurian K, Whitworth CE, Wenham P, Kotele-
vtsev Y, Mullins JJ. Genetic mapping of modifier loci affecting malignant hypertension
in TGRmRen2 rats. Kidney Int 56: 414–420, 1999. doi:10.1046/j.1523-1755.1999.
00571.x.
175. Karp CL, Grupe A, Schadt E, Ewart SL, Keane-Moore M, Cuomo PJ, Köhl J, Wahl L,
Kuperman D, Germer S, Aud D, Peltz G, Wills-Karp M. Identification of complement
factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 1:
221–226, 2000. doi:10.1038/79759.
176. Kato N, Hyne G, Bihoreau MT, Gauguier D, Lathrop GM, Rapp JP. Complete genome
searches for quantitative trait loci controlling blood pressure and related traits in four
segregating populations derived from Dahl hypertensive rats. Mamm Genome 10:
259–265, 1999. doi:10.1007/s003359900983.
177. Kato N, Mashimo T, Nabika T, Cui ZH, Ikeda K, Yamori Y. Genome-wide searches
for blood pressure quantitative trait loci in the stroke-prone spontaneously hyperten-
sive rat of a Japanese colony. J Hypertens 21: 295–303, 2003. doi:10.1097/00004872-
200302000-00020.
178. Kato N, Nabika T, Liang YQ, Mashimo T, Inomata H, Watanabe T, Yanai K, Yamori Y,
Yazaki Y, Sasazuki T. Isolation of a chromosome 1 region affecting blood pressure and
vascular disease traits in the stroke-prone rat model. Hypertension 42: 1191–1197,
2003. doi:10.1161/01.HYP.0000103161.27190.67.
179. Kato N, Sugiyama T, Morita H, Nabika T, Kurihara H, Yamori Y, Yazaki Y. Genetic
analysis of the atrial natriuretic peptide gene in essential hypertension. Clin Sci (Lond)
98: 251–258, 2000. doi:10.1042/cs0980251.
180. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, Tay WT, Chen CH, Zhang
Y, Yamamoto K, Katsuya T, Yokota M, Kim YJ, Ong RT, Nabika T, Gu D, Chang
LC, Kokubo Y, Huang W, Ohnaka K, Yamori Y, Nakashima E, Jaquish CE, Lee JY,
Seielstad M, Isono M, Hixson JE, Chen YT, Miki T, Zhou X, Sugiyama T, Jeon JP,
Liu JJ, Takayanagi R, Kim SS, Aung T, Sung YJ, Zhang X, Wong TY, Han BG,
Kobayashi S, Ogihara T, Zhu D, Iwai N, Wu JY, Teo YY, Tai ES, Cho YS, He J.
Meta-analysis of genome-wide association studies identifies common variants associ-
ated with blood pressure variation in east Asians. Nat Genet 43: 531–538, 2011.
doi:10.1038/ng.834.
181. Katsuya T, Higaki J, Miki T, Kohara K, Yagisawa H, Tanase H, Mikami H, Serikawa T,
Nojima H, Ogihara T. Hypotensive effect associated with a phospholipase C-delta
1 gene mutation in the spontaneously hypertensive rat. Biochem Biophys Res Com-
mun 187: 1359 –1366, 1992. doi:10.1016/0006-291X(92)90452-Q.
182. Kennedy DJ, Kashyap SR. Pathogenic role of scavenger receptor CD36 in the meta-
bolic syndrome and diabetes. Metab Syndr Relat Disord 9: 239–245, 2011. doi:10.
1089/met.2011.0003.
183. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ.
GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to con-
trol of blood pressure. Nat Med 19: 567–575, 2013. doi:10.1038/nm.3128.
184. Klimes I, Weston K, Kovacs P, Gasperikova D, Jezova D, Kvetnansky R, Thompson JR,
Sebokova E, Samani NJ. Mapping of genetic loci predisposing to hypertriglyceridaemia
in the hereditary hypertriglyceridaemic rat: analysis of genetic association with related
traits of the insulin resistance syndrome. Diabetologia 46: 352–358, 2003. doi:10.
1007/s00125-003-1035-6.
185. Klöting I, Kovács P, van den Brandt J. Quantitative trait loci for body weight, blood
pressure, blood glucose, and serum lipids: linkage analysis with wild rats (Rattus
norvegicus). Biochem Biophys Res Commun 284: 1126–1133, 2001. doi:10.1006/bbrc.
2001.5091.
185a.Klöting I, Voigt B, Kovács P. Metabolic features of newly established congenic diabe-
tes-prone BB. SHR rat strains. Life Sci 62: 973–979, 1998.
186. Koffler M. Ambulatory treatment of hypertension with the Kempner rice diet.
Harefuah 49: 45–47, 1955.
187. Koh-Tan HH, McBride MW, McClure JD, Beattie E, Young B, Dominiczak AF, Gra-
ham D. Interaction between chromosome 2 and 3 regulates pulse pressure in the
SANDOSH PADMANABHAN AND BINA JOE
1520 Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
stroke-prone spontaneously hypertensive rat. Hypertension 62: 33–40, 2013. doi:10.
1161/HYPERTENSIONAHA.111.00814.
188. Koonen DP, Febbraio M, Bonnet S, Nagendran J, Young ME, Michelakis ED, Dyck JR.
CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation
116: 2139–2147, 2007. doi:10.1161/CIRCULATIONAHA.107.712901.
189. Korner PI. Essential Hypertension and Its Causes: Neural and Non-neural Mechanisms.
Oxford, UK: Oxford Univ. Press, 2007.
190. Kotchen TA. Historical trends and milestones in hypertension research: a model of
the process of translational research. Hypertension 58: 522–538, 2011. doi:10.1161/
HYPERTENSIONAHA.111.177766.
191. Kotchen TA, Cowley AW Jr, Liang M. Ushering Hypertension Into a New Era of
Precision Medicine. JAMA 315: 343–344, 2016. doi:10.1001/jama.2015.18359.
192. Kotchen TA, Kotchen JM, Grim CE, George V, Kaldunski ML, Cowley AW, Hamet P,
Chelius TH. Genetic determinants of hypertension: identification of candidate phe-
notypes. Hypertension 36: 7–13, 2000. doi:10.1161/01.HYP.36.1.7.
193. Kourtidis A, Anastasiadis PZ. Bringing together cell-to-cell adhesion and miRNA biol-
ogy in cancer research. Future Oncol 12: 1211–1214, 2016. doi:10.2217/fon-2016-
0012.
194. Kourtidis A, Anastasiadis PZ. PLEKHA7 defines an apical junctional complex with
cytoskeletal associations and miRNA-mediated growth implications. Cell Cycle 15:
498–505, 2016. doi:10.1080/15384101.2016.1141840.
195. Kourtidis A, Ngok SP, Pulimeno P, Feathers RW, Carpio LR, Baker TR, Carr JM, Yan
IK, Borges S, Perez EA, Storz P, Copland JA, Patel T, Thompson EA, Citi S, Anasta-
siadis PZ. Distinct E-cadherin-based complexes regulate cell behaviour through
miRNA processing or Src and p120 catenin activity.Nat Cell Biol 17: 1145–1157, 2015.
doi:10.1038/ncb3227.
196. Kovács P, Voigt B, Klöting I. Alleles of the spontaneously hypertensive rat decrease
blood pressure at loci on chromosomes 4 and 13. Biochem Biophys Res Commun 238:
586–589, 1997. doi:10.1006/bbrc.1997.7342.
197. Kovács P, Voigt B, Klöting I. Novel quantitative trait loci for blood pressure and related
traits on rat chromosomes 1, 10, and 18. Biochem Biophys Res Commun 235: 343–348,
1997. doi:10.1006/bbrc.1997.6782.
198. Kren V, Pravenec M, Lu S, Krenova D, Wang JM, Wang N, Merriouns T, Wong A, St
Lezin E, Lau D, Szpirer C, Szpirer J, Kurtz TW. Genetic isolation of a region of
chromosome 8 that exerts major effects on blood pressure and cardiac mass in the
spontaneously hypertensive rat. J Clin Invest 99: 577–581, 1997. doi:10.1172/
JCI119198.
198a.Kren V, Qi N, Krenova D, Zidek V, Sladká M, Jáchymová M, Míková B, Horky K, Bonne
A, Van Lith HA, Van Zutphen BF, Lau YF, Pravenec M, St Lezin E. Y-chromosome
transfer induces changes in blood pressure and blood lipids in SHR. Hypertension 37:
1147–1152, 2001.
199. Kreutz R, Hübner N, James MR, Bihoreau MT, Gauguier D, Lathrop GM, Ganten D,
Lindpaintner K. Dissection of a quantitative trait locus for genetic hypertension on rat
chromosome 10. Proc Natl Acad Sci USA 92: 8778–8782, 1995. doi:10.1073/pnas.92.
19.8778.
200. Kreutz R, Struk B, Rubattu S, Hübner N, Szpirer J, Szpirer C, Ganten D, Lindpaintner
K. Role of the alpha-, beta-, and gamma-subunits of epithelial sodium channel in a
model of polygenic hypertension. Hypertension 29: 131–136, 1997. doi:10.1161/01.
HYP.29.1.131.
201. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, cell biology,
and relevance to renal and cardiovascular injury. Physiol Genomics 44: 237–244, 2012.
doi:10.1152/physiolgenomics.00141.2011.
202. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Marra
MA. Circos: an information aesthetic for comparative genomics. Genome Res 19:
1639–1645, 2009. doi:10.1101/gr.092759.109.
203. Ku DD, Guo L, Dai J, Acuff CG, Steinhelper ME. Coronary vascular and endothelial
reactivity changes in transgenic mice overexpressing atrial natriuretic factor. Am J
Physiol Heart Circ Physiol 271: H2368–H2376, 1996.
204. Kuijpers MH, Gruys E. Spontaneous hypertension and hypertensive renal disease in
the fawn-hooded rat. Br J Exp Pathol 65: 181–190, 1984.
205. Kulkarni H, Meikle PJ, Mamtani M, Weir JM, Barlow CK, Jowett JB, Bellis C, Dyer TD,
Johnson MP, Rainwater DL, Almasy L, Mahaney MC, Comuzzie AG, Blangero J,
Curran JE. Plasma lipidomic profile signature of hypertension in Mexican American
families: specific role of diacylglycerols. Hypertension 62: 621–626, 2013. doi:10.
1161/HYPERTENSIONAHA.113.01396.
206. Kumarasamy S, Waghulde H, Gopalakrishnan K, Mell B, Morgan E, Joe B. Mutation
within the hinge region of the transcription factor Nr2f2 attenuates salt-sensitive
hypertension. Nat Commun 6: 6252, 2015. doi:10.1038/ncomms7252.
207. Kupper N, Willemsen G, Riese H, Posthuma D, Boomsma DI, de Geus EJ. Heritability
of daytime ambulatory blood pressure in an extended twin design. Hypertension 45:
80–85, 2005. doi:10.1161/01.HYP.0000149952.84391.54.
208. Kurtz TW, Simonet L, Kabra PM, Wolfe S, Chan L, Hjelle BL. Cosegregation of the
renin allele of the spontaneously hypertensive rat with an increase in blood pressure.
J Clin Invest 85: 1328–1332, 1990. doi:10.1172/JCI114572.
209. Kuwasako T, Hirano K, Sakai N, Ishigami M, Hiraoka H, Yakub MJ, Yamauchi-Takihara
K, Yamashita S, Matsuzawa Y. Lipoprotein abnormalities in human genetic CD36
deficiency associated with insulin resistance and abnormal fatty acid metabolism.
Diabetes Care 26: 1647–1648, 2003. doi:10.2337/diacare.26.5.1647-a.
210. Lauzier B, Merlen C, Vaillant F, McDuff J, Bouchard B, Beguin PC, Dolinsky VW, Foisy
S, Villeneuve LR, Labarthe F, Dyck JR, Allen BG, Charron G, Des Rosiers C. Post-
translational modifications, a key process in CD36 function: lessons from the sponta-
neously hypertensive rat heart. J Mol Cell Cardiol 51: 99–108, 2011. doi:10.1016/j.
yjmcc.2011.04.001.
211. Lee SJ, Liu J, Westcott AM, Vieth JA, DeRaedt SJ, Yang S, Joe B, Cicila GT. Substitution
mapping in Dahl rats identifies two distinct blood pressure quantitative trait loci within
1.12- and 1.25-mb intervals on chromosome 3. Genetics 174: 2203–2213, 2006.
doi:10.1534/genetics.106.061747.
212. Lee YH, Rosner B, Gould JB, Lowe EW, Kass EH. Familial aggregation of blood
pressures of newborn infants and their mother. Pediatrics 58: 722–729, 1976.
213. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison
AC, Johnson AD, Aspelund T, Aulchenko Y, Lumley T, Köttgen A, Vasan RS, Rivade-
neira F, Eiriksdottir G, Guo X, Arking DE, Mitchell GF, Mattace-Raso FU, Smith AV,
Taylor K, Scharpf RB, Hwang SJ, Sijbrands EJ, Bis J, Harris TB, Ganesh SK, O’Donnell
CJ, Hofman A, Rotter JI, Coresh J, Benjamin EJ, Uitterlinden AG, Heiss G, Fox CS,
Witteman JC, Boerwinkle E, Wang TJ, Gudnason V, Larson MG, Chakravarti A, Psaty
BM, van Duijn CM. Genome-wide association study of blood pressure and hyperten-
sion. Nat Genet 41: 677–687, 2009. doi:10.1038/ng.384.
214. Levy D, Larson MG, Benjamin EJ, Newton-Cheh C, Wang TJ, Hwang SJ, Vasan RS,
Mitchell GF. Framingham Heart Study 100K Project: genome-wide associations for
blood pressure and arterial stiffness. BMC Med Genet 8, Suppl 1: S3, 2007. doi:10.
1186/1471-2350-8-S1-S3.
215. Lewis O. Stephen Hales and the measurement of blood pressure. J Hum Hypertens 8:
865–871, 1994.
216. Liang M, Cowley AW Jr, Mattson DL, Kotchen TA, Liu Y. Epigenomics of hyperten-
sion. Semin Nephrol 33: 392–399, 2013. doi:10.1016/j.semnephrol.2013.05.011.
217. Lieberman-Aiden E, van Berkum NL, Williams L, Imakaev M, Ragoczy T, Telling A,
Amit I, Lajoie BR, Sabo PJ, Dorschner MO, Sandstrom R, Bernstein B, Bender MA,
Groudine M, Gnirke A, Stamatoyannopoulos J, Mirny LA, Lander ES, Dekker J. Com-
prehensive mapping of long-range interactions reveals folding principles of the human
genome. Science 326: 289–293, 2009. doi:10.1126/science.1181369.
218. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11
beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldo-
steronism and human hypertension. Nature 355: 262–265, 1992. doi:10.1038/
355262a0.
219. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell
104: 545–556, 2001. doi:10.1016/S0092-8674(01)00241-0.
220. Lin Y, Lai X, Chen B, Xu Y, Huang B, Chen Z, Zhu S, Yao J, Jiang Q, Huang H, Wen J,
Chen G. Genetic variations in CYP17A1, CACNB2 and PLEKHA7 are associated with
blood pressure and/or hypertension in She ethnic minority of China. Atherosclerosis
219: 709–714, 2011. doi:10.1016/j.atherosclerosis.2011.09.006.
221. Liu C, Li H, Qi Q, Lu L, Gan W, Loos RJ, Lin X. Common variants in or near FGF5,
CYP17A1 and MTHFR genes are associated with blood pressure and hypertension in
Chinese Hans. J Hypertens 29: 70–75, 2011. doi:10.1097/HJH.0b013e32833f60ab.
TOWARDS PRECISION MEDICINE FOR HYPERTENSION
1521Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
222. Liu X, Meng F, Yang P. Association study of CD36 single nucleotide polymorphisms
with essential hypertension in the Northeastern Han Chinese. Gene 527: 410–415,
2013. doi:10.1016/j.gene.2013.05.077.
223. Liu Y, Liu P, Yang C, Cowley AW Jr, Liang M. Base-resolution maps of 5-methylcyto-
sine and 5-hydroxymethylcytosine in Dahl S rats: effect of salt and genomic sequence.
Hypertension 63: 827–838, 2014. doi:10.1161/HYPERTENSIONAHA.113.02637.
224. Liu Y, Taylor NE, Lu L, Usa K, Cowley AW Jr, Ferreri NR, Yeo NC, Liang M. Renal
medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several colla-
gens and related genes. Hypertension 55: 974 –982, 2010. doi:10.1161/
HYPERTENSIONAHA.109.144428.
225. Lodwick D, Kaiser MA, Harris J, Cumin F, Vincent M, Samani NJ. Analysis of the role
of angiotensinogen in spontaneous hypertension. Hypertension 25: 1245–1251, 1995.
doi:10.1161/01.HYP.25.6.1245.
226. Longini IM Jr, Higgins MW, Hinton PC, Moll PP, Keller JB. Environmental and genetic
sources of familial aggregation of blood pressure in Tecumseh, Michigan. Am J Epide-
miol 120: 131–144, 1984. doi:10.1093/oxfordjournals.aje.a113862.
227. Lu X, Wang L, Lin X, Huang J, Charles Gu C, He M, Shen H, He J, Zhu J, Li H, Hixson
JE, Wu T, Dai J, Lu L, Shen C, Chen S, He L, Mo Z, Hao Y, Mo X, Yang X, Li J, Cao J,
Chen J, Fan Z, Li Y, Zhao L, Li H, Lu F, Yao C, Yu L, Xu L, Mu J, Wu X, Deng Y, Hu D,
Zhang W, Ji X, Guo D, Guo Z, Zhou Z, Yang Z, Wang R, Yang J, Zhou X, Yan W, Sun
N, Gao P, Gu D. Genome-wide association study in Chinese identifies novel loci for
blood pressure and hypertension. Hum Mol Genet 24: 865–874, 2015. doi:10.1093/
hmg/ddu478.
228. Luft FC. Twins in cardiovascular genetic research. Hypertension 37: 350–356, 2001.
doi:10.1161/01.HYP.37.2.350.
229. Mackay TF. Epistasis and quantitative traits: using model organisms to study gene-
gene interactions. Nat Rev Genet 15: 22–33, 2014. doi:10.1038/nrg3627.
230. Mackay TF, Moore JH. Erratum to: Why epistasis is important for tackling complex
human disease genetics. Genome Med 7: 85, 2015. doi:10.1186/s13073-015-0205-8.
231. Mackay TF, Moore JH. Why epistasis is important for tackling complex human disease
genetics. Genome Med 6: 124, 2014. doi:10.1186/gm561.
232. Manunta P, Cusi D, Barlassina C, Righetti M, Lanzani C, D’Amico M, Buzzi L, Citterio
L, Stella P, Rivera R, Bianchi G. Alpha-adducin polymorphisms and renal sodium
handling in essential hypertensive patients. Kidney Int 53: 1471–1478, 1998. doi:
10.1046/j.1523-1755.1998.00931.x.
233. Manunta P, Ferrandi M, Cusi D, Ferrari P, Staessen J, Bianchi G. Personalized Therapy
of Hypertension: the Past and the Future. Curr Hypertens Rep 18: 24, 2016. doi:10.
1007/s11906-016-0632-y.
234. Manunta P, Lavery G, Lanzani C, Braund PS, Simonini M, Bodycote C, Zagato L,
Delli Carpini S, Tantardini C, Brioni E, Bianchi G, Samani NJ. Physiological inter-
action between alpha-adducin and WNK1-NEDD4L pathways on sodium-related
blood pressure regulation. Hypertension 52: 366 –372, 2008. doi:10.1161/
HYPERTENSIONAHA.108.113977.
235. Manunta P, Maillard M, Tantardini C, Simonini M, Lanzani C, Citterio L, Stella P,
Casamassima N, Burnier M, Hamlyn JM, Bianchi G. Relationships among endoge-
nous ouabain, alpha-adducin polymorphisms and renal sodium handling in
primary hypertension. J Hypertens 26: 914 –920, 2008. doi:10.1097/HJH.
0b013e3282f5315f.
236. Markel’ AL. [Genetic model of stress-induced arterial hypertension]. Izv Akad Nauk
SSSR Biol 3: 466–469, 1985.
237. Mashimo T, Nabika T, Matsumoto C, Tamada T, Ueno K, Sawamura M, Ikeda K,
Kato N, Nara Y, Yamori Y. Aging and salt-loading modulate blood pressure QTLs
in rats. Am J Hypertens 12: 1098 –1104, 1999. doi:10.1016/S0895-
7061(99)00084-9.
238. Matsukawa N, Nonaka Y, Higaki J, Nagano M, Mikami H, Ogihara T, Okamoto M.
Dahl’s salt-resistant normotensive rat has mutations in cytochrome P450(11
beta), but the salt-sensitive hypertensive rat does not. J Biol Chem 268: 9117–
9121, 1993.
239. Mattson DL, Kunert MP, Kaldunski ML, Greene AS, Roman RJ, Jacob HJ, Cowley AW
Jr. Influence of diet and genetics on hypertension and renal disease in Dahl salt-
sensitive rats. Physiol Genomics 16: 194–203, 2004. doi:10.1152/physiolgenomics.
00151.2003.
240. Mattson DL, Meister CJ, Marcelle ML. Dietary protein source determines the degree
of hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension 45:
736–741, 2005. doi:10.1161/01.HYP.0000153318.74544.cc.
241. McBride MW, Carr FJ, Graham D, Anderson NH, Clark JS, Lee WK, Charchar FJ,
Brosnan MJ, Dominiczak AF. Microarray analysis of rat chromosome 2 congenic
strains. Hypertension 41: 847– 853, 2003. doi:10.1161/01.HYP.0000047103.
07205.03.
242. Mehta G, Mookerjee RP. Breaking bad: the two sides of gut microbiota in portal
hypertension. Liver Int 34: 1295–1297, 2014. doi:10.1111/liv.12598.
243. Mei H, Rice TK, Gu D, Hixson JE, Jaquish CE, Zhao Q, Chen JC, Cao J, Li J, Kelly TN,
Rao DC, He J. Genetic correlation of blood pressure responses to dietary sodium and
potassium intervention and cold pressor test in Chinese population. J Hum Hypertens
25: 500–508, 2011. doi:10.1038/jhh.2010.88.
244. Mell B, Abdul-Majeed S, Kumarasamy S, Waghulde H, Pillai R, Nie Y, Joe B. Multiple
blood pressure loci with opposing blood pressure effects on rat chromosome 1 in a
homologous region linked to hypertension on human chromosome 15. Hypertens Res
38: 61–67, 2015. doi:10.1038/hr.2014.134.
245. Mell B, Jala VR, Mathew AV, Byun J, Waghulde H, Zhang Y, Haribabu B, Vijay-Kumar
M, Pennathur S, Joe B. Evidence for a link between gut microbiota and hypertension
in the Dahl rat. Physiol Genomics 47: 187–197, 2015. doi:10.1152/physiolgenomics.
00136.2014.
246. Mendelsohn AR, Larrick JW. Dietary modification of the microbiome affects risk for
cardiovascular disease. Rejuvenation Res 16: 241–244, 2013. doi:10.1089/rej.2013.
1447.
247. Meng H, Garrett MR, Dene H, Rapp JP. Localization of a blood pressure QTL to a
2.4-cM interval on rat chromosome 9 using congenic strains. Genomics 81: 210–220,
2003. doi:10.1016/S0888-7543(03)00003-X.
248. Menni C, Graham D, Kastenmüller G, Alharbi NH, Alsanosi SM, McBride M, Mangino
M, Titcombe P, Shin SY, Psatha M, Geisendorfer T, Huber A, Peters A, Wang-Sattler
R, Xu T, Brosnan MJ, Trimmer J, Reichel C, Mohney RP, Soranzo N, Edwards MH,
Cooper C, Church AC, Suhre K, Gieger C, Dominiczak AF, Spector TD, Padmanab-
han S, Valdes AM. Metabolomic identification of a novel pathway of blood pressure
regulation involving hexadecanedioate. Hypertension 66: 422–429, 2015. doi:10.
1161/HYPERTENSIONAHA.115.05544.
249. Menni C, Mangino M, Cecelja M, Psatha M, Brosnan MJ, Trimmer J, Mohney RP,
Chowienczyk P, Padmanabhan S, Spector TD, Valdes AM. Metabolomic study of
carotid-femoral pulse-wave velocity in women. J Hypertens 33: 791–796, 2015. doi:
10.1097/HJH.0000000000000467.
250. Miyaoka K, Kuwasako T, Hirano K, Nozaki S, Yamashita S, Matsuzawa Y. CD36
deficiency associated with insulin resistance. Lancet 357: 686–687, 2001. doi:10.
1016/S0140-6736(00)04138-6.
251. Mo R, Omvik P, Lund-Johansen P. The Bergen blood pressure study: offspring of
two hypertensive parents have significantly higher blood pressures than offspring
of one hypertensive and one normotensive parent. J Hypertens 13: 1614 –1617,
1995.
252. Mongeau JG. Heredity and blood pressure in humans: an overview. Pediatr Nephrol 1:
69–75, 1987. doi:10.1007/BF00866887.
253. Monti J, Plehm R, Schulz H, Ganten D, Kreutz R, Hübner N. Interaction between
blood pressure quantitative trait loci in rats in which trait variation at chromosome 1
is conditional upon a specific allele at chromosome 10. Hum Mol Genet 12: 435–439,
2003. doi:10.1093/hmg/ddg041.
254. Monti J, Zimdahl H, Schulz H, Plehm R, Ganten D, Hübner N. The role of Wnk4 in
polygenic hypertension: a candidate gene analysis on rat chromosome 10. Hyperten-
sion 41: 938–942, 2003. doi:10.1161/01.HYP.0000063147.92433.7D.
255. Moreno C, Dumas P, Kaldunski ML, Tonellato PJ, Greene AS, Roman RJ, Cheng Q,
Wang Z, Jacob HJ, Cowley AW Jr. Genomic map of cardiovascular phenotypes of
hypertension in female Dahl S rats. Physiol Genomics 15: 243–257, 2003. doi:10.1152/
physiolgenomics.00105.2003.
256. Moreno C, Hoffman M, Stodola TJ, Didier DN, Lazar J, Geurts AM, North PE, Jacob
HJ, Greene AS. Creation and characterization of a renin knockout rat. Hypertension
57: 614–619, 2011. doi:10.1161/HYPERTENSIONAHA.110.163840.
SANDOSH PADMANABHAN AND BINA JOE
1522 Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
257. Moreno C, Kaldunski ML, Wang T, Roman RJ, Greene AS, Lazar J, Jacob HJ, Cowley
AW Jr. Multiple blood pressure loci on rat chromosome 13 attenuate development of
hypertension in the Dahl S hypertensive rat. Physiol Genomics 31: 228–235, 2007.
doi:10.1152/physiolgenomics.00280.2006.
258. Moreno C, Williams JM, Lu L, Liang M, Lazar J, Jacob HJ, Cowley AW Jr, Roman RJ.
Narrowing a region on rat chromosome 13 that protects against hypertension in Dahl
SS-13BN congenic strains. Am J Physiol Heart Circ Physiol 300: H1530–H1535, 2011.
doi:10.1152/ajpheart.01026.2010.
258a.Moujahidine M, Dutil J, Hamet P, Deng AY. Congenic mapping of a blood pressure
QTL on chromosome 16 of DahI rats. Mamm Genome 13: 153–156, 2002. doi:10.
1007/s00335-00L-21-3.
258b.Moujahidine M, Lambert R, Duti L J, Palijan A, Sivo Z, Ariyarajah A, Deng AY. Com-
bining congenic coverage with gene profiling in search of candidates for blood pres-
sure quantitative trait loci in Dahl rats . Hypertens Res 27: 203–212, 2004.
259. Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV, Li X,
Li H, Kuperwasser N, Ruda VM, Pirruccello JP, Muchmore B, Prokunina-Olsson L,
Hall JL, Schadt EE, Morales CR, Lund-Katz S, Phillips MC, Wong J, Cantley W,
Racie T, Ejebe KG, Orho-Melander M, Melander O, Koteliansky V, Fitzgerald K,
Krauss RM, Cowan CA, Kathiresan S, Rader DJ. From noncoding variant to phe-
notype via SORT1 at the 1p13 cholesterol locus. Nature 466: 714 –719, 2010.
doi:10.1038/nature09266.
260. Mutig K, Kahl T, Saritas T, Godes M, Persson P, Bates J, Raffi H, Rampoldi L, Uchida S,
Hille C, Dosche C, Kumar S, Castañeda-Bueno M, Gamba G, Bachmann S. Activation
of the bumetanide-sensitive Na,K,2Cl- cotransporter (NKCC2) is facilitated by
Tamm-Horsfall protein in a chloride-sensitive manner. J Biol Chem 286: 30200–
30210, 2011. doi:10.1074/jbc.M111.222968.
261. Nabika T, Ohara H, Kato N, Isomura M. The stroke-prone spontaneously hyperten-
sive rat: still a useful model for post-GWAS genetic studies? Hypertens Res 35: 477–
484, 2012. doi:10.1038/hr.2012.30.
262. Nakajima T, Wooding S, Sakagami T, Emi M, Tokunaga K, Tamiya G, Ishigami T,
Umemura S, Munkhbat B, Jin F, Guan-Jun J, Hayasaka I, Ishida T, Saitou N, Pavelka K,
Lalouel JM, Jorde LB, Inoue I. Natural selection and population history in the human
angiotensinogen gene (AGT): 736 complete AGT sequences in chromosomes from
around the world. Am J Hum Genet 74: 898–916, 2004. doi:10.1086/420793.
263. Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D. Gut microbiome in chronic
kidney disease: challenges and opportunities. Transl Res 179: 24–37, 2017 doi:10.
1016/j.trsl.2016.04.007.
263a.Negrín CD, McBride MW, Carswell HV, Graham D, Carr FJ, Clark JS, Jeffs B, Ander-
son NH, Macrae IM, Dominczak AF. Reciprocal consomic strains to evaluate y chro-
mosome effects. Hypertension 37: 391–397, 2001.
264. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS,
Zhao JH, Heath SC, Eyheramendy S, Papadakis K, Voight BF, Scott LJ, Zhang F,
Farrall M, Tanaka T, Wallace C, Chambers JC, Khaw KT, Nilsson P, van der Harst
P, Polidoro S, Grobbee DE, Onland-Moret NC, Bots ML, Wain LV, Elliott KS,
Teumer A, Luan J, Lucas G, Kuusisto J, Burton PR, Hadley D, McArdle WL, Brown
M, Dominiczak A, Newhouse SJ, Samani NJ, Webster J, Zeggini E, Beckmann JS,
Bergmann S, Lim N, Song K, Vollenweider P, Waeber G, Waterworth DM, Yuan
X, Groop L, Orho-Melander M, Allione A, Di Gregorio A, Guarrera S, Panico S,
Ricceri F, Romanazzi V, Sacerdote C, Vineis P, Barroso I, Sandhu MS, Luben RN,
Crawford GJ, Jousilahti P, Perola M, Boehnke M, Bonnycastle LL, Collins FS,
Jackson AU, Mohlke KL, Stringham HM, Valle TT, Willer CJ, Bergman RN, Morken
MA, Döring A, Gieger C, Illig T, Meitinger T, Org E, Pfeufer A, Wichmann HE,
Kathiresan S, Marrugat J, O’Donnell CJ, Schwartz SM, Siscovick DS, Subirana I,
Freimer NB, Hartikainen AL, McCarthy MI, O’Reilly PF, Peltonen L, Pouta A, de
Jong PE, Snieder H, van Gilst WH, Clarke R, Goel A, Hamsten A, Peden JF, Seedorf
U, Syvänen AC, Tognoni G, Lakatta EG, Sanna S, Scheet P, Schlessinger D, Scuteri
A, Dörr M, Ernst F, Felix SB, Homuth G, Lorbeer R, Reffelmann T, Rettig R, Völker
U, Galan P, Gut IG, Hercberg S, Lathrop GM, Zelenika D, Deloukas P, Soranzo N,
Williams FM, Zhai G, Salomaa V, Laakso M, Elosua R, Forouhi NG, Völzke H,
Uiterwaal CS, van der Schouw YT, Numans ME, Matullo G, Navis G, Berglund G,
Bingham SA, Kooner JS, Connell JM, Bandinelli S, Ferrucci L, Watkins H, Spector
TD, Tuomilehto J, Altshuler D, Strachan DP, Laan M, Meneton P, Wareham NJ,
Uda M, Jarvelin MR, Mooser V, Melander O, Loos RJ, Elliott P, Abecasis GR,
Caulfield M, Munroe PB; Wellcome Trust Case Control Consortium. Genome-
wide association study identifies eight loci associated with blood pressure. Nat
Genet 41: 666 – 676, 2009. doi:10.1038/ng.361.
265. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C,
Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S,
Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander
O, Wang TJ. Association of common variants in NPPA and NPPB with circulating
natriuretic peptides and blood pressure. Nat Genet 41: 348–353, 2009. doi:10.1038/
ng.328.
266. Nguyen KD, Pihur V, Ganesh SK, Rakha A, Cooper RS, Hunt SC, Freedman BI, Coresh
J, Kao WH, Morrison AC, Boerwinkle E, Ehret GB, Chakravarti A. Effects of rare and
common blood pressure gene variants on essential hypertension: results from the
Family Blood Pressure Program, CLUE, and Atherosclerosis Risk in Communities
studies. Circ Res 112: 318–326, 2013. doi:10.1161/CIRCRESAHA.112.276725.
267. Nie Y, Kumarasamy S, Waghulde H, Cheng X, Mell B, Czernik PJ, Lecka-Czernik
B, Joe B. High-resolution mapping of a novel rat blood pressure locus on chro-
mosome 9 to a region containing the Spp2 gene and colocalization of a QTL for
bone mass. Physiol Genomics 48: 409 – 419, 2016. doi:10.1152/physiolgenomics.
00004.2016.
268. Nie Y, Kumarasamy S, Waghulde H, Cheng X, Mell B, Czernik PJ, Lecka-Czernik B,
Joe B. High-resolution mapping of a novel rat blood pressure locus on chromosome 9
to a region containing the Spp2 gene and colocalization of a QTL for bone mass.
Physiol Genomics 48: 409–419, 2016. doi:10.1152/physiolgenomics.00004.2016.
269. Nonaka Y, Fujii T, Kagawa N, Waterman MR, Takemori H, Okamoto M. Structure/
function relationship of CYP11B1 associated with Dahl’s salt-resistant rats–expres-
sion of rat CYP11B1 and CYP11B2 in Escherichia coli. Eur J Biochem 258: 869–878,
1998. doi:10.1046/j.1432-1327.1998.2580869.x.
270. Oh YS, Appel LJ, Galis ZS, Hafler DA, He J, Hernandez AL, Joe B, Karumanchi SA,
Maric-Bilkan C, Mattson D, Mehta NN, Randolph G, Ryan M, Sandberg K, Titze J,
Tolunay E, Toney GM, Harrison DG. National Heart, Lung, and Blood Institute
Working Group Report on Salt in Human Health and Sickness: Building on the
Current Scientific Evidence. Hypertension 68: 281–288, 2016 doi:10.1161/
HYPERTENSIONAHA.116.07415.
271. Ohno Y, Tanase H, Nabika T, Otsuka K, Sasaki T, Suzawa T, Morii T, Yamori Y, Saruta
T. Selective genotyping with epistasis can be utilized for a major quantitative trait locus
mapping in hypertension in rats. Genetics 155: 785–792, 2000.
272. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn
Circ J 27: 282–293, 1963. doi:10.1253/jcj.27.282.
273. Oldham PD, Pickering G, Roberts JA, Sowry GS. The nature of essential hypertension.
Lancet 1: 1085–1093, 1960. doi:10.1016/S0140-6736(60)90982-X.
274. Overgaard MT, Boldt HB, Laursen LS, Sottrup-Jensen L, Conover CA, Oxvig C.
Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth fac-
tor-binding protein-5 proteinase. J Biol Chem 276: 21849–21853, 2001. doi:10.1074/
jbc.M102191200.
275. Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hy-
pertension. Circ Res 116: 937–959, 2015. doi:10.1161/CIRCRESAHA.116.303647.
276. Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D,
Hastie CE, Menni C, Monti MC, Delles C, Laing S, Corso B, Navis G, Kwakernaak
AJ, van der Harst P, Bochud M, Maillard M, Burnier M, Hedner T, Kjeldsen S,
Wahlstrand B, Sjögren M, Fava C, Montagnana M, Danese E, Torffvit O, Hedblad
B, Snieder H, Connell JM, Brown M, Samani NJ, Farrall M, Cesana G, Mancia G,
Signorini S, Grassi G, Eyheramendy S, Wichmann HE, Laan M, Strachan DP, Sever
P, Shields DC, Stanton A, Vollenweider P, Teumer A, Völzke H, Rettig R, Newton-
Cheh C, Arora P, Zhang F, Soranzo N, Spector TD, Lucas G, Kathiresan S,
Siscovick DS, Luan J, Loos RJ, Wareham NJ, Penninx BW, Nolte IM, McBride M,
Miller WH, Nicklin SA, Baker AH, Graham D, McDonald RA, Pell JP, Sattar N,
Welsh P, Munroe P, Caulfield MJ, Zanchetti A, Dominiczak AF; Global BPgen
Consortium. Genome-wide association study of blood pressure extremes identi-
fies variant near UMOD associated with hypertension. PLoS Genet 6: e1001177,
2010. doi:10.1371/journal.pgen.1001177.
277. Palijan A, Dutil J, Deng AY. Quantitative trait loci with opposing blood pressure effects
demonstrating epistasis on Dahl rat chromosome 3. Physiol Genomics 15: 1–8, 2003.
doi:10.1152/physiolgenomics.00084.2003.
278. Palijan A, Lambert R, Dutil J, Sivo Z, Deng AY. Comprehensive congenic coverage
revealing multiple blood pressure quantitative trait loci on Dahl rat chrom-
osome 10. Hypertension 42: 515–522, 2003. doi:10.1161/01.HYP.0000090096.
88509.15.
TOWARDS PRECISION MEDICINE FOR HYPERTENSION
1523Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
279. Paschoud S, Jond L, Guerrera D, Citi S. PLEKHA7 modulates epithelial tight junction
barrier function. Tissue Barriers 2: e28755, 2014. doi:10.4161/tisb.28755.
279a.Pausova Z, Sedova L, Berube J, Hamet P, Tremblay J, Dumont M, Gaudet D, Pravenec
M, Kren V, Kunes J. Segment of rat chromosome 20 regulates diet-induced augmen-
tations in adiposity, glucose intolerance, and blood pressure . Hypertension 41: 1047–
1055, 2003.
280. Pickering G. Hypertension. Definitions, natural histories and consequences. Am J Med
52: 570–583, 1972. doi:10.1016/0002-9343(72)90049-6.
281. Pickering G. Normotension and hypertension: the mysterious viability of the false. Am
J Med 65: 561–563, 1978. doi:10.1016/0002-9343(78)90839-2.
282. Pickering GW. High Blood Pressure. New York: Grune & Stratton, 1968, p. viii.
283. Pickering GW. [Relation between genetic and social factors and arterial pressure].
Recenti Prog Med 30: 397–416, 1961.
284. Pillai R, Waghulde H, Nie Y, Gopalakrishnan K, Kumarasamy S, Farms P, Garrett MR,
Atanur SS, Maratou K, Aitman TJ, Joe B. Isolation and high-throughput sequencing of
two closely linked epistatic hypertension susceptibility loci with a panel of bicongenic
strains. Physiol Genomics 45: 729–736, 2013. doi:10.1152/physiolgenomics.00077.
2013.
285. Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, Brunet I, Wan LX,
Rey F, Wang T, Firestein SJ, Yanagisawa M, Gordon JI, Eichmann A, Peti-Peterdi J,
Caplan MJ. Olfactory receptor responding to gut microbiota-derived signals plays a
role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA 110:
4410–4415, 2013. doi:10.1073/pnas.1215927110.
286. Pravenec M, Churchill PC, Churchill MC, Viklicky O, Kazdova L, Aitman TJ, Petretto
E, Hubner N, Wallace CA, Zimdahl H, Zidek V, Landa V, Dunbar J, Bidani A, Griffin K,
Qi N, Maxova M, Kren V, Mlejnek P, Wang J, Kurtz TW. Identification of renal Cd36
as a determinant of blood pressure and risk for hypertension. Nat Genet 40: 952–954,
2008. doi:10.1038/ng.164.
287. Pravenec M, Gauguier D, Schott JJ, Buard J, Kren V, Bila V, Szpirer C, Szpirer J, Wang
JM, Huang H. Mapping of quantitative trait loci for blood pressure and cardiac mass in
the rat by genome scanning of recombinant inbred strains. J Clin Invest 96: 1973–1978,
1995. doi:10.1172/JCI118244.
288. Pravenec M, Klír P, Kren V, Zicha J, Kunes J. An analysis of spontaneous hypertension
in spontaneously hypertensive rats by means of new recombinant inbred strains. J
Hypertens 7: 217–221, 1989. doi:10.1097/00004872-198903000-00008.
289. Pravenec M, Kren V, Krenová D, Zídek V, Simáková M, Musilová A, Vorlícek J, Lezin
ES, Kurtz TW. Genetic isolation of quantitative trait loci for blood pressure develop-
ment and renal mass on chromosome 5 in the spontaneously hypertensive rat. Physiol
Res 52: 285–289, 2003.
290. Pravenec M, Kren V, Kunes J, Scicli AG, Carretero OA, Simonet L, Kurtz TW. Co-
segregation of blood pressure with a kallikrein gene family polymorphism. Hyperten-
sion 17: 242–246, 1991. doi:10.1161/01.HYP.17.2.242.
291. Pravenec M, Kurtz TW. Genetics of Cd36 and the hypertension metabolic syndrome.
Semin Nephrol 22: 148–153, 2002. doi:10.1053/snep.2002.2002.30218.
292. Pravenec M, Simonet L, Kren V, Kunes J, Levan G, Szpirer J, Szpirer C, Kurtz T. The rat
renin gene: assignment to chromosome 13 and linkage to the regulation of blood pres-
sure. Genomics 9: 466–472, 1991. doi:10.1016/0888-7543(91)90412-8.
293. Pravenec M, Zídek V, Musilová A, Vorlícek J, Kren V, St Lezin E, Kurtz TW. Genetic
isolation of a blood pressure quantitative trait locus on chromosome 2 in the sponta-
neously hypertensive rat. J Hypertens 19: 1061–1064, 2001. doi:10.1097/00004872-
200106000-00010.
294. Pravenec M, Zidek V, Simakova M, Kren V, Krenova D, Horky K, Jachymova M,
Mikova B, Kazdova L, Aitman TJ, Churchill PC, Webb RC, Hingarh NH, Yang Y, Wang
JM, Lezin EM, Kurtz TW. Genetics of Cd36 and the clustering of multiple cardiovas-
cular risk factors in spontaneous hypertension. J Clin Invest 103: 1651–1657, 1999.
doi:10.1172/JCI6691.
295. Pulimeno P, Bauer C, Stutz J, Citi S. PLEKHA7 is an adherens junction protein with a
tissue distribution and subcellular localization distinct from ZO-1 and E-cadherin. PLoS
One 5: e12207, 2010. doi:10.1371/journal.pone.0012207.
296. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions.
J Am Soc Nephrol 25: 657–670, 2014. doi:10.1681/ASN.2013080905.
297. Ramos A, Moisan MP, Chaouloff F, Mormède C, Mormède P. Identification of female-
specific QTLs affecting an emotionality-related behavior in rats. Mol Psychiatry 4:
453–462, 1999. doi:10.1038/sj.mp.4000546.
298. Rapp JP. Genetic analysis of inherited hypertension in the rat. Physiol Rev 80: 135–172,
2000.
299. Rapp JP. Theoretical model for gene-gene, gene-environment, and gene-sex interac-
tions based on congenic-strain analysis of blood pressure in Dahl salt-sensitive rats.
Physiol Genomics 45: 737–750, 2013. doi:10.1152/physiolgenomics.00046.2013.
300. Rapp JP, Dahl LK. 18-Hydrox-deoxycorticosterone secretion in experimental hyper-
tension in rats. Circ Res 28, Suppl 2: 153–159, 1971. doi:10.1161/01.RES.28.5.II-153.
301. Rapp JP, Dahl LK. Adrenal steroidogenesis in rats bred for susceptibility and resistance
to the hypertensive effect of salt. Endocrinology 88: 52–65, 1971. doi:10.1210/endo-
88-1-52.
302. Rapp JP, Dahl LK. Mendelian inheritance of 18- and ll beta-steroid hydroxylase activ-
ities in the adrenals of rats genetically susceptible or resistant to hypertension. Endo-
crinology 90: 1435–1446, 1972. doi:10.1210/endo-90-6-1435.
303. Rapp JP, Dahl LK. Mutant forms of cytochrome P-450 controlling both 18- and
11beta-steroid hydroxylation in the rat. Biochemistry 15: 1235–1242, 1976. doi:
10.1021/bi00651a010.
304. Rapp JP, Dahl LK. Possible role of 18-hydroxy-deoxycorticosterone in hypertension.
Nature 237: 338–339, 1972. doi:10.1038/237338a0.
305. Rapp JP, Garrett MR, Dene H, Meng H, Hoebee B, Lathrop GM. Linkage analysis and
construction of a congenic strain for a blood pressure QTL on rat chromosome 9.
Genomics 51: 191–196, 1998. doi:10.1006/geno.1998.5394.
306. Rapp JP, Garrett MR, Deng AY. Construction of a double congenic strain to prove an
epistatic interaction on blood pressure between rat chromosomes 2 and 10. J Clin
Invest 101: 1591–1595, 1998. doi:10.1172/JCI2251.
307. Rapp JP, Joe B. Do epistatic modules exist in the genetic control of blood pressure in
Dahl rats? A critical perspective. Physiol Genomics 45: 1193–1195, 2013. doi:10.1152/
physiolgenomics.00159.2013.
308. Rapp JP, Joe B. Use of contiguous congenic strains in analyzing compound QTLs.
Physiol Genomics 44: 117–120, 2012. doi:10.1152/physiolgenomics.00136.2011.
309. Rapp JP, Tan SY, Margolius HS. Plasma mineralocorticoids, plasma renin, and urinary
kallikrein in salt-sensitive and salt-resistant rats. Endocr Res Commun 5: 35–41, 1978.
doi:10.3109/07435807809073634.
310. Rapp JP, Wang SM, Dene H. Effect of genetic background on cosegregation of renin
alleles and blood pressure in Dahl rats. Am J Hypertens 3: 391–396, 1990. doi:10.1093/
ajh/3.5.391.
311. Rapp JP, Wang SM, Dene H. A genetic polymorphism in the renin gene of Dahl rats
cosegregates with blood pressure. Science 243: 542–544, 1989. doi:10.1126/science.
2563177.
312. Redina OE, Lapteva NE, Khanina SL, Machanova NA, Dymshits GM, Markel AL. The
region of rat chromosome 10 (the ngfr gene locus) is associated with blood pressure
increase in response to emotional stress. Dokl Biochem Biophys 380: 349–351, 2001.
doi:10.1023/A:1012352512006.
313. Redina OE, Machanova NA, Efimov VM, Markel AL. Rats with inherited stress-in-
duced arterial hypertension (ISIAH strain) display specific quantitative trait loci for
blood pressure and for body and kidney weight on chromosome 1. Clin Exp Pharmacol
Physiol 33: 456–464, 2006. doi:10.1111/j.1440-1681.2006.04387.x.
314. Redina OE, Smolenskaya SE, Maslova LN, Markel AL. The genetic control of blood
pressure and body composition in rats with stress-sensitive hypertension. Clin Exp
Hypertens 35: 484–495, 2013. doi:10.3109/10641963.2012.758274.
315. Vietri Rudan M, Hadjur S, Sexton T. Detecting Spatial Chromatin Organization by
Chromosome Conformation Capture II: Genome-Wide Profiling by Hi-C. Methods
Mol Biol 1589: 47–74, 2017. doi:10.1007/7651_2015_261.
316. Rudemiller N, Lund H, Jacob HJ, Geurts AM, Mattson DL; PhysGen Knockout Pro-
gram. CD247 modulates blood pressure by altering T-lymphocyte infiltration in the
kidney. Hypertension 63: 559–564, 2014. doi:10.1161/HYPERTENSIONAHA.113.
02191.
SANDOSH PADMANABHAN AND BINA JOE
1524 Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
317. Rudemiller NP, Lund H, Priestley JR, Endres BT, Prokop JW, Jacob HJ, Geurts AM,
Cohen EP, Mattson DL. Mutation of SH2B3 (LNK), a genome-wide association
study candidate for hypertension, attenuates Dahl salt-sensitive hypertension via
inflammatory modulation. Hypertension 65: 1111–1117, 2015. doi:10.1161/
HYPERTENSIONAHA.114.04736.
318. Saad Y, Garrett MR, Manickavasagam E, Yerga-Woolwine S, Farms P, Radecki T, Joe
B. Fine-mapping and comprehensive transcript analysis reveals nonsynonymous vari-
ants within a novel 1.17 Mb blood pressure QTL region on rat chromosome 10.
Genomics 89: 343–353, 2007. doi:10.1016/j.ygeno.2006.12.005.
319. Saad Y, Garrett MR, Rapp JP. Multiple blood pressure QTL on rat chromosome 1
defined by Dahl rat congenic strains. Physiol Genomics 4: 201–214, 2001.
320. Saad Y, Yerga-Woolwine S, Saikumar J, Farms P, Manickavasagam E, Toland EJ, Joe B.
Congenic interval mapping of RNO10 reveals a complex cluster of closely-linked
genetic determinants of blood pressure. Hypertension 50: 891–898, 2007. doi:10.
1161/HYPERTENSIONAHA.107.097105.
321. Salvi E, Kutalik Z, Glorioso N, Benaglio P, Frau F, Kuznetsova T, Arima H, Hoggart
C, Tichet J, Nikitin YP, Conti C, Seidlerova J, Tikhonoff V, Stolarz-Skrzypek K,
Johnson T, Devos N, Zagato L, Guarrera S, Zaninello R, Calabria A, Stancanelli B,
Troffa C, Thijs L, Rizzi F, Simonova G, Lupoli S, Argiolas G, Braga D, D’Alessio
MC, Ortu MF, Ricceri F, Mercurio M, Descombes P, Marconi M, Chalmers J,
Harrap S, Filipovsky J, Bochud M, Iacoviello L, Ellis J, Stanton AV, Laan M, Pad-
manabhan S, Dominiczak AF, Samani NJ, Melander O, Jeunemaitre X, Manunta P,
Shabo A, Vineis P, Cappuccio FP, Caulfield MJ, Matullo G, Rivolta C, Munroe PB,
Barlassina C, Staessen JA, Beckmann JS, Cusi D. Genomewide association study
using a high-density single nucleotide polymorphism array and case-control design
identifies a novel essential hypertension susceptibility locus in the promoter re-
gion of endothelial NO synthase. Hypertension 59: 248 –255, 2012. doi:10.1161/
HYPERTENSIONAHA.111.181990.
322. Samani NJ, Gauguier D, Vincent M, Kaiser MA, Bihoreau MT, Lodwick D, Wallis R,
Parent V, Kimber P, Rattray F, Thompson JR, Sassard J, Lathrop M. Analysis of quan-
titative trait loci for blood pressure on rat chromosomes 2 and 13. Age-related
differences in effect. Hypertension 28: 1118–1122, 1996. doi:10.1161/01.HYP.28.6.
1118.
323. Samani NJ, Lodwick D, Vincent M, Dubay C, Kaiser MA, Kelly MP, Lo M, Harris J,
Sassard J, Lathrop M. A gene differentially expressed in the kidney of the spontane-
ously hypertensive rat cosegregates with increased blood pressure. J Clin Invest 92:
1099–1103, 1993. doi:10.1172/JCI116616.
324. Santisteban MM, Kim S, Pepine CJ, Raizada MK. Brain-Gut-Bone Marrow Axis: Impli-
cations for Hypertension and Related Therapeutics. Circ Res 118: 1327–1336, 2016.
doi:10.1161/CIRCRESAHA.116.307709.
325. Sati S, Cavalli G. Chromosome conformation capture technologies and their impact in
understanding genome function. Chromosoma 126: 33–44, 2017 doi:10.1007/s00412-
016-0593-6.
326. Schlager G, Chao CS. The role of dominance and epistasis in the genetic control of
blood pressure in rodent models of hypertension. Clin Exp Hypertens A 13: 947–953,
1991.
327. Schork NJ, Krieger JE, Trolliet MR, Franchini KG, Koike G, Krieger EM, Lander ES,
Dzau VJ, Jacob HJ. A biometrical genome search in rats reveals the multigenic basis of
blood pressure variation. Genome Res 5: 164–172, 1995. doi:10.1101/gr.5.2.164.
328. Schulz A, Litfin A, Kossmehl P, Kreutz R. Genetic dissection of increased urinary
albumin excretion in the Munich Wistar Frömter rat. J Am Soc Nephrol 13: 2706–2714,
2002. doi:10.1097/01.ASN.0000031803.55613.86.
329. Schüpbach T, Xenarios I, Bergmann S, Kapur K. FastEpistasis: a high performance
computing solution for quantitative trait epistasis. Bioinformatics 26: 1468–1469,
2010. doi:10.1093/bioinformatics/btq147.
330. Schutte AE, Huisman HW, van Rooyen JM, Malan L, Malan NT, Fourie CM, Louw R,
van der Westhuizen FH, Schutte R. A significant decline in IGF-I may predispose young
Africans to subsequent cardiometabolic vulnerability. J Clin Endocrinol Metab 95:
2503–2507, 2010. doi:10.1210/jc.2009-2329.
331. Seidlerová J, Staessen JA, Bochud M, Nawrot T, Casamassima N, Citterio L,
Kuznetsova T, Jin Y, Manunta P, Richart T, Struijker-Boudier HA, Fagard R, Fili-
povský J, Bianchi G. Arterial properties in relation to genetic variations in the
adducin subunits in a white population. Am J Hypertens 22: 21–26, 2009. doi:10.
1038/ajh.2008.261.
332. Shah J, Guerrera D, Vasileva E, Sluysmans S, Bertels E, Citi S. PLEKHA7: Cytoskeletal
adaptor protein at center stage in junctional organization and signaling. Int J Biochem
Cell Biol 75: 112–116, 2016. doi:10.1016/j.biocel.2016.04.001.
333. Shear CL, Burke GL, Freedman DS, Berenson GS. Value of childhood blood
pressure measurements and family history in predicting future blood pressure
status: results from 8 years of follow-up in the Bogalusa Heart Study. Pediatrics 77:
862– 869, 1986.
334. Shear CL, Freedman DS, Burke GL, Harsha DW, Berenson GS. Body fat patterning
and blood pressure in children and young adults. The Bogalusa Heart Study. Hyper-
tension 9: 236–244, 1987. doi:10.1161/01.HYP.9.3.236.
335. Shibao CA, Celedonio JE, Ramirez CE, Love-Gregory L, Arnold AC, Choi L,
Okamoto LE, Gamboa A, Biaggioni I, Abumrad NN, Abumrad NA. A Common
CD36 Variant Influences Endothelial Function and Response to Treatment with
Phosphodiesterase 5 Inhibition. J Clin Endocrinol Metab 101: 2751–2758, 2016
doi:10.1210/jc.2016-1294.
336. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan
M, Gill JR Jr, Ulick S, Milora RV, Findling JW, Canessa CM, Rossier BC, Lifton RP.
Liddle’s syndrome: heritable human hypertension caused by mutations in the beta
subunit of the epithelial sodium channel. Cell 79: 407–414, 1994. doi:10.1016/0092-
8674(94)90250-X.
337. Shiozawa M, Provoost AP, van Dokkum RP, Majewski RR, Jacob HJ. Evidence of
gene-gene interactions in the genetic susceptibility to renal impairment after unilateral
nephrectomy. J Am Soc Nephrol 11: 2068–2078, 2000.
338. Siegel AK, Kossmehl P, Planert M, Schulz A, Wehland M, Stoll M, Bruijn JA, de Heer E,
Kreutz R. Genetic linkage of albuminuria and renal injury in Dahl salt-sensitive rats on
a high-salt diet: comparison with spontaneously hypertensive rats. Physiol Genomics
18: 218–225, 2004. doi:10.1152/physiolgenomics.00068.2004.
339. Siegel AK, Planert M, Rademacher S, Mehr AP, Kossmehl P, Wehland M, Stoll M,
Kreutz R. Genetic loci contribute to the progression of vascular and cardiac hyper-
trophy in salt-sensitive spontaneous hypertension. Arterioscler Thromb Vasc Biol 23:
1211–1217, 2003. doi:10.1161/01.ATV.0000079509.20542.C9.
340. Silva GJ, Pereira AC, Krieger EM, Krieger JE. Genetic mapping of a new heart rate
QTL on chromosome 8 of spontaneously hypertensive rats. BMC Med Genet 8: 17,
2007. doi:10.1186/1471-2350-8-17.
341. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter’s syn-
drome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the
Na-K-2Cl cotransporter NKCC2. Nat Genet 13: 183–188, 1996. doi:10.1038/
ng0696-183.
342. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata
F, Cushner HM, Koolen M, Gainza FJ, Gitleman HJ, Lifton RP. Gitelman’s variant of
Bartter’s syndrome, inherited hypokalaemic alkalosis, is caused by mutations in
the thiazide-sensitive Na-Cl cotransporter. Nat Genet 12: 24 –30, 1996. doi:10.
1038/ng0196-24.
343. Smirk FH, Hall WH. Inherited hypertension in rats. Nature 182: 727–728, 1958.
doi:10.1038/182727a0.
344. Smolarek I, Wyszko E, Barciszewska AM, Nowak S, Gawronska I, Jablecka A, Bar-
ciszewska MZ. Global DNA methylation changes in blood of patients with essential
hypertension. Med Sci Monit 16: CR149–CR155, 2010.
345. Soler JM, Pereira AC, Tôrres CH, Krieger JE. Gene by environment QTL mapping
through multiple trait analyses in blood pressure salt-sensitivity: identification of a
novel QTL in rat chromosome 5. BMC Med Genet 7: 47, 2006. doi:10.1186/1471-
2350-7-47.
346. St Lezin E, Liu W, Wang JM, Yang Y, Qi N, Kren V, Zidek V, Kurtz TW, Pravenec M.
Genetic analysis of rat chromosome 1 and the Sa gene in spontaneous hypertension.
Hypertension 35: 225–230, 2000. doi:10.1161/01.HYP.35.1.225.
346a.St Lezin E, Zhang L, Yang Y, Wang JM, Wang N, Qi N, Steadman JS, Liu W, Kren V,
Zidek V, Krenova D, Churchill PC, Churchill MC, Pravenec M. Effect of chromosome
19 transfer on blood pressure in the spontaneously hypertensive rat. Hypertension 33:
256–260, 1999.
347. Staessen JA, Thijs L, Stolarz-Skrzypek K, Bacchieri A, Barton J, Espositi ED, de Leeuw
PW, Dłuz˙niewski M, Glorioso N, Januszewicz A, Manunta P, Milyagin V, Nikitin Y,
Souek M, Lanzani C, Citterio L, Timio M, Tykarski A, Ferrari P, Valentini G,
Kawecka-Jaszcz K, Bianchi G. Main results of the ouabain and adducin for Specific
TOWARDS PRECISION MEDICINE FOR HYPERTENSION
1525Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-
controlled phase-2 dose-finding study of rostafuroxin. Trials 12: 13, 2011. doi:10.
1186/1745-6215-12-13.
348. Stec DE, Trolliet MR, Krieger JE, Jacob HJ, Roman RJ. Renal cytochrome P4504A
activity and salt sensitivity in spontaneously hypertensive rats. Hypertension 27: 1329–
1336, 1996. doi:10.1161/01.HYP.27.6.1329.
349. Steinmetz LM, Sinha H, Richards DR, Spiegelman JI, Oefner PJ, McCusker JH, Davis
RW. Dissecting the architecture of a quantitative trait locus in yeast. Nature 416:
326–330, 2002. doi:10.1038/416326a.
350. Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wägele B, Altmaier E,
Deloukas P, Erdmann J, Grundberg E, Hammond CJ, de Angelis MH, Kastenmüller G,
Köttgen A, Kronenberg F, Mangino M, Meisinger C, Meitinger T, Mewes HW, Milburn
MV, Prehn C, Raffler J, Ried JS, Römisch-Margl W, Samani NJ, Small KS, Wichmann
HE, Zhai G, Illig T, Spector TD, Adamski J, Soranzo N, Gieger C; CARDIoGRAM.
Human metabolic individuality in biomedical and pharmaceutical research. Nature
477: 54–60, 2011. doi:10.1038/nature10354.
351. Sun L, McArdle S, Chun M, Wolff DW, Pettinger WA. Cosegregation of the renin gene
with an increase in mean arterial blood pressure in the F2 rats of SHR-WKY cross. Clin
Exp Hypertens 15: 797–805, 1993. doi:10.3109/10641969309041642.
352. Takami S, Higaki J, Miki T, Katsuya T, Nakata Y, Rakugi H, Serikawa T, Ogihara T. Analysis
and comparison of new candidate loci for hypertension between genetic hypertensive rat
strains. Hypertens Res 19: 51–56, 1996. doi:10.1291/hypres.19.51.
353. Taylor MB, Ehrenreich IM. Higher-order genetic interactions and their contribution
to complex traits. Trends Genet 31: 34–40, 2015. doi:10.1016/j.tig.2014.09.001.
354. Thiel BA, Chakravarti A, Cooper RS, Luke A, Lewis S, Lynn A, Tiwari H, Schork NJ,
Weder AB. A genome-wide linkage analysis investigating the determinants of blood
pressure in whites and African Americans. Am J Hypertens 16: 151–153, 2003. doi:10.
1016/S0895-7061(02)03246-6.
355. Toland EJ, Saad Y, Yerga-Woolwine S, Ummel S, Farms P, Ramdath R, Frank BC, Lee
NH, Joe B. Closely linked non-additive blood pressure quantitative trait loci. Mamm
Genome 19: 209–218, 2008. doi:10.1007/s00335-008-9093-1.
356. Toland EJ, Yerga-Woolwine S, Farms P, Cicila GT, Saad Y, Joe B. Blood pressure and
proteinuria effects of multiple quantitative trait loci on rat chromosome 9 that differ-
entiate the spontaneously hypertensive rat from the Dahl salt-sensitive rat. J Hyper-
tens 26: 2134–2141, 2008. doi:10.1097/HJH.0b013e32830ef95c.
357. Tomaszewski M, Debiec R, Braund PS, Nelson CP, Hardwick R, Christofidou P,
Denniff M, Codd V, Rafelt S, van der Harst P, Waterworth D, Song K, Vollenweider P,
Waeber G, Zukowska-Szczechowska E, Burton PR, Mooser V, Charchar FJ, Thomp-
son JR, Tobin MD, Samani NJ. Genetic architecture of ambulatory blood pressure in
the general population: insights from cardiovascular gene-centric array. Hypertension
56: 1069–1076, 2010. doi:10.1161/HYPERTENSIONAHA.110.155721.
358. Tong AH, Lesage G, Bader GD, Ding H, Xu H, Xin X, Young J, Berriz GF, Brost RL,
Chang M, Chen Y, Cheng X, Chua G, Friesen H, Goldberg DS, Haynes J, Humphries
C, He G, Hussein S, Ke L, Krogan N, Li Z, Levinson JN, Lu H, Ménard P, Munyana C,
Parsons AB, Ryan O, Tonikian R, Roberts T, Sdicu AM, Shapiro J, Sheikh B, Suter B,
Wong SL, Zhang LV, Zhu H, Burd CG, Munro S, Sander C, Rine J, Greenblatt J, Peter
M, Bretscher A, Bell G, Roth FP, Brown GW, Andrews B, Bussey H, Boone C. Global
mapping of the yeast genetic interaction network. Science 303: 808–813, 2004. doi:
10.1126/science.1091317.
359. Torielli L, Tivodar S, Montella RC, Iacone R, Padoani G, Tarsini P, Russo O, Sarnataro
D, Strazzullo P, Ferrari P, Bianchi G, Zurzolo C. alpha-Adducin mutations increase
Na/K pump activity in renal cells by affecting constitutive endocytosis: implications for
tubular Na reabsorption. Am J Physiol Renal Physiol 295: F478–F487, 2008. doi:10.
1152/ajprenal.90226.2008.
360. Tripodi G, Florio M, Ferrandi M, Modica R, Zimdahl H, Hubner N, Ferrari P, Bianchi
G. Effect of Add1 gene transfer on blood pressure in reciprocal congenic strains of
Milan rats. Biochem Biophys Res Commun 324: 562–568, 2004. doi:10.1016/j.bbrc.
2004.09.079.
361. Trudu M, Janas S, Lanzani C, Debaix H, Schaeffer C, Ikehata M, Citterio L, Demaretz
S, Trevisani F, Ristagno G, Glaudemans B, Laghmani K, Dell’Antonio G, Loffing J,
Rastaldi MP, Manunta P, Devuyst O, Rampoldi L; Swiss Kidney Project on Genes in
Hypertension (SKIPOGH) team. Common noncoding UMOD gene variants induce
salt-sensitive hypertension and kidney damage by increasing uromodulin expression.
Nat Med 19: 1655–1660, 2013. doi:10.1038/nm.3384.
362. Tyler AL, Lu W, Hendrick JJ, Philip VM, Carter GW. CAPE: an R package for combined
analysis of pleiotropy and epistasis. PLOS Comput Biol 9: e1003270, 2013. doi:10.1371/
journal.pcbi.1003270.
363. Ueno T, Tremblay J, Kunes J, Zicha J, Dobesova Z, Pausova Z, Deng AY, Sun YL, Jacob
HJ, Hamet P. Resolving the composite trait of hypertension into its pharmacogenetic
determinants by acute pharmacological modulation of blood pressure regulatory sys-
tems. J Mol Med (Berl) 81: 51–60, 2003. doi:10.1007/s00109-002-0394-7.
364. van Berkum NL, Lieberman-Aiden E, Williams L, Imakaev M, Gnirke A, Mirny LA,
Dekker J, Lander ES. Hi-C: a method to study the three-dimensional architecture of
genomes. J Vis Exp 39: 1869, 2010. doi:doi:10.3791/1869.
365. Vincent M, Samani NJ, Gauguier D, Thompson JR, Lathrop GM, Sassard J. A pharma-
cogenetic approach to blood pressure in Lyon hypertensive rats. A chromosome 2
locus influences the response to a calcium antagonist. J Clin Invest 100: 2000–2006,
1997. doi:10.1172/JCI119731.
366. Wade B, Abais-Battad JM, Mattson DL. Role of immune cells in salt-sensitive hyper-
tension and renal injury. Curr Opin Nephrol Hypertens 25: 22–27, 2016. doi:10.1097/
MNH.0000000000000183.
367. Wain LV, Verwoert GC, O’Reilly PF, Shi G, Johnson T, Johnson AD, Bochud M,
Rice KM, Henneman P, Smith AV, Ehret GB, Amin N, Larson MG, Mooser V,
Hadley D, Dörr M, Bis JC, Aspelund T, Esko T, Janssens AC, Zhao JH, Heath S,
Laan M, Fu J, Pistis G, Luan J, Arora P, Lucas G, Pirastu N, Pichler I, Jackson AU,
Webster RJ, Zhang F, Peden JF, Schmidt H, Tanaka T, Campbell H, Igl W, Milan-
eschi Y, Hottenga JJ, Vitart V, Chasman DI, Trompet S, Bragg-Gresham JL, Aliza-
deh BZ, Chambers JC, Guo X, Lehtimäki T, Kühnel B, Lopez LM, Polašek O,
Boban M, Nelson CP, Morrison AC, Pihur V, Ganesh SK, Hofman A, Kundu S,
Mattace-Raso FU, Rivadeneira F, Sijbrands EJ, Uitterlinden AG, Hwang SJ, Vasan
RS, Wang TJ, Bergmann S, Vollenweider P, Waeber G, Laitinen J, Pouta A, Zitting
P, McArdle WL, Kroemer HK, Völker U, Völzke H, Glazer NL, Taylor KD, Harris
TB, Alavere H, Haller T, Keis A, Tammesoo ML, Aulchenko Y, Barroso I, Khaw
KT, Galan P, Hercberg S, Lathrop M, Eyheramendy S, Org E, Sõber S, Lu X, Nolte
IM, Penninx BW, Corre T, Masciullo C, Sala C, Groop L, Voight BF, Melander O,
O’Donnell CJ, Salomaa V, d’Adamo AP, Fabretto A, Faletra F, Ulivi S, Del Greco
F, Facheris M, Collins FS, Bergman RN, Beilby JP, Hung J, Musk AW, Mangino M,
Shin SY, Soranzo N, Watkins H, Goel A, Hamsten A, Gider P, Loitfelder M,
Zeginigg M, Hernandez D, Najjar SS, Navarro P, Wild SH, Corsi AM, Singleton A,
de Geus EJ, Willemsen G, Parker AN, Rose LM, Buckley B, Stott D, Orru M, Uda
M, van der Klauw MM, Zhang W, Li X, Scott J, Chen YD, Burke GL, Kähönen M,
Viikari J, Döring A, Meitinger T, Davies G, Starr JM, Emilsson V, Plump A, Linde-
man JH, Hoen PA, König IR, Felix JF, Clarke R, Hopewell JC, Ongen H, Breteler M,
Debette S, Destefano AL, Fornage M, Mitchell GF, Smith NL, Holm H, Stefansson
K, Thorleifsson G, Thorsteinsdottir U, Samani NJ, Preuss M, Rudan I, Hayward C,
Deary IJ, Wichmann HE, Raitakari OT, Palmas W, Kooner JS, Stolk RP, Jukema JW,
Wright AF, Boomsma DI, Bandinelli S, Gyllensten UB, Wilson JF, Ferrucci L,
Schmidt R, Farrall M, Spector TD, Palmer LJ, Tuomilehto J, Pfeufer A, Gasparini P,
Siscovick D, Altshuler D, Loos RJ, Toniolo D, Snieder H, Gieger C, Meneton P,
Wareham NJ, Oostra BA, Metspalu A, Launer L, Rettig R, Strachan DP, Beckmann
JS, Witteman JC, Erdmann J, van Dijk KW, Boerwinkle E, Boehnke M, Ridker PM,
Jarvelin MR, Chakravarti A, Abecasis GR, Gudnason V, Newton-Cheh C, Levy D,
Munroe PB, Psaty BM, Caulfield MJ, Rao DC, Tobin MD, Elliott P, van Duijn CM;
LifeLines Cohort Study; EchoGen consortium; AortaGen Consortium; CHARGE
Consortium Heart Failure Working Group; KidneyGen consortium; CKDGen
consortium; Cardiogenics consortium; CardioGram. Genome-wide association
study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat
Genet 43: 1005–1011, 2011 doi:10.1038/ng.922.
368. Wang F, Li L, Xu H, Liu Y, Yang C, Cowley AW Jr, Wang N, Liu P, Liang M. Charac-
teristics of long non-coding RNAs in the Brown Norway rat and alterations in the
Dahl salt-sensitive rat. Sci Rep 4: 7146, 2014. doi:10.1038/srep07146.
369. Wang NY, Young JH, Meoni LA, Ford DE, Erlinger TP, Klag MJ. Blood pressure change
and risk of hypertension associated with parental hypertension: the Johns Hopkins
Precursors Study. Arch Intern Med 168: 643–648, 2008. doi:10.1001/archinte.168.6.
643.
370. Wang QZ, Gao HQ, Liang Y, Zhang J, Wang J, Qiu J. Cofilin1 is involved in hyperten-
sion-induced renal damage via the regulation of NF-B in renal tubular epithelial cells.
J Transl Med 13: 323, 2015. doi:10.1186/s12967-015-0685-8.
371. Wang X, Falkner B, Zhu H, Shi H, Su S, Xu X, Sharma AK, Dong Y, Treiber F, Gutin
B, Harshfield G, Snieder H. A genome-wide methylation study on essential hyperten-
sion in young African American males. PLoS One 8: e53938, 2013. doi:10.1371/journal.
pone.0053938.
SANDOSH PADMANABHAN AND BINA JOE
1526 Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
372. Wang X, Prins BP, Sõber S, Laan M, Snieder H. Beyond genome-wide association
studies: new strategies for identifying genetic determinants of hypertension. Curr
Hypertens Rep 13: 442–451, 2011. doi:10.1007/s11906-011-0230-y.
373. Wang X, Snieder H. Genome-wide association studies and beyond: what’s next in
blood pressure genetics? Hypertension 56: 1035–1037, 2010. doi:10.1161/
HYPERTENSIONAHA.110.157214.
374. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, Ntalla I, Suren-
dran P, Liu C, Cook JP, Kraja AT, Drenos F, Loh M, Verweij N, Marten J, Karaman
I, Lepe MP, O’Reilly PF, Knight J, Snieder H, Kato N, He J, Tai ES, Said MA,
Porteous D, Alver M, Poulter N, Farrall M, Gansevoort RT, Padmanabhan S, Mägi
R, Stanton A, Connell J, Bakker SJ, Metspalu A, Shields DC, Thom S, Brown M,
Sever P, Esko T, Hayward C, van der Harst P, Saleheen D, Chowdhury R, Cham-
bers JC, Chasman DI, Chakravarti A, Newton-Cheh C, Lindgren CM, Levy D,
Kooner JS, Keavney B, Tomaszewski M, Samani NJ, Howson JM, Tobin MD,
Munroe PB, Ehret GB, Wain LV, Wain LV, Vaez A, Jansen R, Joehanes R, van der
Most PJ, Erzurumluoglu AM, O’Reilly P, Cabrera CP, Warren HR, Rose LM,
Verwoert GC, Hottenga J-J, Strawbridge RJ, Esko T, Arking DE, Hwang S-J, Guo
X, Kutalik Z, Trompet S, Shrine N, Teumer A, Ried JS, Bis JC, Smith AV, Amin N,
Nolte IM, Lyytikäinen L-P, Mahajan A, Wareham NJ, Hofer E, Joshi PK, Kristians-
son K, Traglia M, Havulinna AS, Goel A, Nalls MA, Sõber S, Vuckovic D, Luan J, M
FDG, Ayers KL, Marrugat J, Ruggiero D, Lopez LM, Niiranen T, Enroth S, Jackson
AU, Nelson CP, Huffman JE, Zhang W, Marten J, Gandin I, Harris SE, Zemonik T,
Lu Y, Evangelou E, Shah N, de Borst MH, Mangino M, Prins BP, Campbell A,
Li-Gao R, Chauhan G, Oldmeadow C, Abecasis G, Abedi M, Barbieri CM, Barnes
MR, Batini C, Blake T, Boehnke M, Bottinger EP, Braund PS, Brown M, Brumat M,
Campbell H, Chambers JC, Cocca M, Collins F, Connell J, Cordell HJ, Damman JJ,
Davies G, de Geus EJ, de Mutsert R, Deelen J, Demirkale Y, Doney ASF, Dörr M,
Farrall M, Ferreira T, Frånberg M, Gao H, Giedraitis V, Gieger C, Giulianini F, Gow
AJ, Hamsten A, Harris TB, Hofman A, Holliday EG, Jarvelin M-R, Johansson Å,
Johnson AD, Jousilahti P, Jula A, Kähönen M, Kathiresan S, Khaw K-T, Kolcic I,
Koskinen S, Langenberg C, Larson M, Launer LJ, Lehne B, Liewald DCM, Lin L,
Lind L, Mach F, Mamasoula C, Menni C, Mifsud B, Milaneschi Y, Morgan A, Morris
AD, Morrison AC, Munson PJ, Nandakumar P, Nguyen QT, Nutile T, Oldehinkel
AJ, Oostra BA, Org E, Padmanabhan S, Palotie A, Paré G, Pattie A, Penninx BWJH,
Poulter N, Pramstaller PP, Raitakari OT, Ren M, Rice K, Ridker PM, Riese H,
Ripatti S, Robino A, Rotter JI, Rudan I, Saba Y, Pierre AS, Sala CF, Sarin A-P,
Schmidt R, Scott R, Seelen MA, Shields DC, Siscovick D, Sorice R, Stanton A, Stott
DJ, Sundström J, Swertz M, Taylor KD, Thom S, Tzoulaki I, Tzourio C, Uitterlin-
den AG, Völker U, Vollenweider P, Wild S, Willemsen G, Wright AF, Yao J,
Thériault S, Conen D, John A, Sever P, Debette S, Mook-Kanamori DO, Zeggini E,
Spector TD, van der Harst P, Palmer CNA, Vergnaud A-C, Loos RJF, Polasek O,
Starr JM, Girotto G, Hayward C, Kooner JS, Lindgren CM, Vitart V, Samani NJ,
Tuomilehto J, Gyllensten U, Knekt P, Deary IJ, Ciullo M, Elosua R, Keavney BD,
Hicks AA, Scott RA, Gasparini P, Laan M, Liu YM, Watkins H, Hartman CA,
Salomaa V, Toniolo D, Perola M, Wilson JF, Schmidt H, Zhao JH, Lehtimäki T, van
Duijn CM, Gudnason V, Psaty BM, Peters A, Rettig R, James A, Jukema JW,
Strachan DP, Palmas W, Metspalu A, Ingelsson E, Boomsma DI, Franco OH,
Bochud M, Newton-Cheh C, Munroe PB, Elliott P, Chasman DI, Chakravarti A,
Knight J, Morris AP, Levy D, Tobin MD, Snieder H, Caulfield MJ, Ehret GB, Barnes
MR, Tzoulaki I, Caulfield MJ, Elliott P; International Consortium of Blood Pressure
(ICBP) 1000G Analyses; BIOS Consortium; Lifelines Cohort Study; Understanding
Society Scientific group; CHD Exome Consortium; ExomeBP Consortium;
T2D-GENES Consortium; GoT2DGenes Consortium; Cohorts for Heart and
Ageing Research in Genome Epidemiology (CHARGE) BP Exome Consortium;
International Genomics of Blood Pressure (iGEN-BP) Consortium; UK Biobank
CardioMetabolic Consortium BP working group. Genome-wide association analy-
sis identifies novel blood pressure loci and offers biological insights into cardiovascular
risk. Nat Genet 49: 403–415, 2017 doi:10.1038/ng.3768.
375. Watkin DM, Froeb HG, Hatch FT, Gutman AB. Effects of diet in essential hyperten-
sion. II. Results with unmodified Kempner rice diet in 50 hospitalized patients. Am J
Med 9: 441–493, 1950. doi:10.1016/0002-9343(50)90200-2.
376. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyri-
bose nucleic acid. Nature 171: 737–738, 1953. doi:10.1038/171737a0.
377. Watson JD, Crick FH. The structure of DNA. Cold Spring Harb Symp Quant Biol 18:
123–131, 1953. doi:10.1101/SQB.1953.018.01.020.
378. Watt G. Design and interpretation of studies comparing individuals with and without
a family history of high blood pressure. J Hypertens 4: 1–7, 1986. doi:10.1097/
00004872-198602000-00001.
379. Weder AB. Evolution and hypertension. Hypertension 49: 260–265, 2007. doi:10.
1161/01.HYP.0000255165.84684.9d.
380. Wellcome Trust Case Control Consortium. Genome-wide association study of
14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:
661–678, 2007. doi:10.1038/nature05911.
381. White PC. Inherited forms of mineralocorticoid hypertension. Hypertension 28: 927–
936, 1996. doi:10.1161/01.HYP.28.6.927.
382. White PC, Hautanen A, Kupari M. Aldosterone synthase (CYP11B2) polymor-
phisms and cardiovascular function. Endocr Res 24: 797– 804, 1998. doi:10.3109/
07435809809032690.
383. Williamson CR. Observations on the management of hypertension by the Kempner
rice diet. N Engl J Med 243: 177–182, 1950. doi:10.1056/NEJM195008032430502.
384. Wilson FH, Disse-Nicodème S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter
I, Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin
RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X, Lifton RP. Human hypertension
caused by mutations in WNK kinases. Science 293: 1107–1112, 2001. doi:10.1126/
science.1062844.
385. Woelfle J, Roth CL, Wunsch R, Reinehr T. Pregnancy-associated plasma protein A in obese
children: relationship to markers and risk factors of atherosclerosis and members of the
IGF system. Eur J Endocrinol 165: 613–622, 2011. doi:10.1530/EJE-11-0423.
386. Wu C, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y, Regev A, Kuchroo VK. Induction
of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 496: 513–517,
2013. doi:10.1038/nature11984.
387. Xiao B, Harada Y, Kawakami K, Nabika T. A 1.8-Mbp fragment on chromosome 1
affects sympathetic response to stress: evaluation in reciprocal congenic strains be-
tween stroke-prone spontaneously hypertensive rat and Wistar-Kyoto rat. J Hyper-
tens 29: 257–265, 2011. doi:10.1097/HJH.0b013e32834137cd.
388. Yagil C, Hubner N, Kreutz R, Ganten D, Yagil Y. Congenic strains confirm the presence of
salt-sensitivity QTLs on chromosome 1 in the Sabra rat model of hypertension. Physiol
Genomics 12: 85–95, 2003. doi:10.1152/physiolgenomics.00111.2002.
389. Yagil C, Sapojnikov M, Kreutz R, Katni G, Lindpaintner K, Ganten D, Yagil Y. Salt suscep-
tibility maps to chromosomes 1 and 17 with sex specificity in the Sabra rat model of
hypertension. Hypertension 31: 119–124, 1998. doi:10.1161/01.HYP.31.1.119.
390. Yagil C, Sapojnikov M, Kreutz R, Zürcher H, Ganten D, Yagil Y. Role of chromosome
X in the Sabra rat model of salt-sensitive hypertension. Hypertension 33: 261–265,
1999. doi:10.1161/01.HYP.33.1.261.
391. Yamori Y, Ooshima A, Okamoto K. Genetic factors involved in spontaneous hyper-
tension in rats an analysis of F2 segregate generation. Jpn Circ J 36: 561–568, 1972.
doi:10.1253/jcj.36.561.
392. Yan X, Baxter RC, Firth SM. Involvement of pregnancy-associated plasma protein-A2
in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a
potential mechanism for increasing IGF bioavailability. J Clin Endocrinol Metab 95:
1412–1420, 2010. doi:10.1210/jc.2009-2277.
393. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, Madden PA,
Heath AC, Martin NG, Montgomery GW, Goddard ME, Visscher PM. Common SNPs
explain a large proportion of the heritability for human height. Nat Genet 42: 565–569,
2010. doi:10.1038/ng.608.
394. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M,
Gong M, Qi Y, Zubcevic J, Sahay B, Pepine CJ, Raizada MK, Mohamadzadeh M.
Gut dysbiosis is linked to hypertension. Hypertension 65: 1331–1340, 2015. doi:
10.1161/HYPERTENSIONAHA.115.05315.
395. Ye P, West MJ. Cosegregation analysis of natriuretic peptide genes and blood pressure
in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 30: 930–936, 2003.
doi:10.1111/j.1440-1681.2003.03937.x.
396. Young JH, Chang YP, Kim JD, Chretien JP, Klag MJ, Levine MA, Ruff CB, Wang NY,
Chakravarti A. Differential susceptibility to hypertension is due to selection during the
out-of-Africa expansion. PLoS Genet 1: e82, 2005. doi:10.1371/journal.pgen.0010082.
397. Yu H, Harrap SB, Di Nicolantonio R. Cosegregation of spontaneously hypertensive rat
renin gene with elevated blood pressure in an F2 generation. J Hypertens 16: 1141–
1147, 1998. doi:10.1097/00004872-199816080-00010.
398. Zagato L, Modica R, Florio M, Torielli L, Bihoreau MT, Bianchi G, Tripodi G. Genetic
mapping of blood pressure quantitative trait loci in Milan hypertensive rats. Hyperten-
sion 36: 734–739, 2000. doi:10.1161/01.HYP.36.5.734.
TOWARDS PRECISION MEDICINE FOR HYPERTENSION
1527Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
399. Zennaro MC, Boulkroun S, Fernandes-Rosa F. An update on novel mechanisms of
primary aldosteronism. J Endocrinol 224: R63–R77, 2015. doi:10.1530/JOE-14-
0597.
400. Zhang L, Summers KM, West MJ. Angiotensin I converting enzyme gene cosegregates
with blood pressure and heart weight in F2 progeny derived from spontaneously
hypertensive and normotensive Wistar-Kyoto rats. Clin Exp Hypertens 18: 753–771,
1996. doi:10.3109/10641969609081779.
401. Zhang L, Xu D, West MJ, Summers KM. Association of the brain natriuretic peptide
gene with blood pressure and heart weight in the rat. Clin Exp Pharmacol Physiol 24:
442–444, 1997. doi:10.1111/j.1440-1681.1997.tb01220.x.
402. Zhang QY, Dene H, Deng AY, Garrett MR, Jacob HJ, Rapp JP. Interval mapping and
congenic strains for a blood pressure QTL on rat chromosome 13. Mamm Genome 8:
636–641, 1997. doi:10.1007/s003359900528.
403. Zhang S, Mao G, Zhang Y, Tang G, Wen Y, Hong X, Jiang S, Yu Y, Xu X. Association
between human atrial natriuretic peptide Val7Met polymorphism and baseline blood
pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy
of irbesartan in rural Chinese patients with essential hypertension. Clin Ther 27:
1774–1784, 2005. doi:10.1016/j.clinthera.2005.11.008.
404. Zhang Y, Zang J, Wang B, Li B, Yao X, Zhao H, Li W. CD36 genotype associated with
ischemic stroke in Chinese Han. Int J Clin Exp Med 8: 16149–16157, 2015.
405. Zhao Y, Peng J, Lu C, Hsin M, Mura M, Wu L, Chu L, Zamel R, Machuca T, Waddell
T, Liu M, Keshavjee S, Granton J, de Perrot M. Metabolomic heterogeneity of
pulmonary arterial hypertension. PLoS One 9: e88727, 2014. doi:10.1371/journal.
pone.0088727.
406. Zheng Y, Yu B, Alexander D, Mosley TH, Heiss G, Nettleton JA, Boerwinkle E.
Metabolomics and incident hypertension among blacks: the atherosclerosis risk in
communities study. Hypertension 62: 398–403, 2013. doi:10.1161/
HYPERTENSIONAHA.113.01166.
407. Zhu Z, Xiong S, Liu D. The Gastrointestinal Tract: an Initial Organ of Metabolic
Hypertension? Cell Physiol Biochem 38: 1681–1694, 2016. doi:10.1159/000443107.
408. Zhuo JL. SH2B3 (LNK) as a novel link of immune signaling, inflammation, and hyper-
tension in Dahl salt-sensitive hypertensive rats. Hypertension 65: 989–990, 2015.
doi:10.1161/HYPERTENSIONAHA.115.04887.
409. Zinner SH, Levy PS, Kass EH. Familial aggregation of blood pressure in childhood. N
Engl J Med 284: 401–404, 1971. doi:10.1056/NEJM197102252840801.
SANDOSH PADMANABHAN AND BINA JOE
1528 Physiol Rev • VOL 97 • OCTOBER 2017 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (130.209.115.082) on March 7, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
